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Patients with impaired kidney function are at risk of excessive drug 
exposure and toxicity when standard doses of renally cleared drugs are used. 
Dose adjustment to normalise drug exposure between patients may be required 
to optimise the safety and effectiveness of treatment. Renal drug dosing in 
clinical practice generally assumes a linear relationship between dose and 
glomerular filtration rate (GFR). The theory underpinning this assumption is the 
intact nephron hypothesis (INH). The INH suggests that kidney disease is the 
result of a reduction in the number of complete (intact) nephrons. Under this 
model, renal drug clearance is assumed to be a linear function of glomerular 
function while tubular handling is not accounted for. The INH is a widely 
accepted model for renal drug handling even though it was not originally 
developed for this purpose. 
There is concern that the INH may overly simplify renal drug handling 
such that it may not, in all cases, be a suitable model for renal dose adjustment. 
The exception will be drugs with low protein binding that are handled almost 
entirely by glomerular filtration (e.g. gentamicin, vancomycin). Here the renal 
clearance of the drug would be expected to approximate GFR and the INH 
should hold as a suitable model to describe renal handling. However, there is 
increasing evidence to suggest that the assumption of a linear relationship 
between GFR and renal clearance for drugs that are mainly secreted by the 
tubules may not be reasonable. This represents a large number of commonly 
prescribed drugs such as metformin, ACE inhibitors, some beta-lactam 
antibiotics, furosemide, and some anticancer drugs (e.g. methotrexate, cisplatin). 
Renal dose adjustment generally recommended in clinical practice hinges 
on the INH being true. However, this assumption has not been thoroughly 
investigated. The standard phase I renal drug studies assessing the need for dose 
adjustment in patients with kidney disease in drug development also rely on the 
INH being true. This means that dosing information on product labels are 




as Cockcroft-Gault) based on creatinine as a renal biomarker, itself subject to 
tubular secretion, might distort the relationship that exists between drug 
clearance and GFR.  
In this thesis, it is hypothesised that the INH may not be a suitable model 
for renal drug handling and hence dose prediction for drugs that are cleared 
predominantly by tubular secretion. This raises two falsifiable predictions; 1) for 
drugs that are secreted predominantly by tubular secretion the relationship 
between renal drug clearance and GFR will be non-linear, and, 2) renal drug 
study design will influence the ability to capture the non-linear relationship. The 
aims of this thesis are to investigate the INH in the context of renal drug handling 
and to propose study designs for testing the INH. 
The first prediction was explored by performing a systematic literature 
review and two model-based analyses. The evidence-base explored suggests that 
the INH may not be a suitable model for renal drug handling. Additionally, the 
studies that did not support the INH were robust in some design components in 
comparison to those supporting the INH. The INH was further explored by 
performing model-based analyses using data from a renal drug study using 
probes for glomerular and tubular function. The renal drug study design 
appeared to be inadequate to inform about the appropriateness of the INH as a 
model for renal drug handling. 
The second prediction was investigated by evaluating the performance of 
different renal drug study designs. The European Medicines Agency (EMA) 
based renal drug study designs performed better compared to those based on 
the Food and Drug Administration (FDA) in terms of power calculated as the 
probability of correctly identifying the “true” relationship between renal drug 
clearance and GFR over the misspecified relationship under a given study 
design. The performance of the study design was dependent on the method used 
to determine GFR. However, the performance of both the designs were poor in 
terms of parameter precision when standard number of subjects (n = 24) were 
enrolled. An optimal design methodology was used to construct a composite 




parameter with adequate precision with the standard number of subjects (n = 
24). 
Three difference approaches were identified and explored for the purpose 
of testing the INH using data from a renal drug study. The three approaches 
were based on; 1) comparison of renal drug clearance with respect to GFR, 2) 
linear regression of renal drug clearance against GFR, and, 3) the time course of 
amount of drug excreted in urine, where subjects with a range of renal function 
were included. The utility of the three approaches to test the INH were 
successfully demonstrated. 
The findings in this thesis suggest that the INH may not be a suitable 
general model for renal drug handling. An empirical non-linear model proposed 
in this thesis can be used to account for both non-linear (non-INH) and linear 
(INH) renal drug handling. Moreover, appropriately designed studies are 
required for accurately estimating the change in renal drug clearance with 
respect to change in renal function and thus improve the prediction of required 
dose adjustment. This research represents a step towards the safe and effective 
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1.1. Rationale and thesis aims 
The use of standard doses for renally cleared drugs in patients with kidney 
disease would be expected to result in elevated steady-state plasma 
concentrations and for drugs with a narrow therapeutic range, an increased risk 
of toxicity. Equally, for patients with increased renal clearance, such as the obese 
or critically unwell patients with hyperfiltration and augmented renal clearance, 
use of standard doses may result in under-dosing and a loss of efficacy. 
Therefore, dose adjustment to normalise drug exposure between patients may 
be required to ensure safe and effective treatment. 
In clinical practice, when toxicity is the main concern, renal drug dosing 
usually involves a reduction of the dose-rate relative to the estimated glomerular 
filtration rate (GFR). The relationship between dose and GFR is usually assumed 
to be linear. However, drug handling by the nephron involves two other 
mechanisms; reabsorption from the tubule back into the blood stream and 
tubular secretion where drug is transported into the lumen. The latter 
mechanism acts as an additional, and sometimes dominate, elimination route for 
drugs along with glomerular filtration. The tubular handling of drugs is 
therefore usually ignored when adjusting doses for renally cleared drugs.  
The implicit assumptions dose adjustment in renal impairment can be 
summarised as follows: 







2. Assumption 2: 𝐶𝐶𝐶𝐶𝑅𝑅 ∝ 𝑚𝑚𝑚𝑚𝐶𝐶 , 
3. Assumption 3: 𝑒𝑒𝑠𝑠𝑡𝑡𝑖𝑖𝑚𝑚𝑒𝑒𝑡𝑡𝑒𝑒𝑑𝑑 𝑚𝑚𝑚𝑚𝐶𝐶 ≈ 𝑚𝑚𝑚𝑚𝐶𝐶, 
4. Axiom: 𝑀𝑀𝑒𝑒𝑖𝑖𝑛𝑛𝑡𝑡𝑒𝑒𝑛𝑛𝑒𝑒𝑛𝑛𝑐𝑐𝑒𝑒 𝑑𝑑𝑑𝑑𝑠𝑠𝑒𝑒 𝑟𝑟𝑒𝑒𝑡𝑡𝑒𝑒 ∝ 𝐶𝐶𝐶𝐶𝑅𝑅, 
5. Therefore: 𝑀𝑀𝑒𝑒𝑖𝑖𝑛𝑛𝑡𝑡𝑒𝑒𝑛𝑛𝑒𝑒𝑛𝑛𝑐𝑐𝑒𝑒 𝑑𝑑𝑑𝑑𝑠𝑠𝑒𝑒 𝑟𝑟𝑒𝑒𝑡𝑡𝑒𝑒 ∝ 𝑒𝑒𝑠𝑠𝑡𝑡𝑖𝑖𝑚𝑚𝑒𝑒𝑡𝑡𝑒𝑒𝑑𝑑 𝑚𝑚𝑚𝑚𝐶𝐶, 
where, 𝐶𝐶𝐶𝐶𝑠𝑠𝑒𝑒𝑠𝑠𝐶𝐶𝑒𝑒𝑟𝑟𝑝𝑝𝑟𝑟𝑝𝑝  is drug clearance by secretion, 𝐶𝐶𝐶𝐶𝐶𝐶𝑒𝑒𝑟𝑟𝑟𝑟𝑠𝑠𝑟𝑟𝐶𝐶𝑝𝑝𝑟𝑟𝑝𝑝𝑟𝑟𝑝𝑝  is clearance by 
tubular reabsorption (in this case clearance back into the body), and CLR is renal 
clearance. Assumption 1 says that the rate of change for each drug handling 
mechanisms in the nephron are proportional. Assumption 2 suggests that CLR is 
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proportional to GFR and any additional influence due to tubular processes are 
not accounted for. An easily obtainable estimated GFR is assumed to be a good 
approximation of the true GFR (Assumption 3). Therefore, the recommended 
maintenance dose rate is proportional to CLR (in this case, an Axiom), which is 
in turn proportional to estimated GFR (Assumption 5). 
The theory underpinning the assumptions outlined above is the intact 
nephron hypothesis (INH) [1]. The INH considers the basic functional unit of the 
kidney to be the nephron, where each nephron is either fully functional (intact) 
or fully non-function (lost). Under the INH, renal impairment occurs when there 
is progressive loss of intact nephrons and the remaining nephrons cannot 
maintain the normal renal function. In practical terms, this suggests that partial 
damage to a section of the nephron results in a complete loss of that nephron. 
Therefore, GFR is assumed to be a sufficient summary metric for renal drug 
handling, and to reflect other drug handling mechanisms by the nephron. 
Logically, under this scenario, a reduction in GFR will be accompanied by a 
proportional reduction is tubular drug reabsorption and secretion.  
There is concern that the INH may over-simplify renal drug handling and 
will not, in all circumstances, be a suitable model for renal dose adjustment. The 
exception will be drugs with low protein binding that are handled almost 
entirely by glomerular filtration (e.g. gentamicin, vancomycin). Here the renal 
clearance of the drug would be expected to approximate GFR and the INH 
should hold as a suitable model to describe renal handling. However, there is 
increasing evidence to suggest that the assumption of a linear relationship 
between GFR and renal clearance for drugs that are mainly secreted by the 
tubules may not be reasonable. This represents a large number of commonly 
prescribed drugs such as some beta-lactam antibiotics, ACE inhibitors, beta 
blockers, metformin, furosemide, and some anticancer drugs (e.g. methotrexate, 
cisplatin).  
Most renal dose adjustment recommended in clinical practice, as well as 
the assessment of renal dose requirements in regulatory submissions for new 
drugs, hinge on the INH being true. However, this assumption has not been 
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thoroughly interrogated. It is unclear if standard study designs used to assess 
renal drug handling will be adequate to detect a non-linear relationship between 
renal drug clearance and GFR if it did in fact exist. Equally, it is not known if the 
use of estimated GFR (such as Cockcroft-Gault) based on creatinine as a renal 
biomarker, itself subject to tubular secretion, might obscure any relationships 
that does exists between drug clearance and GFR. 
In this thesis, it is hypothesised that the INH will not be a suitable model 
for renal drug handling (and therefore dose prediction) for agents that are 
excreted predominantly by tubular secretion. This raises two falsifiable 
predictions; 1) the relationship between renal drug clearance and GFR will be 
non-linear for drugs that are secreted by tubular mechanisms, and, 2) renal drug 
study design, including the nature of the GFR probe used, the range of renal 
function and the number of subjects enrolled in the study will alter the 
probability of capturing this non-linearity. 
1.1.1. Aims and objectives of the thesis 
The aims of this thesis are to investigate the INH in the context of renal 
drug handling and to propose study designs for testing the INH. The outcomes 
from this work will inform the applicability of the INH as a general model of 
renal drug handling and provide study designs that can distinguish renal drug 
handling that aligns with the INH from the non-INH scenario. The specific 
objectives of this thesis were; 
1. To perform a systematic literature review of published studies that aimed 
to test the INH (Chapter 2) 
2. To test the INH by analysing renal probe data using a population 
pharmacokinetic modelling approach (Chapter 3) 
3. To evaluate the renal drug studies recommended by the EMA and FDA 
for the purpose of testing the INH (Chapter 4) 
4. To construct a study design robust for parameter estimation and for 
distinguishing INH from non-INH (Chapter 5) 
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5. To explore approaches for analysing data generated by typical clinical 
pharmacological studies for the purpose of testing the INH (Chapter6) 
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1.1.2. Overview of the introduction 
The introduction is divided into four sections: 
1. Section 1.2. A general overview of the kidney, the INH, methods for 
estimating renal function, and renal drug handling 
2. Section 1.3. An overview of pharmacometric methods (models and 
modelling)  
3. Section 1.4. An overview of study design   
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1.2. The kidneys 
1.2.1. Anatomy  
The kidneys are the primary functional organ of the renal system. A pair of 
kidneys are located in the back of the abdomen on either side of the vertebral 
column in a human body. The internal anatomy of the kidney, the nephron, and 
associated blood vessels are described below. 
1.2.1.1. Internal anatomy 
The internal anatomy of the kidney is shown in Figure 1.1. The kidneys 
have fibrous tissue on the outermost surface called renal capsule. The 
parenchyma of the kidneys is divided into two layers: the outer renal cortex and 
the inner renal medulla. The renal cortex accommodates arterioles and venules 
that extend from the renal artery and vein to perfuse the kidneys. The renal 
medulla consists of multiple triangular tissue masses called the renal pyramids. 
They are separated by connective tissue called the renal column that extend from 
the cortex to the medulla. A bundle of collecting ducts form the renal papillae 
that transfers urine to the calyces of the kidney.  
The renal hilum is located in a recessed area on its concave border, where 
the renal artery and nerves enters the kidney and the renal vein and ureter leave. 
The renal arteries extend from the abdominal aorta. The renal veins carry blood 
from the kidneys directly to the inferior vena cava. The minor and major calyces 
forms the renal pelvis, which emerges out of the renal hilum and funnels urine 
into the ureter. 




Figure 1.1 A general anatomy of the kidney [2] 
(Figure from Anatomy and Physiology by OpenStax is licensed under Creative 
Commons Attribution License v4.0) 
1.2.1.2. Nephron 
The basic structural and functional unit of the kidney is the nephron. There 
are about one million nephrons in each kidney [3, 4]. A general microscopic 
anatomical structure of the nephron is shown in Figure 1.2. Each nephron 
consists of five main structures: the renal corpuscle, proximal tubule, loop of 
Henle, distal tubule and collecting duct. The renal corpuscle, proximal tubule 
and distal tubule are located within the cortex, while the loop of Henle and 
collecting duct extend further into the medulla. A description of each of the 
structures of the nephron are given below.  
Renal corpuscle. The nephron consists of an initial filtering component called 
the renal corpuscles, that consists of the glomerulus and Bowman’s capsule. The 
glomerulus is a tuft of capillaries formed from the afferent arterioles which are 
made up of fenestrated endothelium with a high porosity and allow formation 
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of filtrate. The Bowman’s capsule is a cup-shaped hollow structure that 
surrounds the glomerulus. 
Proximal tubule. The proximal tubule includes prominent microvilli on the 
luminal surface called the ‘brush border’. These create a large surface area to 
maximise the absorption and secretion of electrolytes and other endogenous 
compounds (e.g. sodium, chlorine, glucose). 
Loop of Henle. The loop of Henle consists of three segments. The thin 
descending limb that makes a hairpin turn at the deepest point of descent to 
become the thin ascending limb. This is followed by the thick ascending limb.  
Distal tubule. The distal tubule includes the distal convoluted tubule and the 
connecting tubule. The tubular fluid is further concentrated along the distal 
tubule. 
Collecting duct. Collecting ducts merge as they extend further into the medulla 
and collectively from several terminal ducts, called papilla. Under the 
stimulation by antidiuretic hormone, this segment can passively reabsorb a large 
amount of water from the filtrate back into the blood stream [5].  
1.2.1.3. Renal blood vessels 
The major blood vessels associated with the kidney are shown in Figure 1.1. 
Each of the renal arteries branches into the interlobar arteries and extend into the 
kidneys. The interlobar arteries branch further into arcuate arteries and then into 
cortical radiate arteries. The microvasculature of the nephron is shown in Figure 
1.2. The afferent arterioles supply blood to the nephrons and the glomerulus. The 
blood flows out from the glomerulus via the efferent arterioles. These extend into 
the peritubular capillaries that surround the renal tubules. 




Figure 1.2 A general anatomy and blood flow of the nephron [2] 
(Figure from Anatomy and Physiology by OpenStax is licensed under Creative 
Commons Attribution License v4.0)
Efferent 
arteriole 




The primary function of the kidneys is to maintain a stable internal 
environment (homeostasis) within the body. This involves the following four 
primary physiological functions that include: 
1. Excretory: removal of toxic metabolic (e.g. urea, uric acid, ammonia) 
and xenobiotics from the bloodstream, 
2. Regulatory: regulation of extracellular volume, osmolarity, ion 
concentration and pH, 
3. Endocrine: Examples: renin erythropoietin production,  
4. Metabolism: Example: hydroxylation of calcifediol to form calcitriol 
(active form of Vitamin D).  
The research work described in this thesis focuses on the excretory function 
of the kidneys. The excretory function of the kidney involves three processes: 
glomerular filtration, tubular reabsorption and tubular secretion. A general 
overview of excretory function of the kidney in the context of drug handling is 
given in Section 1.2.6. 
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1.2.3. Kidney dysfunction 
Kidney dysfunction can be caused by a comorbid diseases, such as type 2 
diabetes and hypertension, and by a range of other etiological factors like 
bacteria, an unwanted immune response, toxic chemical exposure, tumours, 
kidney stones, and obstruction of the urinary system. 
Based on the aetiology and duration of kidney disease, it can be broadly 
classified as acute kidney injury and chronic kidney disease. Acute kidney injury 
is a sudden reduction in kidney function that covers both structural damage and 
loss of function [6]. It is mainly caused by sudden alterations in cardiac output, 
damage to the kidney tissues by infection or chemicals, or obstruction of urinary 
tract [6]. It may be self-limiting if the underlying cause is treated [6]. Chronic 
kidney disease develops over a span of years and is defined by abnormalities in 
kidney structure or function that persists over at least 3 months. [7, 8].  
Chronic kidney disease is classified into categories to guide screening, 
diagnosis, management and prognosis. While there are several schemes, in this 
thesis the Kidney Disease: Improving Global Outcomes (KDIGO) Chronic 
Kidney Disease (CKD) guideline with will be used. The stages of CKD are given 
in Table 1.1.
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Table 1.1 Classification of chronic kidney disease by glomerular filtration rate 
categories based on Kidney Disease: Improvement Global Outcome 2012 [7] 
Group Description GFRa range 
(mL/min/ 1.73m2) 
G1 Normal or high ≥ 90 
G2 Mildly decreased 60-89 
G3a Mildly to moderately 
decreased 
45-59 
G3b Mildly to severely 
decreased 
30-44 
G4 Severely decreased 15-29 
G5 Kidney failure <15 
a GFR is estimated with the CKD-EPI equation and standardised serum creatinine [7] 
Chapter 1: Introduction 
 14 
 
1.2.4. Intact nephron hypothesis 
The INH provides a general model for kidney dysfunction. It considers that 
renal impairment is the result of a decrease in the absolute number of completely 
functional (intact) nephrons. Differential loss of function in one section of the 
nephron is not considered. This means that a change in glomerular filtration will 
be proportional to changes in tubular reabsorption and tubular secretion. The 
implications for drug therapy are that it will only be necessary to measure GFR 
to predict the impact of renal disease on drug handling in renal disease .  
The INH is often attributed to Dr Neal Bricker and colleagues who 
published a seminal paper on the topic in 1960 [1]. However, some of the ground 
work for the INH can be traced to previous work by Hayman et al. [9] and Platt 
et al. [10], who originally proposed the idea that kidney dysfunction resulted 
from the loss of intact nephrons. Bricker et al. [1] extended this theory by 
proposing that the INH provided an overarching theory to describe the suite of 
symptoms and signs observed in patients with kidney disease. 
Bricker et al. conducted a series of experiments on animals measuring 
various endogenous and exogenous compounds to access kidney function. The 
authors compared the relationship between glomerular and tubular function in 
the diseased and normal kidney based on the following [1]: 
1. filtration fraction – the ratio of GFR and renal plasma flow, where 
the latter represents overall tubular function, 
2. the ratio of GFR and maximal rate of PAH transport, where the latter 
represents an estimate of tubular secretory function, and, 
3. the ratio of GFR and maximal rate of glucose reabsorption, where 
the latter represents an estimate of tubular reabsorption function. 
Each of the tests were found to produce similar results in both normal and 
diseased kidneys over the period of 3 to 8 months [1]. Based on these findings, 
Bricker et al. proposed that in the diseased kidney, glomerular and tubular 
function decreased in parallel. In addition, Bricker et al suggested that the 
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complete (intact) nephrons are lost so that no partially functioning nephrons 
remained.  
Chapter 2 of this thesis will present a complete review of published studies 
designed specifically to test the INH, including the seminal work by Bricker et al 
[1]. It is noteworthy that Bricker et al. [1] acknowledged an important limitation 
of their theory indicating that damage to specific portions of the nephrons might 
be expected to result in a differences between glomerular and tubular function. 
In addition, in no writing did Bricker et al. [1] imply that the INH was anything 
other than a falsifiable hypothesis. The thesis that follows will explore this 
further. 
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1.2.5. Estimating renal function 
An estimate of renal function is important in clinical practice for the early 
detection of kidney disease, its prognosis, and for decision-making around 
treatment plans. GFR is widely used as the metric of choice for estimating renal 
function. GFR is also used to determine renal drug clearance for drugs that are 
entirely or partly cleared by the kidneys and to guide dosing decisions for renally 
cleared drugs.  
1.2.5.1. Probes for GFR 
An ideal probe for GFR has low protein binding, is freely filtered by the 
glomerulus and is neither secreted nor reabsorbed by the renal tubules. Probes 
for GFR are either endogenous or exogenous compounds.  
Endogenous Probes. The steady-state concentration of an endogenous probe 
that is cleared entirely by the kidneys might be used as a probe of renal function. 
Note that the concentration of the probe will be a product of endogenous 
production and elimination, so altered production can also impact the 
concentration. Measurement is ideally routine, inexpensive, and easily accessible 
in the clinic [11]. Methods for estimating the clearance of the probes will be 
discussed in the subsequent section. Endogenous filtration probes commonly 
used in practice are listed below: 
• Creatinine. Creatinine is the most widely used endogenous probe for 
measuring GFR. Serum creatinine is a breakdown product of creatine 
phosphate in skeletal muscle [11-13]. Creatinine production may be 
influenced by muscle mass, patient age, sex, some foods, health status, 
and physical activity [11-13]. Creatinine is freely filtered at the glomerulus 
and is not reabsorbed, however it is actively secreted by the tubules up to 
15% [13]. The proportion of the tubular secretion of creatinine is increased 
in chronic kidney disease patients [14]. The normal range for serum 
creatinine concentration is 53 to 106 μmol/L for men and 44 to 97 μmol/L 
for women [15]. 
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• Cystatin C. Cystatin C is a cationic non-glycosylated cysteine protein. It 
is freely filtered in the glomerulus and is also reabsorbed and catabolised 
in the proximal tubules [12, 16, 17]. Only a small amount of cystatin C is 
excreted in the urine so renal clearance cannot be determined using urine 
excretion data. At present, cystatin C has been suggested as an additional 
test along with creatinine and equations that incorporate both probes are 
available [7, 11].  
Exogenous probes. The advantage of using an exogenous probe for estimating 
GFR is that the dose can be controlled and therefore the input (“production” for 
an endogenous probe) is known. The clearance of an exogenous probe generally 
provides a more accurate measure of GFR than endogenous probes, such as 
creatinine [11, 13]. Exogenous probes are not routinely used in clinical practice 
to estimate GFR because they are time consuming and relatively expensive, may 
require an invasive study and, in the case of inulin, a 24 hour infusion. Some of 
the commonly used exogenous probes for GFR are briefly outlined below: 
• Inulin. Inulin is an inert uncharged polymer of fructose that is considered 
an ideal filtration probe since it is neither reabsorbed nor secreted by the 
tubules [11-13]. Inulin clearance can be determined after a bolus dose of 
inulin followed by an infusion to achieve a steady plasma concentration. 
The blood and urine samples are collected over several hours at regular 
intervals after administration of inulin [11, 13]. Inulin is primarily used in 
research as a reference standard for the evaluation of alternative probes 
of GFR [11]. 
• Iohexol. Iohexol is a non-radioactive, non-ionic, iodinated X-ray contrast 
medium introduced in 1980 [18]. Iohexol is administered as a bolus 
intravenous injection and GFR is determined from its plasma clearance or 
urinary excretion. A simplified method for calculating iohexol plasma 
clearance has been proposed which requires only a single blood samples 
at 4 hours after administration in subjects with normal to mild renal 
impairment [19, 20].  
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• Iothalamate. Iothalamate is an iodine-containing organic anion. It is 
administered as a radioactive iodine label (125I-iothalalamate) but it can 
also be used in a non-radiolabelled form [21]. Plasma clearance of 
iothalamate can be measured either after continuous infusion or 
intravenous bolus injection [22].  
• 51Cr-EDTA. 51Cr-EDTA is a complex of isotope 51chromium with ethylene 
diamine tetra acetic acid. It is a stable radioisotope with a physical (i.e., 
radioactive) half-life of 27.7 days [23]. It is not appreciably bound to 
plasma proteins and is freely filtered through the glomerulus with no 
tubular secretion or reabsorption [24-26]. An intravenous bolus dose of 
51Cr EDTA is administered and GFR determined by calculating the 
clearance of the radioisotope. Plasma samples for the measurement of 
isotopic counts are collected for several hours after the dose [27]. The 
plasma clearance of 51Cr-EDTA is highly correlated with the renal 
clearance of inulin in comparative studies [28, 29]. 51Cr-EDTA is 
considered as the “gold-standard” method for measuring GFR where an 
accurate value of GFR is required, for example in oncology or in kidney 
transplant patients. [30-32]. 
• 99mTc-DTPA. Technetium-99m-diethylenetriaminepentacetic acid (99mTc-
DTPA) is an organic radiolabelled molecule with a half-life of 6 hours. 
99mTc-DTPA is believed to be freely filtered in kidney with minimal 
tubular secretion and reabsorption [11, 33].  
1.2.5.2. Methods for determining GFR from endogenous and exogenous 
probes 
For the purposes this thesis, two general methods for determining GFR are 
defined; estimated GFR (eGFR) and measured GFR (mGFR). Each is described 
below.  
Estimated glomerular filtration rate (eGFR). eGFR refers to any method used to 
estimate GFR from a regression equation. The equation is designed for easy use 
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in the clinical setting. The variables included in different equations may vary but 
will usually include steady state serum creatinine and/or cystatin C 
concentrations and demographic details such as weight, age and sex.  
• Cockcroft-Gault equation. The Cockcroft-Gault equation gives an 
estimate of creatinine clearance [34], rather than GFR per se. However, in 
this thesis, it will be referred to generically as “eGFR”. 
D.W. Cockcroft and M.H. Gault developed the equation that bears their 
name as a means of verifying the accuracy of a nomogram which 
predicted creatinine clearance based on serum creatinine, age, sex, and 
weight [34]. The equation was derived by regressing creatinine clearance 
corrected for body weight against age, along with an empirical correction 
for female sex [34]. The equation is given by;  
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶(mL/min) =
(140 − 𝐴𝐴𝑔𝑔𝑒𝑒) × 𝑀𝑀𝑒𝑒𝑠𝑠𝑠𝑠 (in kg) × [0.85 if Female]
72 × 𝑆𝑆𝐶𝐶𝐶𝐶 (mg/dl)
 
Equation 1.1 Cockcroft –Gault equation 
where, 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 is creatinine clearance in mL/min, 𝐴𝐴𝑔𝑔𝑒𝑒 is age in years, 𝑀𝑀𝑒𝑒𝑠𝑠𝑠𝑠 
is body weight in kg, 𝑆𝑆𝐶𝐶𝐶𝐶 is serum creatinine concentration in mg/dl. 
The Cockcroft and Gault equation is commonly used for the estimation of 
creatinine clearance in the clinical setting. It is important to note that the 
Cockcroft-Gault equation has not been calibrated for the isotope dilution 
mass spectrometry (IDMS)-traceable serum creatinine assay, which was 
introduced in 2005 [35]. While some bias might be expected, any impact 
on drug dosing is unclear.  
• Modification of Diet in Renal Disease (MDRD) equation. In 1999, Levey 
and colleagues developed an equation to predict GFR from data collected 
in the Modification of Diet in Renal Disease (MDRD) study involving 1628 
chronic kidney disease patients with serum creatinine concentration, GFR 
measured with 125I-iothalamate, and demographic data. The prediction 
equation was developed by stepwise regression to determine a set of 
variables that jointly predicted GFR [36]. Originally, the MDRD equation 
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included 6-variables [36] and later it was simplified for ease in clinical use 
to include 4-variables only [37]. The MDRD equation was re-estimated to 
align with the IDMS calibrated method for measuring serum creatinine in 
2007 [38]. The IDMS-traceable MDRD equation with 4 variables is given 
below. 
𝑚𝑚𝑚𝑚𝐶𝐶(mL/ min per 1.73 m2)
= 175 × 𝑆𝑆𝐶𝐶𝐶𝐶−1.154 × [𝐴𝐴𝑔𝑔𝑒𝑒]−0.203 × [0.742 if female]
× [1.212 if African American] 
Equation 1.2 Modification of Diet in Renal Disease Study equation 
• Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
Equation. Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation was developed by the Levey and colleagues [39] from a 
pooled data sets including 8254 participants in 10 studies (development 
data set) and 3896 participants in 16 studies (validation data set) with 
diverse clinical characteristics, with and without kidney disease, and a 
wide range of GFR. The serum creatinine values were calibrated to the 
standardized IDMS method for creatinine measurements [39]. The CKD-
EPI equation is expressed as: 
𝑚𝑚𝑚𝑚𝐶𝐶(mL/ min per 1.73 m2)
= 141 × 𝑚𝑚𝑖𝑖𝑛𝑛 (𝑆𝑆𝐶𝐶𝐶𝐶/𝐾𝐾, 1)𝛼𝛼 × 𝑚𝑚𝑒𝑒𝑥𝑥 (𝑆𝑆𝐶𝐶𝐶𝐶/𝐾𝐾, 1)−1.209 × 0.993𝐶𝐶𝐴𝐴𝑒𝑒
× [1.018 if female] × [1.159 if black] 
Equation 1.3 Chronic Kidney Disease Epidemiology Collaboration equation 
where, 𝐾𝐾 is 0.7 for females and 0.9 for males, 𝛼𝛼 is -0.329 for males and -0.411 for 
males, 𝑚𝑚𝑖𝑖𝑛𝑛  indicates the minimum of 𝑆𝑆𝐶𝐶𝐶𝐶/𝐾𝐾  or 1, and 𝑚𝑚𝑒𝑒𝑥𝑥  indicates the 
maximum of 𝑆𝑆𝐶𝐶𝐶𝐶/𝐾𝐾 or 1. 
Note that other eGFR equations like Jelliffe equation [40], Wright equation 
[41] are not discussed in this thesis. Also, equations for estimating GFR in 
paediatrics (e.g. Schwartz equation [42]) are not covered here. 
Measured glomerular filtration rate (mGFR). In this thesis, mGFR refers to GFR 
measured by determining the urinary or plasma clearance of a probe for GFR 
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using a pharmacokinetic experiment. The probes for determining mGFR can be 
exogenous (e.g. iothalamate, 51Cr EDTA, inulin) or endogenous (creatinine when 
used to determine CLcr from 24 hour urine collection). 
mGFR can be determined by estimating the clearance of the GFR probe, 
which is calculated using different pharmacokinetic experiments, as follows; 
• Area under the plasma concentration-time curve. This method requires 
sufficient plasma samples in order to characterise the plasma 
concentration time profile of the compound being used as a probe for GFR 





Equation 1.4 Area under the plasma concentration curve method for 
calculating mGFR. 
where, 𝐷𝐷𝑑𝑑𝑠𝑠𝑒𝑒 is the dose of the probe administered and AUC0−∝ is the area 
under the plasma concentration curve from time zero to infinity. 
• Clearance determined urinary excretion data. This method requires the 
collection of timed urine samples usually over a period of 24-hours and 
blood samples at mid-points of the urine collection periods. The volume 
of urine and concentration of the probe (e.g. creatinine) in plasma and 
urine are used for calculating mGFR [43], as follows; 
𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶 =
𝑈𝑈 ×  𝑉𝑉  
𝑃𝑃  
Equation 1.5 Equation for determining mGFR using urinary excretion 
data  
where, 𝑈𝑈 is the creatinine concentration in the urine sample, 𝑉𝑉 is volume of 
urine during the collection period (i.e. volume/time) and 𝑃𝑃  is average 
creatinine concentration in plasma. 
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The major limitation of using urinary excretion data is that reporting 
of timed urine samples can be inaccurate and obtaining complete urine 
collection is often difficult [11, 44]. 
• Slope-intercept method. The slope-intercept method has traditionally 
been used for calculating mGFR when radioisotopes are used, for 
example 51CrEDTA, 99mTc DTPA [24]. This method requires two to four 
plasma samples from the terminal elimination phase of the radio-isotope 
plasma count-time decay curve [24]. The logarithm of plasma 
concentration is plotted as a function of time and the apparent plasma 
concentration at time equal to zero is determined by linear extrapolation 
of the terminal phase of the plasma concentration time profile [24]. The 
apparent volume of distribution denoted as 𝑉𝑉 is then determined by the 





Equation 1.6 Apparent volume of distribution calculated based on dose 
and apparent plasma concentration at time equal to zero 
where, Dose  is the dose of probe that is administered and 𝐶𝐶0  is the 
extrapolated plasma concentration at time zero. 
The half-life of the probe, denoted as 𝑡𝑡1/2 , is determined from the 
linear elimination phase of the plasma concentration time profile [24]. The 






Equation 1.7 Slope-intercept method for calculating the clearance of a 
probe  
The slope-intercept method is useful and easy but may produce biased 
results if the compound exhibits two-compartment behaviour [45]. 
• mGFR determined using compartmental analysis. A compartmental 
analysis allows for drug movement between hypothetical body 
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compartments to describe the time course of drug concentrations in the 
body. Plasma concentration time profiles are fit to a compartmental model 
for the probe. The estimated clearance parameter for the probe is mGFR.  
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1.2.6. Renal drug handling 
Renal drug handling involves three primary processes; glomerular 
filtration, active tubular secretion, and tubular reabsorption. The renal clearance 
is therefore the net result the amount that is excreted from the body via 
glomerular filtration and tubular secretion minus the amount that is reabsorbed 
back into the body. This can be expressed as: 
𝐶𝐶𝐶𝐶𝑅𝑅 = (𝑓𝑓𝑢𝑢 × GFR) +  𝐶𝐶𝐶𝐶𝑠𝑠𝑒𝑒𝑠𝑠𝐶𝐶𝑒𝑒𝑟𝑟𝑝𝑝𝑟𝑟𝑝𝑝 − 𝐶𝐶𝐶𝐶𝐶𝐶𝑒𝑒𝑟𝑟𝑟𝑟𝑠𝑠𝑟𝑟𝐶𝐶𝑝𝑝𝑟𝑟𝑝𝑝𝑟𝑟𝑝𝑝 
Equation 1.8 Renal drug handling processes involved in renal clearance of a drug 
where, 𝐶𝐶𝐶𝐶𝑅𝑅 is the renal clearance of the drug, 𝑓𝑓𝑢𝑢 is the fraction unbound in the 
plasma, GFR is the glomerular filtration rate, 𝐶𝐶𝐶𝐶𝑠𝑠𝑒𝑒𝑠𝑠𝐶𝐶𝑒𝑒𝑟𝑟𝑝𝑝𝑟𝑟𝑝𝑝 is the tubular secretion 
and 𝐶𝐶𝐶𝐶𝐶𝐶𝑒𝑒𝑟𝑟𝑟𝑟𝑠𝑠𝑟𝑟𝐶𝐶𝑝𝑝𝑟𝑟𝑝𝑝𝑟𝑟𝑝𝑝 is the tubular reabsorption. 
Each of the renal drug handling processes are described below.  
1.2.6.1. Glomerular filtration 
Glomerular filtration is a unidirectional process where the contents of the 
blood are filtered through glomerulus to form a filtrate. The renal blood flow i.e., 
the volume of blood that reaches the kidneys per unit time, is more than 1000 
mL/min, while about 120 mL/min is filtered by the glomerulus [46, 47]. 
Filtration by the glomerulus is the net result of three opposing forces: (1) the 
hydrostatic pressure exerted by the blood in the glomerular capillaries, (2) the 
hydrostatic pressure exerted by the fluid in the Bowman’s capsule, and, (3) the 
osmotic force caused due to the presence of protein in the glomerular capillaries. 
Glomerular filtration is a non-selective process where all molecules with 
molecular weight less than 65,000 Daltons are filtered [48, 49]. The filtrate 
therefore contains essentially low-molecular-weight substances (e.g. calcium, 
fatty acids, many drugs) that are not bound to plasma proteins but not larger 
compounds like proteins and cells [4, 48]. Therefore, the amount filtered through 
glomerulus is determined by the extent of protein binding [46].  
1.2.6.2. Tubular reabsorption 
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Tubular reabsorption is the process by which the filtrate in the tubular 
lumen are partially reabsorbed back into the blood stream. This allows the body 
to recover essential substances like electrolytes, glucose etc. Tubular 
reabsorption can occur either by passive diffusion or mediated transport via 
facilitated diffusion, uniporter, co-transporters/symporters or 
antiporters/exchangers, active transport protein from the lumen to the 
interstitial fluid [46, 47]. Most of the essential components of plasma such as 
water, electrolytes, glucose and other organic nutrients are nearly completely 
reabsorbed [4, 48].  
Reabsorption of drugs usually occurs through passive diffusion as a result 
of difference in concentration between the filtrate and the blood in peritubular 
capillaries [46]. The diffusion process favours non-ionised drugs that can cross 
the lipid bilayer of tubular membranes. Therefore, for the drugs that are weak 
acids or bases, urine pH can greatly influence the extent of their reabsorption 
[46]. 
1.2.6.3. Tubular secretion 
Tubular secretion is the process of excretion of substances in the blood from 
the peritubular capillaries into the tubular lumen. Tubular secretion can occur 
by diffusion or by mediated transport processes mentioned above [46, 47]. 
Hydrogen and potassium ions are the most prominent endogenous substances 
secreted by the renal tubules.  
Tubular secretion usually involves carrier-mediated system so that drugs 
can be transported against a concentration gradient. This process may be 
saturable [46, 47]. Drugs like carbapenems, beta lactam antibiotics, metformin, 
uricosurics, furosemide, and some ACE inhibitors [47, 50, 51] are predominantly 
secreted in renal tubules. 
The tubular reabsorption and/or secretion of many substances are 
controlled by regulating the activity or concentrations of the membrane channels 
and transporters proteins involved in tubular handling. 
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1.2.6.4. Renal transporters 
A brief overview of membrane transporter proteins involved in tubular 
secretion or reabsorption is given below. A more detailed review can be found 
elsewhere [46, 52, 53].  
The membrane transporters involved in renal drug handling are located in 
the basolateral and apical membrane of the tubular epithelium. An active tubular 
secretion of a drug will require a transporter at the basolateral membrane of the 
tubular epithelium and another transporter at the apical membrane to transfer 
the drug into the filtrate in the renal tubule [46]. In some cases, the same 
transporter, but with different variants is involved in active tubular secretion, 
e.g. the secretion of urate by GLUT9/SLC2A9 [54].  
Over 400 membrane transporters are encoded in the human genome, which 
fall under the two gene superfamilies: the ATP-binding cassette (ABC) and 
solute carrier (SLC) [46, 52, 53]. These membrane transporters are further 
categorised into gene families based on similarities in the amino acid sequence. 
The ABC transporters involved in renal drug disposition include P-glycoprotein 
(P-gp/ABCB1) and members of the Multidrug Resistance Associated Protein 
(MRP/ABCC) subfamily [46, 52, 53]. Similarly, the SLC subfamilies involved in 
renal drug handling are SLC22, the organic anion transporting polypeptide 
family OATP/SLCO and multidrug and toxic compound extrusion family 
MATE/SLC47 [46, 52, 53].  
The membrane transporters expressed in the renal tubules from ABC and 
SLC superfamily can be largely categorised based on the charge of the drugs as 
organic cationic transporter (OCT) and organic anionic transporter (OAT), with 
some intersection [46, 52, 53]. Examples of major membrane transporters 
involved in renal handling of drugs are shown in Figure 1.3. 




Figure 1.3 Major drug transporters expressed in human renal tubular epithelium 
1.2.6.5. Models for renal drug handling 
In this thesis, two primary models for renal drug clearance will be used. 
Further details are available in Chapters 3, 4, 5 and 6. 
Model 1 The linear model (M1). Renal drug handling is a complex system 
of interplay between the glomerular filtration, tubular reabsorption and 
secretion. This can be simplified by assuming that each of the three renal drug 
handling process work independent of each other to provide the overall drug 
clearance. This assumes that the three processes are proportional to each other 
across all levels of physiological regulation and pathological impact and aligns 
with the INH, described above. It follows that the three processes can be scaled 
to each other by a proportionality constant term. Considering the model for renal 
clearance as a function of GFR, it can be given by: 
𝐶𝐶𝐶𝐶𝑅𝑅 = 𝜃𝜃1 ∙ GFR 
Equation 1.9 Renal drug clearance as a linear function of GFR 
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where, 𝜃𝜃1 is composite of the unbound drug fraction and the linear coefficients 
describing the proportionality of the non-glomerular processes (secretion and 
reabsorption), and GFR is either mGFR or eGFR.  
This model for renal clearance is widely used in pharmacokinetic 
modelling analyses to explaining renal drug handling. It assumes that there is a 
proportional change in renal clearance with respect to GFR, regardless of how 
the drug is handled in the tubule or how the underlying physiology or pathology 
influences renal drug handling processes.  
Model 2 The non-linear model (M2). A pathological condition may affect 
the drug handling mechanism to different level such that it cannot be 
compensated by the physiological control system. Under this scenario, the 
assumption of the linear model aligning with the INH is violated. A non-
proportional change in tubular processes relative to GFR can be permitted by 
allowing for non-linearity in the model. In the absence of a mechanistic model to 
describe the underlying mechanism, this can be accomplished by using an 
exponent. Then, renal clearance can be expressed as: 
𝐶𝐶𝐶𝐶 = 𝜃𝜃1 ∙ 𝑚𝑚𝑚𝑚𝐶𝐶𝜃𝜃2  
Equation 1.10 Renal drug clearance as a non-linear function of GFR 
where, θ2 is a composite of exponents that describes the divergence of various 
tubular processes from GFR and other parameters are same as described in 
Equation 1.9. This model is equivalent to the model proposed by Wright and 
Duffull [55]. This non-linear model can be considered to be a general model for 
renal drug handling, where the linear model (Equation 1.9) is a special case of 
the non-linear model when the exponent 𝜃𝜃2 is equal to 1. 
In theory, the non-linear model provides an empirical approximation of the 
overall change in renal drug handling profile in renal impairment. The use of an 
exponent to capture any non-linearity in the relationship between renal drug 
clearance and GFR should provide a flexible solution, accounting for drug 
handling that confirms to the INH (linear) as well as to a non-INH (non-linear) 
scenario. However, it is important to note that the non-linear model cannot be 
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used to learn about the underlying mechanism by which renal drug handling is 
influenced by physiological and pathological change in renal impairment.  
  




Benet and Rowland introduced the term “pharmacometrics” in 1982 when 
they announced a new section called Pharmacometrics in the Journal of 
Pharmacokinetics and Biopharmaceutics [56]. Pharmacometrics deals with the 
science of quantifying the complex interplay between biology, physiology, and 
pathophysiology, in subjects (human or animal) taking medicinal agents by 
using mathematical, structural, and statistical models to describe the observed 
pharmacokinetic and pharmacodynamic data. Within the field of 
pharmacometrics there are several subfields including; quantitative systems 
pharmacology, optimal design, physiologically based pharmacokinetics, 
population pharmacokinetics/ pharmacodynamics, and, disease progression 
modelling.  
In the pharmaceutical industry, pharmacometrics plays an important role 
in the analysis of data collected from human studies during drug development, 
and to a lesser extent, data that arises from pre-clinical trials [57]. The analyses 
aid dose selection, inform experimental design for phase 3 studies, assess 
exposure links to efficacy and safety events, and, inform the dosing information 
that will be presented on the drug label [57]. In clinical practice, 
pharmacometrics is focused largely on the optimisation of doses for individual 
patients. This is particularly important for drugs with narrow therapeutic range, 
and in special population (e.g. paediatrics, renal impairment patients, the 
critically unwell etc.). 




In this section, the concept of a mathematical pharmacokinetic model is 
presented in the context of pharmacometric analysis. All pharmacometric 
analysis are based on some form of model to describe the data and, to varying 
degrees, the biological system with which the drug interacts. A compartmental 
pharmacokinetic model is an example of a model in the context of 
pharmacometrics. The compartmental structure does not represent true 
physiological compartments but represent a simplified version of drug 
behaviour within the complex human physiological system. 
A general form of a mathematical model can be defined as: 
𝒀𝒀 = 𝑓𝑓(𝑿𝑿,𝜽𝜽) + 𝜺𝜺 
Equation 1.11 A general form of a mathematical model 
where, 𝒀𝒀 is 𝑛𝑛 × 1 vector of output variable, 𝒇𝒇 is the function that describes the 
relationship between input and output variables, 𝑿𝑿 is a 𝑛𝑛 × 𝑝𝑝 matrix of input 
variable, 𝜽𝜽 is 𝑝𝑝 × 1 vector of model parameters and 𝜺𝜺 is 𝑛𝑛 × 1 vector of residual 
error. Note that in this thesis, the vectors and matrices are written in capital and 
bold font. 
In this thesis, only population pharmacokinetic models will be considered. 
Population pharmacokinetic models allow us to quantify the time course of drug 
concentrations, the variability in drug dose-concentration relationship between 
subjects, and the random unexplained variability within a subject. A population 
pharmacokinetic model is therefore based on a hierarchical structure with three 
layers:  
1) A structural model to describe the time course of drug concentrations 
(pharmacokinetic model), 
2) A statistical model for uncertainty in drug concentration measurements 
(RUV),  
3) A statistical model for variability between subjects (BSV). 
These hierarchical models are described below. 
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1.3.1.1. A structural model to describe the time course of drug concentrations 
(pharmacokinetic model) 
Pharmacokinetics is the science that deals with the relationship between 
the administered dose of a drug and the concentration-time profile in the body. 
The underlying processes that drive the time course of drug concentrations are 
absorption, distribution, metabolism and elimination. These processes can be 
captured using a model where the parameters are unknown constants that 
describe the pharmacokinetics. A typical pharmacokinetic model can be 
represented as: 
𝑦𝑦 = 𝑓𝑓𝑃𝑃𝑃𝑃(𝐷𝐷, 𝑡𝑡,𝜽𝜽𝑷𝑷𝑷𝑷) 
Equation 1.12 A general mathematical form of a pharmacokinetic model 
where, 𝑦𝑦 is the plasma drug concentration as a function, 𝑓𝑓𝑃𝑃𝑃𝑃 , of administered 
dose of drug, 𝐷𝐷, time, 𝑡𝑡, and a 𝑝𝑝 × 1 vector of pharmacokinetic parameters, 𝜽𝜽𝑷𝑷𝑷𝑷. 
For a pharmacokinetic model, the primary pharmacokinetic parameters 
include clearance (𝐶𝐶𝐶𝐶), volume of distribution (𝑉𝑉), absorption rate constant (𝑘𝑘𝑟𝑟), 
bioavailability (𝑚𝑚), and the derived parameter, the elimination rate constant (𝑘𝑘𝑒𝑒) 
(the ratio of 𝐶𝐶𝐶𝐶 to 𝑉𝑉). 𝐶𝐶𝐶𝐶 is a proportionality constant that is defined as the ratio 
of the rate of drug elimination to the steady-state average plasma drug 
concentration. 𝑉𝑉 is an apparent volume that gives information on distribution of 
drug in the body and is determined by body size, body composition, protein 
binding and the lipophilicity of the drug. 𝑘𝑘𝑟𝑟 is a rate of drug absorption and 𝑚𝑚 is 
a fraction of drug that is reaches the systemic circulation. 
A pharmacokinetic model can be built using a compartmental structure. 
Here, a group of tissues or organs are lumped to form a compartment where they 
have similar blood flow and fat content and partitioning of a drug of interest 
between them is considered to be homogeneous. Links between the 
compartments represent the blood or lymphatic circulation and transfer of a dug 
between compartments are characterised by transfer rate constants and defined 
by mass balance differential equations. Each compartment is characterised by its 
own volume and drug concentration are proportional to the dose of drug. 
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Compartments, their volumes and rate constants do not have a direct anatomical 
or physiological significance. 
The simplest pharmacokinetic model is a one compartment model with 
first order absorption and elimination. A schematic representation of a one- and 
two-compartment pharmacokinetic model is shown in Figure 1.4. The human 
body is represented as a series of discrete compartmental units from which drug 
is absorbed, distributed into and ultimately eliminated. It is assumed that the 
drug behaviour is similar within each compartment. In a one compartment 
model (Figure 1.4 (a)), the drug is assumed to be distributed homogenously and 
instantaneously within a single compartment. For this model, a typical drug 
concentration time profile is characterised by a mono-exponential decline in 
drug concentration in the elimination phase. A plot of drug concentration and 
time data on semi-logarithmic scale (y-axis is the natural log) will produce 
straight line. In a two-compartment model (Figure 1.4 (b)), the drug is assumed 
to be distributed in an additional peripheral compartment. A typical drug 
concentration profile from a two-compartment model is characterised by a 
biphasic-exponential decline in drug concentration. A semi-log plot of the drug 
concentration time profile shows two distinct linear phases. 
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Figure 1.4 A schematic representation of (a) a one-compartment pharmacokinetic 
model and (b) a two-compartment pharmacokinetic model for an orally 
administered drug with first-order absorption and elimination. 
The time course of drug concentrations for a one compartment model can 




= −𝑘𝑘𝑟𝑟 ∙ 𝐴𝐴1; at 𝑡𝑡 = 0,𝐴𝐴1 = 𝑚𝑚 ∙ 𝐷𝐷 
𝑑𝑑𝐴𝐴2
𝑑𝑑𝑡𝑡






;  at 𝑡𝑡 = 0,𝐴𝐴2 = 0 
Equation 1.13 Ordinary differential equations for one compartment 





 are the rate of change in amount of drug at the absorption 
compartment, and central compartment, respectively, over time, 𝑡𝑡 . 𝑘𝑘𝑟𝑟  is 
absorption rate constant, and 𝑘𝑘𝑒𝑒 is elimination rate constant. The initial condition 
at t = 0 for depot compartment is dose (D) and that for central compartment is 
zero. 
The system of ordinary differential equation given in Equation 1.13 can be 
solved to get a value of drug concentration (𝐶𝐶) at a given time. 
𝐶𝐶 =
𝑚𝑚 ∙ 𝐷𝐷 ∙ 𝑘𝑘𝑟𝑟
𝑉𝑉 ∙ (𝑘𝑘𝑟𝑟 − 𝑘𝑘𝑒𝑒)
∙ �𝑒𝑒(−𝑘𝑘𝑎𝑎∙𝑟𝑟) − 𝑒𝑒(−𝑘𝑘𝑎𝑎∙𝑟𝑟)� 
Equation 1.14 The equation for a one compartment pharmacokinetic model with 
first order absorption and elimination 
1.3.1.2. Statistical models for uncertainty in drug concentration measurements 
(RUV) 
A statistical model is included in a population pharmacokinetic model to 
describe the deviation of the model-predicted drug concentrations from the 
observed concentrations. This is often termed residual unexplained variability 
(RUV) and may occur due to multiple reasons including assay error, errors in 
dosing or sample collection time, and model misspecification. Commonly used 
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residual error model include additive residual error, proportional error and 
combined additive and proportional residual error. 
A general form of model with residual error for an individual can be 
expressed as: 
𝒚𝒚𝒋𝒋 = 𝒇𝒇𝑷𝑷𝑷𝑷�𝐷𝐷, 𝒕𝒕𝒋𝒋,𝜽𝜽𝑷𝑷𝑷𝑷� + 𝜺𝜺𝒋𝒋 
Equation 1.15 A general form of a model with residual error 
where, the statistical model for uncertainty gives prediction of the 𝑗𝑗𝑟𝑟ℎ  ( 𝑗𝑗 =
1, … , 𝑛𝑛 ) observation (e.g. drug concentration) denoted by 𝒚𝒚𝒋𝒋  as a function, 
𝒇𝒇𝑷𝑷𝑷𝑷 ( 𝜂𝜂𝑝𝑝 × 1 ), of administered dose, 𝐷𝐷 , time, 𝒕𝒕𝒋𝒋 ( 𝜂𝜂𝑝𝑝 × 1 ), vector of the 
pharmacokinetic parameters, 𝜽𝜽𝑷𝑷𝑷𝑷(𝑝𝑝 × 1), and vector of the residual errors, 𝜺𝜺𝒋𝒋. 
Here, the 𝑗𝑗𝑟𝑟ℎ  observation deviates from the model prediction by 𝜺𝜺𝒋𝒋 , which is 
assumed to be normally distributed with mean equal to zero and variance equal 
to 𝜎𝜎2; 
𝜺𝜺𝒋𝒋~𝑁𝑁(0,𝜎𝜎2) 
Equation 1.16 Distribution of residual error 
1.3.1.3. Statistical models for variability between subjects (BSV) 
A model to account for some of the (predictable) variability in the 
parameters between individuals is often termed between subject variability 
(BSV), inter-individual variability (IIV) or population parameter variability 
(PPV). One of the main goals of population pharmacokinetic modelling is to 
explore and establish the relationship between pharmacokinetic parameters of 
interest and covariates (e.g. age, sex, weight, renal function, liver enzyme). Some 
of the BSV can be accounted for by including covariates and thus provide a 
means for individualising dose based on subject-specific covariates.  
A general form of population pharmacokinetic model for repeated 
measured in a group of individuals can be expressed as: 
𝒚𝒚𝒊𝒊𝒋𝒋 = 𝒇𝒇𝑷𝑷𝑷𝑷�𝑫𝑫𝒊𝒊, 𝒕𝒕𝒊𝒊𝒋𝒋,𝜽𝜽𝑷𝑷𝑷𝑷;𝜼𝜼𝒊𝒊� + 𝜺𝜺𝒊𝒊𝒋𝒋 
Equation 1.17 A general form of a population model with between subject 
variability and residual error 
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where, the population model gives predictions of the jth (j = 1,…,ni) observed 
concentration for ith individual (i = 1,…, N) denoted by 𝒚𝒚𝒊𝒊𝒋𝒋 as a function, 𝒇𝒇𝑷𝑷𝑷𝑷 
(𝜂𝜂𝑝𝑝 × 1), of administered dose, 𝑫𝑫𝒊𝒊, time, 𝒕𝒕𝒊𝒊𝒋𝒋(𝜂𝜂𝑝𝑝 × 1), vector of the pharmacokinetic 
parameters, 𝜽𝜽𝑷𝑷𝑷𝑷  ( 𝑝𝑝 × 1 ), vector of the difference between the parameter 
estimates, 𝜼𝜼𝒊𝒊(𝑝𝑝 × 1), and vector of the residual errors, 𝜺𝜺𝒊𝒊𝒋𝒋. The distribution of 𝜼𝜼𝒊𝒊 
for the study population is generally assumed to be normally distributed with 
mean equal to zero and variance-covariance matrix given by 𝛀𝛀 (𝑝𝑝 × 𝑝𝑝). 
𝜼𝜼𝒊𝒊~𝑁𝑁(0,𝛀𝛀) 






Equation 1.19 Variance-covariance matrix 
The diagonal elements of 𝛀𝛀  gives between subject variances in the 
pharmacokinetic parameters and the off-diagonal elements of 𝛀𝛀  gives the 
covariance between the corresponding variance terms. 
Because physiological parameters naturally have a lower boundary of zero, each 
element of 𝜽𝜽𝑷𝑷𝑷𝑷  is usually assumed to follow a log-linear distribution and an 
exponential model is used to describe BSV (Equation 1.20). 
𝜽𝜽𝑷𝑷𝑷𝑷 = 𝜃𝜃 ⋅ 𝑒𝑒η𝒊𝒊 
Equation 1.20 A general form of exponential model for pharmacokinetic 
parameter 
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1.3.2. Modelling  
‘Modelling’, the verb, refers to the process of fitting a model to data. This is 
distinguished from a ‘model’ (described above) which is simply a mathematical 
representation of the data.  
Standard pharmacokinetic analyses can be performed in two stages. This is 
a simple form of population modelling. In the first stage, the individual 
pharmacokinetic parameters are estimated. In the second stage, mean 
(arithmetic or geometric) and variances of the parameters are calculated to infer 
about the population parameters. This is called the “two-stage” approach [58]. 
Using this method, the BSV is generally overestimated, being a mix of BSV and 
RUV, especially when only sparse data is available [58, 59]. Additionally, with 
this approach each individual contributes equally to the estimation of the 
population estimates, which makes it less suitable where all individuals do not 
provide the same amount of information (e.g. unbalanced study design) [58]. 
1.3.2.1. Non-linear mixed effects modelling 
A brief introduction to the non-linear mixed effects modelling in the context 
of modelling pharmacokinetic data is given below. A detailed description of the 
technical aspects of non-linear mixed effects modelling can be found in several 
textbooks and papers, including; Bonate [60], Davidian and Gilintan [61], Bauer 
[62, 63]. Non-linear mixed effects modelling allows for the estimation of the 
typical values for the parameters in a population and the BSV and RUV variance 
terms simultaneously for the study population. This modelling approach is also 
referred to as population pharmacokinetic approach. This approach uses both 
fixed effects and random effects, thus the designation ‘mixed effects’. The fixed 
effects are the structural parameters of the model (e.g. mean 𝐶𝐶𝐶𝐶 in a population) 
and the random effect are the variance terms (e.g. BSV for CL in a population, 
RUV in measurement of drug concentration). An advantage of this modelling 
approach is that sparse data and unbalanced study designs can potentially be 
accommodated (albeit with limitations, see Siripuram et al. [64]). 
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Similar to all regression models, the non-linear mixed effects modelling 
intends to describe a dependent variable (e.g. observed concentration) as a 
function of the independent variable (e.g. time). The difference is that the non-
linear mixed effects modelling can estimate the mean parameters of individuals 
in a population by partitioning the total variability into its different sources e.g. 
between-subject, within-subject, residual etc. The parameter estimation for non-
linear mixed effects modelling involves the computation of the likelihood of the 
observed data given the structural and variance models [65]. The integral for the 
expectation and variance of the likelihood do not have closed from solutions for 
a non-linear mixed effects model [65]. This is because 1) the random effects 
parameters 𝜀𝜀 and 𝜂𝜂 are not independent i.e., the estimate of 𝜀𝜀 depends on the 
estimate of 𝜂𝜂  and 2) the non-linearity of the structural model (e.g., drug 
concentration is described by a non-linear model Equation 1.14) [65]. 
Global fit of the model to the data is described by the objective function 
value [66]. This value is analogous to the sum of squares statistics and lower 
values represent a better fit. Two nested pharmacokinetic models can be 
compared using a statistical test called the log-likelihood ratio test. This test 
compares nested models using difference between their objective function 
values (OFV). The difference is asymptotically chi-squared distributed with a 
degree of freedom equal to the difference in the number of parameters between 
the two models. Therefore, a reduction in OFV by more than 3.84 for one added 
parameter represents a statistically significant improvement in model fit (p < 
0.05). The log-likelihood ratio test is not valid if following conditions are not 
fulfilled [67-69]: 
• model under the null hypothesis is nested within the alternative 
model 
• models are identifiable 
• log-likelihood ratio test statistic under the alternative model is 
asymptotically chi-squared distributed 
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Local fit of the model to the data is described by the standard error of the 
estimated parameters. It can be used to determine the significance of the 
parameters that describes the model. It is important to note that the global fit and 
local fit may not always agree, where global fit is generally preferred [70]. 
Several non-linear mixed effects modelling software are available, among 
which NONMEM® is most commonly used by pharmacometricians. 
NONMEM® was developed by Lewis Sheiner and Stuart Beal [71]. This software 
was used to analyse data for Chapter 3, 4, 5 and 6. NONMEM® uses a maximum 
likelihood estimation approach to estimate the population mean parameters, 
BSV and RUV simultaneously. The first method proposed by Sheiner and Beal 
[71] was the first-order (FO) method for approximating the likelihood in 
NONMEM®. This method transforms the non-linear mixed effects model into a 
linear mixed effects model using a first-order Taylor series approximation about 
𝜼𝜼𝒊𝒊 = 0 and then estimates the model parameters based on the linearised model. 
The first-order conditional estimation (FOCE) method basically uses similar 
principle, where the approximation is conditional around estimate of 𝜼𝜼 and the 
empirical Bayes estimates (EBEs) is estimated at each iteration. The FOCE 
method with interaction (FOCE-I) has an interaction term for heteroscedastic 
error models that allows interaction between 𝜼𝜼 and 𝜺𝜺. The Laplacian method 
uses a second order Taylor series approximation with respect to the conditional 
estimates of 𝜼𝜼 [60, 72]. 
The FO method was used in Chapter 4, 5 and 6 for the linear model with 
only one level of variability. This method is not commonly used currently. The 
FOCE-I method is generally used for non-linear mixed effects modelling, which 
was also used in Chapter 3. The Laplacian method is used for categorical data. 
This method is used in Chapter 3 for implementing “M3” method for handling 
below limit of quantification data.  
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1.4. Study design 
A brief, non-technical, introduction of study design in the context of clinical 
pharmacological studies is given in this section. Further details concerning the 
statistical underpinnings of study design research can be found in Atkinson and 
Donev [73], and Foo and Duffull [74]. 
Study design is the formulation of experiments that encompasses the sets 
of methods and procedures used to collect and analyse data. A well-designed 
study maximises the ability to address the given research question. The design 
of any study is more important than using the appropriate statistical analysis 
methods. Data from a well-designed study can be reanalysed using an 
appropriate statistical method to answer the research question, while bias 
(inaccuracy) and large variability (imprecision) resulting from a poorly designed 
study cannot be amended. In this thesis, study design for a typical phase I renal 
drug studies recommended by the Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) were explored for the purpose of testing the 
INH. A detailed review of the designs for the renal drug studies recommended 
by the regulatory agencies is provided in Chapter 4. 
The objective of a pharmacokinetic study is to set up an efficient and 
successful experiment to describe and predict the time course of drug 
concentrations. An efficient study optimises the balance between information to 
be gathered from a study and resources available for conducting a study. In 
practice, there is always some study constrains (e.g. number of samples collected 
from a single patient, value of GFR in enrolled subject etc.) and limit in available 
resources (e.g. number of subjects enrolled, duration of study etc.). So, the 
methods that optimises the efficiency of the design of experiments have practical 
relevance. The optimal design techniques are generally used to optimise the 
pharmacokinetic and/ or pharmacodynamics study [74, 75]. In this thesis, the 
optimal design techniques were used to explore the minimum conditions for a 
study design intended to test the INH. The theory and criteria for constructing 
optimal design will be described in Chapter 5. 
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The following two chapters explore the intact nephron hypothesis (INH) as 
a model for renal drug handling. The hypothesis proposed in Section 1.1 is that 
the INH will not be a suitable model for renal drug handling for those agents 
cleared mainly by tubular section. In this setting, two falsifiable predictions were 
suggested; 1) that the relationship between GFR and tubular clearance will be 
non-linear, and 2) that the study designs will be important for detecting this 
relationship. Chapter 2 explores the evidence-base in the published literature 
that either supports or does not support the INH as a model for renal drug 
handling. Additionally, the study designs of the reviewed studies were 
evaluated. Chapter 3 analyses the relationship between GFR and tubular 
function using probes from a published renal drug handling study in order to 
test the INH. The overarching goal of Chapters 2 and 3 was to determine if there 
is sufficient evidence to support the INH as a general model for renal drug 
handling. 
2.1. Introduction 
The INH is a widely accepted model for renal impairment. Under the INH, 
the smallest functional unit of the kidney is the nephron, where each nephron is 
either fully functional (intact) or non-functional (lost) [1]. Renal impairment 
occurs when there is a progressive loss of intact nephrons and compensatory 
mechanisms within the residual nephrons can no longer maintain homeostasis 
[1]. In practical terms, this suggests that significant damage to any region of the 
nephron results in a total loss of that nephron.  
Renal drug handling of drug involves three processes in the nephron: 
glomerular filtration, tubular secretion and tubular reabsorption. Total renal 
clearance is therefore be given by; 
𝐶𝐶𝐶𝐶𝑅𝑅,𝑎𝑎𝐶𝐶𝑢𝑢𝐴𝐴  =  (𝑓𝑓𝑢𝑢 × 𝑚𝑚𝑚𝑚𝐶𝐶) + 𝐶𝐶𝐶𝐶𝑠𝑠𝑒𝑒𝑠𝑠𝐶𝐶𝑒𝑒𝑟𝑟𝑝𝑝𝑟𝑟𝑝𝑝 + (−𝐶𝐶𝐶𝐶𝐶𝐶𝑒𝑒𝑟𝑟𝑟𝑟𝑠𝑠𝑟𝑟𝐶𝐶𝑝𝑝𝑟𝑟𝑝𝑝𝑟𝑟𝑝𝑝) 
Equation 2.1 Renal drug handling processes involved in renal clearance of a 
drug 
where, 𝐶𝐶𝐶𝐶𝑅𝑅,𝑎𝑎𝐶𝐶𝑢𝑢𝐴𝐴 is the renal clearance of the drug, 𝑓𝑓𝑢𝑢 is the fraction unbound in 
the plasma, 𝑚𝑚𝑚𝑚𝐶𝐶 is the glomerular filtration rate, 𝐶𝐶𝐶𝐶𝑠𝑠𝑒𝑒𝑠𝑠𝐶𝐶𝑒𝑒𝑟𝑟𝑝𝑝𝑟𝑟𝑝𝑝 is tubular clearance 
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and 𝐶𝐶𝐶𝐶𝐶𝐶𝑒𝑒𝑟𝑟𝑟𝑟𝑠𝑠𝑟𝑟𝐶𝐶𝑝𝑝𝑟𝑟𝑝𝑝𝑟𝑟𝑝𝑝  is tubular reabsorption. Based on the INH, all three of the 
processes are assumed to decline at an equal rate in the setting of renal 
dysfunction. Therefore, for drugs that are mainly cleared by the kidneys with 
linear pharmacokinetics, dose adjustment in renal impairment will usually be 
based on the assumption that renal clearance, and hence the maintenance dose 
rate, is a linear relationship with GFR. Here, the contribution of tubular secretion 
is not accounted for and dose adjustment is solely guided by an estimate of GFR. 
The simple notion that a linear relationship exists between renal drug 
clearance and GFR has not been consistently demonstrated in the literature. 
Much of the evidence generated from renal drug studies, where clearance and 
GFR are often regressed to show linearity, use creatinine clearance to estimate 
GFR. Creatinine, itself, undergoes tubular secretion, an elimination pathway that 
becomes more important as renal function declines [76]. This would be expected 
to confound the true relationship between drug clearance and GFR. In addition, 
recent evidence [55, 77] as well as earlier works [78-80], suggests that GFR may 
not correlate with changes in renal drug handling, particularly for drugs that 
undergo extensive tubular secretion.  
2.2. Aims 
To date, the evidence-base to support the INH as a model for renal drug 
handling has not been reviewed. The aims of this chapter are to 1) systematically 
review published studies designed to test the INH, and 2) evaluate the study 
designs employed quantitatively and qualitatively using a bespoke strength of 
evidence score. 




2.3.1. Literature search 
A comprehensive literature search was conducted in MEDLINE (Ovid 
MEDLINE(R) 1946 to Present with Daily Update; 1946-May 2017), EMBASE 
(EMBASE Classic+EMABSE; 1947-May 2017) and Google Scholar (1947-May 
2017). Two search strategies were employed; a ‘static’ search and a learning-
based approach [81]. The ‘static’ search was conducted in MEDLINE and 
EMBASE using MeSH terms “chronic disease”, “glomerulonephritis”, 
“nephritis”, “nephron” (in MEDLINE); “biological model”, 
“glomerulonephritis”, “kidney”, “nomenclature”, “pathophysiology” (in 
EMBASE) and keywords “intact nephron hypothesis” and “whole nephron 
hypothesis”. The details of the learning-based approach have been published 
elsewhere [81]. In brief, it involved an iterative process where relevant MeSH 
terms were extracted from an index study (in this case Bricker et al. [1]) and 
searched. The studies found in the first iteration of the search were then mined 
for additional MeSH terms and the process repeated until no new unique MeSH 
term were identified. The identified MeSH terms and number of studies found 
in the learning-based approach are summarised in Appendix A1.1 (Table A1.1). 
Relevant review papers were mined for additional studies. A citation search was 
also conducted in Google Scholar to identify publications including a citation for 
the index article by Bricker et al [1].  
2.3.2. Study selection criteria 
Studies were included if they were; 1) published in a peer-review journal, 
and, 2) compared relative changes in glomerular and tubular function across 
different levels of renal function in human studies, animal models, or ex vivo. 
Studies were excluded if they; 1) were published in a language other than 
English, 2) were not related to the INH, or, 3) did not include data suitable for 
extraction. Review papers, textbooks and commentaries were also excluded. The 
studies were initially screened for inclusion/ exclusion based on the title and 
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abstract. The remaining studies were subjected to a full text review and further 
assessed for eligibility.  
Only studies that were specifically designed to understand the relationship 
between glomerular and tubular function were included. Pharmacokinetic 
studies designed to inform drug dosing in renal dysfunction were not included 
in this review. 
Screening and study selection were conducted by the thesis author (S.P.). 
The excluded studies were reviewed by a thesis supervisor as a quality assurance 
procedure. Any discrepancies were resolved by the other thesis supervisor.  
2.3.3. Data extraction 
The following information was extracted from each study; 1) support (or 
not) for the INH (see definitions below), 2) the method used to estimate or 
measure GFR including the GFR probe, 3) details of the probes used to measure 
tubular function, 4) the number of human subjects or animals included in the 
study, and, 5) the range of GFR values studied. For (4) and (5) above, either 
individual or summary data were extracted (graphical data were digitally 
extracted using WebPlotDigitizer [82]).  
Studies were deemed to support the INH when the analysis failed to reject 
the null hypothesis, i.e. that the decline in renal drug handling processes (GFR, 
tubular reabsorption and tubular secretion) occurred at an equal rate in renal 
dysfunction. Studies were deemed to have rejected the INH if their analysis 
yielded a p-value of less than their pre-defined alpha-error value (assumed to be 
0.05 if not provided for the three renal handing processes not being 
proportional). 
Data extraction from the included studies was done by the thesis author 
(S.P.). The extracted data was checked by a thesis supervisor and disagreements 
were resolved by discussion. If no agreement was reached, it was resolved by 
the other thesis supervisor. 
2.3.4. Bespoke strength of evidence score  
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A bespoke strength of evidence score was developed to assess elements of 
the study designs used in the published literature. The score evaluated four 
study design features; 1) measurement of GFR, 2) measurement of tubular 
function, 3) sample size, and, 4) GFR range. The score could range from -2 to 8. 
Details of the scoring system are summarised in in Table 2.1. 
Table 2.1 Bespoke strength of evidence score 
 
Bespoke strength of evidence score Score 
1 Measure of GFR 
 
 eGFR 0  
mGFR method using creatinine  1  
mGFR method using radioisotopes or other probes only 
filtered through glomerulus 
2 
2 Measure of tubular processes 
 
 
Single probe (secretion or reabsorption) 1  
Two or more probes (secretion and/or reabsorption) 2 
3 Sample size 
 
 
Less than the sample size mentioned below 0  
Human (n ≥ 30) 2  
Animals (Dog, Rat) (n ≥ 8) 2 
4 Range of GFR values included 
 
 
Plasma data only: 
(GFR values covering all three CKD groups and 
continuous data with at least 25% of data from each of 
group I and III) 
2 
 
Plasma + Urine data: 
(GFR values covering two groups with at least 25% of 
data from each of group I and III) 
2 
 
Data not fulfilling above criteria -2  
Minimum score -2 
 
Maximum score 8 
eGFR, estimated glomerular filtration rate, GFR, glomerular filtration rate, group I, eGFR category G1 and G2 (≥60 
mL/min/1.73 m2); group III, eGFR category G4 and G5 (≤29 mL/min/1.73 m2; patients on renal replacement therapy 
or transplantation excluded); mGFR, measured glomerular filtration rate; n, sample size
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Each of the study design features covered by the bespoke strength of 
evidence score are discussed below: 
2.3.4.1. Measurement of GFR 
As noted in Section 1.2.5.2 of Chapter 1, eGFR is defined as an estimated 
GFR determined using a creatinine or cystatin C-based equation such as the 
Cockcroft-Gault equation [34], the MDRD equation [36], or the CKD-EPI 
equation [83]. mGFR is defined as either; 1) a pharmacokinetic experiment 
involving the administration of an exogenous probe for glomerular filtration 
(e.g. a radioisotope, inulin, sinistrin) or 2) a pharmacokinetic experiment using 
an endogenous probe for glomerular filtration (e.g. creatinine) where renal 
clearance is determined using urinary excretion data (e.g. 24 hour urine 
collection). In the strength of evidence score, studies that used eGFR were scored 
lower than mGFR since eGFR is considered to be less accurate [84]. The studies 
which measured creatinine clearance using 24 hour urine data were assigned a 
lower score than those using exogenous probes (e.g. radioisotopes, inulin, 
sinistrin). This was to account for the possible confounding effects of tubular 
creatinine handling [76].  
2.3.4.2. Measurement of tubular function 
A higher weighting was assigned to those studies that used multiple probes 
to assess tubular function, particularly if they included probes for both cationic 
and anionic secretory processes. Para-aminohippurate (PAH) is a commonly 
used probe in renal handling studies [85]. It can used at different doses to assess 
renal blood flow (low dose protocol) or at higher doses to assess tubular function 
(high dose protocol). Both protocols were assumed to provide a reasonable 
measure of tubular function and were weighted equally. 
2.3.4.3. Sample size 
The maximum score was assigned for human studies that included n≥30 
participants. This was based on the European Medicines Agency guidance for 
Phase I pharmacokinetic studies in renal patients [86]. For animal studies, the 
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maximum score for sample size was assigned if the study included n≥8 animals. 
This was based on the assumption that the between-subject variability in 
pharmacokinetic parameters for various animal species (e.g. dogs, rats) are 
typically lower than in humans. For example, the between subject 
variability(quantified as the coefficient of variation (CV%)) for clearance has 
been found to be 9% for dogs [87] and 12% for rats [88] compared to humans, 
which is typically about 40% [89]. For the purpose of this analysis, between 
subject variability in animals was assumed to be about half of that in humans. 
The sample size required would therefore be four times less than that required 
for human studies. Studies with a sample size that were less than the designated 
sample size cut off for humans and animals were given a null score. 
2.3.4.4. GFR range  
For studies in humans, renal function was divided into three categories 
based on the Kidney Disease Improving Global Outcomes guideline (which 
recommends the use of the CKD-EPI equation [39]) for chronic kidney disease 
(CKD) to estimate the eGFR value [7];  
Group I: eGFR category G1 and G2 (≥60 mL/min/1.73 m2),  
Group II: eGFR category G3a and G3b (30-59 mL/min/1.73 m2), and,  
Group III: eGFR category G4 and G5 (≤29 mL/min/1.73 m2; patients on 
renal replacement therapy or transplantation excluded) 
For studies where eGFR was not estimated using the CKD-EPI equation 
[39] any estimate of GFR (eGFR or mGFR) reported in the study was used for the 
allocation to the GFR groups. Summary GFR estimates were extracted verbatim 
regardless of body size normalisation (e.g. normalised to 1.73m2 body surface 
area (BSA) or body weight). Where individual level data were reported, 
including GFR estimates, weight or BSA, the GFR values were normalised to 
body size (BSA for humans; body weight for animals) before allocation to the 
renal function groups. For studies in animals, mGFR was the only GFR estimate 
reported. This was grouped based on the usual classification of renal impairment 
for each animal species from published studies [78, 90, 91].  
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The allocation of eGFR to each CKD group was determined for humans 
relative to the normal adult human GFR of about 120 mL/min/1.73m2. For 
example, for humans, group I included GFR ≥ 60 mL/min/1.73 m2, which is 50% 
of the normal adult human GFR. Similarly, for rats and dogs, group I included ≥ 
5 mL/min/kg and 1 mL/min/kg, respectively, which is 50% of the normal rat 
and dog GFR of 10 mL/min/kg [78, 91] and 2 mL/min/kg [90], respectively. 
Studies with an even distribution of subjects within each renal function 
group, or that included subjects at the extremes of renal function (groups I and 
III) were assumed to constitute a strong study design and were weighted 
accordingly. In addition, the scoring accounted for studies that used only the 
plasma concentrations of probes versus those that measured both plasma and 
urine concentrations (the latter was considered to be a stronger study design). 
The details are as follows; 
• In studies where GFR was measured using only the plasma 
concentrations of a probe, a higher weighting was assigned if GFR 
measurements were equally distributed over all three groups and at 
least 25% of the data were in groups I and 25% in group III.  
• For those studies where GFR was measured using both plasma and 
urine probe data, a higher weighting was assigned if GFR 
measurements included groups I and III, and at least 25% of the data 
in group I and 25% in group III.  
2.3.5. Data analysis 
The median strength of evidence score for each of the four study design 
components (GFR, tubular processes, samples size and GFR range) as well as for 
the total score was determined for the group of studies that supported the INH 
and for those that did not. The total strength of evidence score and the four 
individual components were separately compared between the groups. This was 
done using a non-parametric Mann Whitney U test (p = 0.05 two-tailed, for 
significance) implemented in R (v3.4.0, The R Foundation). 




A total of 2,996 studies were identified. After removing duplicates, the titles 
and abstracts of the remaining 2,878 studies were screened for 
inclusion/exclusion criteria. The following papers were excluded; n = 53 were 
not in English, n = 3 appeared in non-peer-reviewed journals, n = 421 were 
review papers, textbooks or commentaries, and n = 2,141 did not present 
research assessing the relationship between glomerular and tubular function. 
The remaining 229 studies were subjected to a full text review and further 
assessed for eligibility. Of these, n = 165 were found to present research 
unrelated to the INH and n = 34 did not present data suitable for extraction. The 
remaining thirty studies constituted the final analysis dataset and were subjected 
to data extraction.  
A flow diagram of the study identification process is presented in Figure 
2.1. Most of the eligible studies involved animal models (n=19) [1, 78-80, 92-105]. 
Ten studies involved human subjects with different levels of kidney function [77, 
106-114]. One study explored the INH using a mathematical model [115]. It was 
not possible to define a summary effect size for the studies, therefore a meta-
analysis was not performed.  




Figure 2.1 Flow diagram for the identification of studies assessing the intact 
nephron hypothesis. a ‘Other approaches’ includes mining of relevant articles for 
































(n = 2878) 
Did not meet inclusion 
 Records excluded  
(n = 2649) 
Full-text articles assessed 
for inclusion/exclusion 
criteria (n = 229) 
Studies included in study 
design assessment  
 (n = 30) 
Static search 
strategy  
(n = 184) 
Learning based 
approach  
(n = 2117) 
Other approachesa 
(n = 695) 
Full-text articles excluded  
(n = 199): 
• Not subject of interest  
(n = 142) 
• Not enough data/method 
(n = 28) 
• Not outcome of interest  
(n = 23) 
• Inadequate study design  
(n = 6) 
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2.4.1. Studies that support the intact nephron hypothesis 
Of the thirty studies reviewed, six supported the INH [1, 92-95, 113]. A 
summary of the studies is presented in Table 2.2. Five studies involved animal 
models [1, 92-95] and one involved human subjects [113]. In the animal studies, 
kidney dysfunction was induced experimentally either by injecting nephrotoxic 
substances, anti-kidney serum, or pathogenic bacteria into the kidney tissue or 
by partial or complete nephrectomy [1, 92-95]. Studies reported mGFR measures 
using inulin [94, 95], creatinine [92, 93] or both [1, 113] as probe of GFR. All of 
the studies used PAH as probe to assess tubular function either as effective renal 
plasma flow (ERPF) [1], maximum renal tubular PAH secretion rate (𝑇𝑇𝑚𝑚𝑃𝑃𝐶𝐶𝑃𝑃) [93, 
113] or clearance of PAH (𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃) [92-95].  
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Table 2.2 Summary of studies supporting the intact nephron hypothesis 
Study 
[reference] Population (n) Renal failure model GFR measure 
Tubular function 
measure Key observations 
Bricker et al. 
1960 [1] 






Measured ERPF Comparable ratios of GFR and ERPF, 
and GFR and TmPAH intact and diseased 
kidney irrespective of the underlying 
renal disease. 










Measured CLPAH Similar increase in CLCr(ex) (69.8%) and 
CLPAH (66.5%) in pyelonephritic kidney 
after removal of intact kidney. 
Dontas et al. 
1972 [113] 




Measured TmPAH Change in TmPAH occurs in parallel with 
similar changes in GFR, so that 
TmPAH/CLIn ratios remain constant. 










CLCr(ex)/CLPAH for intact (0.25) and 
disease (0.31) kidneys (p <0.05); 
TmPAH/GFR for intact (18.9 mg per 
100mL) and disease (19.7 mg per 
100mL) kidneys; both were nearly equal. 




Isotonic Ringer's solution 
perfusion 
Measured CLIn Measured TPAH Parallel relationship between CLPAH by 
single proximal convolution and CLIn by 
single nephron as well as those by the 
whole kidney. 






NA  Measured CLIn Measured TPAH Under unsaturated PAH transport 
system, a parallel decrease in CLPAH and 
CLIn. 
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CLCr, creatinine clearance; CLCr(ex), exogenous creatinine clearance; CLPAH, PAH clearance; ERPF, effective renal plasma flow; n, number of subjects; TPAH, renal tubular PAH secretion rate; 
TmPAH, maximum renal tubular PAH secretion rate 
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2.4.2. Studies that do not support the intact nephron hypothesis 
Twenty-four of thirty studies did not support the INH [77-80, 96-112, 114-
116]. The details of these studies are summarised in Table 2.3. Overall, nine 
studies involved human subjects, one used simulated data and the remaining 
studies involved animals. All of the studies determined GFR using either the 24 
hour urine collection of creatinine or exogenous probes such as inulin, 51Cr 
EDTA, sinistrin and others (details in Table 2.3). The tubular function was 
estimated using probes like PAH or other similar compounds or drugs that are 
mainly cleared through tubular processes. Only one of the studies performed an 
a priori power analysis, where a sample size of n = 6, in each of the three groups, 
was estimated to detect a 50% reduction in renal clearance with 70% to 80% 
power [111]. 
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Table 2.3 Summary of studies not supporting the intact nephron hypothesis 
Study 
[reference] Population (n) Renal failure model GFR measure 
Tubular function 
measure Key observations 
Rieselbach et 
al. 1964 [96] 
Mongrel dogs, 
female (5) 
Stage I: normal kidneys; 
Stage II: induced 
experimental 
pyelonephritis in 1 of the 





Measured TmPAH Marked increase in TmPAH, such that the 
TmPAH/GFR ratio in the diseased kidney 
was doubled after removal of the control 
kidney. 
Morrison et 
al. 1966 [97] 
Rats (18) Partial nephrectomy Measured CLIn Measured CLPAH Progressive impairment of glomerular 
filtration unattended by a parallel change 
in tubular function was observed. 




ARF induced by 
potassium dichromate or 
mercuric chloride 
Measured CLIn Measured CLPAH 
and CLUrea 
Glomerular function did not fall in parallel 
with the decline in tubular function. 




Renal failure induced by 
potassium dichromate and 
mercuric chloride 
CL14C-In  Measured TmPAH The TmPAH/GFR ratio was increased above 
normal indicating a shift toward functional 
tubular predominance. 








TmPAH /CLCr(ex) showed a downward trend 
throughout the study. 
Wagnild et 










CLCr(ex)/CLPAH decreased significantly in 
dogs with renal failure; TmPAH /CLCr(ex) was 
greater in dogs with renal failure. 
 
 




[reference] Population (n) Renal failure model GFR measure 
Tubular function 
measure Key observations 
Kampf et al. 
1981 [107] 





and cefoxitin total 
body clearance 
Percentage difference between the 
measured total body clearance of cefoxitin 
and that calculated by CLPAH, CLCr(ex) and 
CLIn amounted to 26%, 35% and 46%, 
respectively. 
Rakhit et al. 
1988 [110] 
Human (15) Mild to moderate renal 
insufficiency 
Measured   
CL3H-In 
Measured CLPAH, 
pentopril and its 
active metabolite 
CLrenal 
Renal secretion of pentopril and its active 
metabolite were correlated with CLPAH; 
hyperbolic relationship between CLCr and 
CLPAH was observed. 
Lin et al. 1988 
[108] 
Human (36) Mild to severe renal 
insufficiency 
Measured CLCr Measured 
famotidine CLrenal 
Decrease in famotidine tubular secretion in 
renal insufficiency was much greater than 
GFR compared to healthy volunteers. 





ARF induced by uranyl 




Measured CLPAH or 
CLTEAB 
Non-parallel decline of CLPAH and CLTEAB 
compared to CLIN in uranyl nitrate ARF. 
Gloff et al. 
1989 [78] 
Rats (23) Renal failure induced by 
uranyl nitrate 
Measured CLIn Measured CLPAH Decrease in CLPAH by 42% without change 
in CLIn observed at low dose (0.3 mg/kg). 













Non-parallel decline in CLIn and CLNMN  
was observed in different renal failure 
models. For drugs that are handled by 
renal tubules, CLNMN predicted CLrenal 
better than CLIn. 





(Same as in Maiza et al. 
1990) 
Measured CLIn Measured CLPAH, 
CLNMN and 
cimetidine CLrenal 
A non-parallel decline in CLIn and CLNMN  
was observed in different renal failure 
models. CLNMN was better predictor of 
CLrenal of cimetidine than CLIn. 




[reference] Population (n) Renal failure model GFR measure 
Tubular function 
measure Key observations 





(Same as in Maiza et al. 
1990) 
Measured CLIn Measured CLNMN 
and cephalexin 
CLrenal 
A non-parallel decline in CLIn and CLNMN  
was observed in different renal failure 
models. CLNMN was better predictor of 





NA Simulated Simulated CLrenal of a drug that is eliminated via renal 
secretion has negligible reabsorp- tion and 
moderate plasma binding has nonlinear 
relation with GFR. 
Janku et al. 
1993 [106] 
Human (34) Various renal disease Measured 
CLIn, CLCr and 
kanamycin CL 
Measured CLPAH A significant improvement in goodness of 
fit was obtained for CLPAH data when non-
linear relationship between CLrenal of the 
compound and GFR was used. 
Paap et al. 
1993 [109] 
Human (10) Various extrinsic and 
intrinsic renal disease 




Greater loss of tubular function as well as 
back leak reabsorption was anticipated in 
extrinsic renal disease compared to 
intrinsic renal disease. 
Shi et al. 1996 
[111] 








The relationship between CLrenal of 
sematilide and CLIn and CLPAH is described 
by nonlinear function. 
Nakamura et 
al. 1997 [104] 
Wistar albino 
rats, male (12) 
ARF induced by uranyl 
nitrate or cisplatin 
Measured CLIn Measured 
vancomycin CLrenal 
The decrease in secretory CLrenal of 
vancomycin was more pronounced than 
that in CLIn. 




ARF induced by BEA, 
neomycin, uranyl nitrate 
or ischemia  
Measured CLIn Measured CLNMN 
and NAPA CLrenal 
CLrenal of NAPA/CLIn was significantly 
reduced in rats with ARF; CLrenal of NAPA 
was better predicted by CLNMN compared 
to CLIn. 




[reference] Population (n) Renal failure model GFR measure 
Tubular function 
measure Key observations 





Young rats (1 month) to 
aged rats (16 month) 
kidney in recirculating 
perfused system 
Measured CLCr Measured CLPAH Nonlinear relationship was observed 
between CLPAH and CLCr. 
Ilic et al. 2001 
[114] 




Non parallel change in CL99mTC-DTPA 
and CL131I-OIH in advanced stage CRF 
and oligoanuric ARF patient 
compared to healthy volunteers. 
Udy et al. 
2014 [112] 
Human (32) Augmented renal 










CLCr, Sinistrin CLrenal, CLPAH and 
fluconazole reabsorption were elevated in 
patients while (S)-pindolol and (R)-
pindolol CLrenal were reduced. 
Putt et al. 
2014 [77] 










Change in CL51Cr EDTA was parallel to 
change in CLUrate as well as fluconazole 
reabsorption but it did not correlate with 
change in (S)-pindolol and (R)-pindolol. 
ARF, acute renal failure; BEA, 2-bromoethylamine hydrobromide; CLCr , creatinine clearance; CLCr(ex), exogenous creatinine clearance; CLPAH, PAH clearance; CLUrea, urea clearance; CLrenal, 
renal clearance; CL3H-In, 3H-Inulin clearance; CL12C-In, 12C-Inulin clearance; CLTEAB, tetraethylammonium bromide clearance; CLNMN, N-1-methylnicotinamide;CRF, chronic renal failure; CL131I-
OIH, iodine-131 sodium o-iodohippurate clearance; ICU, intensive care unit; n, number of subjects; NAPA, N-acetyl procainamide; TmPAH, maximum renal tubular PAH secretion rate 
Chapter 2: The intact nephron hypothesis as a model for renal drug handling 
 60 
 
2.4.3. Strength of evidence score 
The strength of evidence score is summarised in Table 2.4. The overall 
median scores of the studies supporting and not supporting the INH were 3 and 
4, respectively (p = 0.13 two-tailed, Mann Whitney U test). In the analysis of each 
component, where scores were compared between the INH and non INH 
supporting studies, a significant difference was found for the measurement of 
tubular function (p = 0.04 two-tailed, Mann Whitney U test), with a higher score 
for the studies that did not support the INH than the studies that supported the 
INH. No other component of the score (method for measuring GFR, sample size, 
or GFR range) was found to be significantly different between the groups.
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Table 2.4 Bespoke strength of evidence score for studies supporting and not supporting the intact nephron hypothesis 




Sample size Range of GFR Total 
Studies supporting the intact 
nephron hypothesis      
1 Wagnild et al. 1974 [25] 1 1 2 2 6 
2 Haberle et al. 1978 [27] 2 1 2 -2 3 
3 Haberle et al. 1975 [26] 2 1 2 -2 3 
4 Dontas et al. 1972 [46] 2 1 2 -2 3 
5 Bricker et al. 1964 [24] 1 1 2 -2 2 
6 Bricker et al. 1960 [1] 2 1 0 -2 1 
 Median score 2 1* 2 -2 3 
Studies not supporting the intact 
nephron hypothesis      
1 Maiza et al. 1993 [8] 2 2 2 2 8 
2 Janku 1993 [48] 2 1 2 2 7 
3 Janku et al. 1993 [39] 2 1 2 2 7 
4 Maiza et al. 1991 [7] 1 2 2 2 7 
5 Gloff et al. 1989 [6] 2 1 2 2 7 
6 Ilic et al. 2001 [47] 2 1 2 2 7 
7 Shi et al. 1996 [44] 2 2 0 2 6 
8 Paap et al. 1993 [42] 1 2 0 2 5 
9 Rakhit et al. 1988 [43] 2 1 0 2 5 
10 He et al. 2001 [37] 2 2 2 -2 4 
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Sample size Range of GFR Total 
11 Biber et al. 1968 [30] 2 2 2 -2 4 
12 Udy et al. 2014 [45] 2 2 2 -2 4 
13 Putt et al. 2014 [5] 2 2 2 -2 4 
14 Kampf et al. 1981 [40] 2 2 2 -2 4 
15 Lin et al. 1988 [34] 2 2 2 -2 4 
16 Nakamura et al. 1997 [36] 2 1 2 -2 3 
17 Morrison et al. 1966 [29] 2 1 2 -2 3 
18 Kramp et al. 1974 [31] 2 1 2 -2 3 
19 Maiza et al. 1990 [35] 2 2 0 -2 2 
20 Savant et al. 2001 [38] 1 1 2 -2 2 
21 Lin et al., 1988 [41] 1 1 2 -2 2 
22 Olesen et al. 1975 [32] 1 1 2 -2 2 
23 Wagnild et al. 1976 [33] 1 1 2 -2 2 
24 Rieselbach et al. 1964 [28] 1 1 2 -2 2 
 Median score 2 1* 2 -2 4 
*A significant difference was found in the strength of evidence scores for the measurement of tubular function (p = 0.04 two-tailed, Mann Whitney U test), with a higher score for the studies that 
did not support the INH than the studies that supported the INH. 




In this chapter, a systematic review of published studies designed to 
explore the INH was performed. The evidence to support the INH arose from six 
studies [1, 92-95, 113] while 24 studies were found to support a non-linear 
relationship between GFR and tubular function [77-80, 96-112, 114-116]. This 
result, in itself, supports the idea that the INH may not be a suitable model for 
renal drug handling. Of the six studies supporting the INH, five involved animal 
models with artificially induced renal dysfunction. It is noteworthy that much of 
this early work has been questioned because the surgical techniques used to 
induce renal damage may not have been optimal or because the high doses of 
nephrotoxins administered would not allow selective damage to specific areas 
of the nephron to be discerned [78].  
Overall, there was no statistical difference in the strength of evidence score 
between studies supporting or not supporting the INH. The score for the 
measurement of tubular function was significantly higher for the studies that did 
not support the INH than the studies that supported the INH although both 
groups had a median score equal to 1. This is because the Mann Whitney U test 
tests the whole distribution, which cannot be characterised by a single measure 
of central tendency. The studies that did not support the INH had a greater 
probability of accurately assessing tubular function since they used multiple 
probes (n=11). For example, Putt et al. simultaneously administered a cocktail of 
probes, 51Cr EDTA, fluconazole, (S)-pindolol and urate to assess GFR, proximal 
tubular reabsorption, cationic tubular secretion and anionic tubular secretion, 
respectively. Additionally, there was a wider range of measured GFR in studies 
that did not support the INH [78-80, 106, 109-111, 114, 115] compared to a single 
study that supported the hypothesis [93]. Both of these factors are important for 
establishing the nature of the relationship between glomerular function and 
tubular function in the kidney.  
The studies that did not support the INH were predominately published 
after 1980. It is conceivable that techniques for creating animal models for renal 
failure have become more refined. If so, then more recent studies are more likely 
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to capture the discordance between GFR and tubular function. One 
interpretation is that the studies published since 1980 that did not support the 
INH might have been better designed to access the relationship between GFR 
and tubular function. It is important to note that there are no reports of study 
designs that have been optimised to test the INH and hence the most critical 
design feature cannot be confirmed. 
In the animal models for renal dysfunction in the studies assessed for this 
chapter, glomerular and tubular damage were inflicted to varying degrees using 
a variety of technics. Chemically induced experimental renal failure models (e.g. 
uranyl nitrate, cisplatin) in animals exhibited preferential damage to the renal 
tubular function [79, 80, 98, 102-105] while nephritis induced by antiserum 
preferentially damaged glomeruli [79, 80, 96, 101, 103]. Renal failure induced by 
glycerol, which is ischemic type, produced parallel decline in GFR and clearance 
of TEAB (organic cation), while the clearance of PAH (organic anion) declined 
comparatively to greater extent [102]. The greater decline of organic anion 
clearance may be possibly due to accumulation of naturally occurring organic 
acids (hippuric acid, indoleacetic acid) in the renal failure that could selectively 
inhibit PAH secretion [117, 118].  
Animal models involving partial or unilateral nephrectomy caused gross 
damage to all functional components of the kidney and were quite variable [92, 
96, 97, 100]. It is noted that the difference in the rate of change of glomerular and 
tubular function can only be seen after about 2 years and will not be obvious 
over shorted time periods [100].  
A significant alteration in the ratio of GFR to tubular clearance of probes 
was observed only in the advanced stages of renal failure in the human studies 
assessed here, compared to newly developed or recovering renal disease where 
the ratio did not change significantly [114]. Paap et al. [109] noted that 
preferential damage to glomerular or tubular function will depend on the type 
of kidney disease. Taken together, this evidence suggests that the results of 
animal or human studies designed to test the INH must be interpreted in light 
of the type and stage of renal failure. 
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An important limitation of this work is that renal drug studies designed to 
explore renal drug dosing or handling, that may have inadvertently assessed the 
INH, were not reviewed. A pharmacokinetic renal drug study where renal drug 
clearance is regressed against an estimate of GFR might provide insight into the 
INH by chance. There are potentially a large number of these types of studies in 
the literature, but a review of these publications was beyond the scope of the 
current work. Secondly, the use of different units for GFR measures, i.e. eGFR 
indexed by different body size (body surface area or weight), in the studies may 
have introduced bias in the allocation to the renal function groups. While 
important, it was not possible to account for these differences in the studies 
reviewed. 
In summary, 24 of the 30 studies included in this systematic review did not 
support the INH. Overall, this finding casts doubt on the INH as a general model 
for renal drug handling, particularly for drugs that are eliminated extensively by 
tubular mechanisms. The following chapter will continue to interrogate the INH 
as a model for renal drug handling by conducting an analysis of renal function 
probes. 
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Chapter 3:  Testing the intact nephron hypothesis 























The intact nephron hypothesis (INH) states that impaired renal function 
results from a reduction in the number of complete (intact) nephrons. Under this 
model, the glomerular filtration rate is considered a reasonable summary of renal 
excretory function, including tubular secretion. While the INH provides a useful 
prognostic model for understanding renal function, it was found in Chapter 2 
that most studies do not support the INH as a general model for renal drug 
handling.  
This chapter will further explore the INH by analysing data from a 
published study using probes for GFR and tubular function. 
3.2. Aim and objectives 
The aim of this chapter was to test the INH by analysing the relationship 
between GFR and tubular secretion using two model-based analyses. The 
specific objectives were (1) to develop population pharmacokinetic models for 
51Cr EDTA (a GFR probe) and (S)-pindolol (a probe for cationic tubular 
secretion), (2) to develop a joint population pharmacokinetic model for 
simultaneous estimation of 51Cr EDTA clearance and (S)-pindolol renal 
clearance, (3) to test the INH by regressing the individual post-hoc estimates 
(also called Empirical Bayes Estimates, or EBEs) for (S)-pindolol renal clearance 
against 51Cr EDTA clearance from the individual probe models using a linear 
regression methodology, and, (4) to test the INH using the joint model where (S)-
pindolol renal clearance is conditioned on 51Cr EDTA clearance to explore linear 
and non-linear relationships. 




3.3.1. Data available for analysis 
The data were available from a published observational study designed to 
examine renal drug handling conducted in Dunedin, New Zealand [77]. A total 
of 40 subjects were recruited. The study was approved by the Northern Y 
Regional Ethics Committee and a written consent was obtained prior to 
commencement of the study. It was registered with the Australian and NZ 
Clinical Trials Registry number ACTRN 12611000035921 and was conducted in 
accordance with the Declaration of Helsinki. 
Study recruitment was stratified by age, renal function and comorbidities, 
as reported elsewhere [77]. In brief, subjects aged 20-40 years or over 65 years of 
age with and without established chronic kidney disease (creatinine <105 or >125 
µmol/L) and co-morbid disease (such as hypertension, diabetes or hear disease) 
were included. Exclusion criteria included; the inability to give consent, asthma, 
pregnancy, known allergy to the renal probes, and concomitant use of drugs 
known to inhibit tubular transporters including diuretics, trimethoprim or other 
antibiotics and cimetidine [119]. Participants were asked to stop taking these 
medications 4 days before commencement of the study and in the case of 
antibiotics, they were asked to stop taking medications two weeks before. 
The subjects were administered a cocktail of three probes under medical 
supervision: 
• Fluconazole 100 mg given orally, as a probe for tubular reabsorption 
• Racemic pindolol 15 mg given orally, as a probe for cationic tubular 
secretion 
• 51Cr EDTA 2 mL by volume, given intravenously, as a probe for GFR 
Previous studies have shown that a cocktail of probes can be used to 
simultaneously investigate renal drug handling without significant interaction 
[120]. For the current analysis, only glomerular filtration and cationic tubular 
secretion were considered, so 51Cr EDTA plasma count data, (S)-pindolol plasma 
concentrations and (S)-pindolol renal excretion data were used. The tubular 
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reabsorption was not considered in this analysis, so the fluconazole plasma 
concentration data was not used. 
Plasma samples for 51Cr EDTA counts were obtained at 2, 4, 6 and 24 hours 
following intravenous administration. 51Cr EDTA radioactive count data was 
measured at the Department of Nuclear Medicine, Radiology Department, 
Dunedin Hospital. Plasma samples for (S)-pindolol were obtained at 15-30 
minutes, 30-60 minutes, 90 minutes and 2, 4, 6, 24 hours post administration. 
Urine was collected at three periods over 24 hours for the measurement of (S)-
pindolol and creatinine – 0 to 3 hours, 3 to 6 hours, and 6 to 24 hours. (S)-pindolol 
plasma concentrations and timed urine samples were measured at the 
Department of Human Nutrition Laboratory, Otago University. Of note, analysis 
of (S)-pindolol is based on two assumptions; 1) pindolol enantiomers are stable 
at physiological conditions and do not interconvert [121], and, 2) racemic 
pindolol dose consists of 50% of the total racemic dose i.e., 7.5 mg [77]. Details 
on the assays can be found elsewhere [77].  
3.3.2. Probes for GFR and tubular secretion 
51Cr EDTA is a complex of the isotope, 51Chromium with ethylene diamine 
tetra acetic acid. It has a physical half-life of 27.7 days, which is solely based on 
radioactive decay [122]. This results in a total count loss of 1% during the whole 
examination procedure so that the count loss of the isotope due to radioactive 
decay can be taken as negligible [122]. The effective half-life, which is based on 
both biological elimination and radioactive decay, is approximately 2.4 hours 
[122]. In this case, the effective half-life is close to biological half-life because of 
minimum radioactive decay of 51Cr EDTA during the procedure. Determination 
of isotopic GFR requires an intravenous administration of bolus 51Cr EDTA and 
collection of blood samples for several hours after the dose for the measurement 
of radioactivity [27]. Isotopic GFR is has been shown to provide a more accurate 
estimate of the ‘true’ GFR compared to creatinine-based equations [123]. 51Cr 
EDTA is entirely cleared through glomerular filtration and is neither secreted 
nor reabsorbed by the tubules [24, 25].  
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Pindolol is a non-selective beta-blocker composed of a racemic mixture of 
(R)- and (S)-enantiomers. Its absorption is fast and almost complete with a 
reported bioavailability of 90% [124]. It has an elimination half-life of 3 hours 
[125]. (S)-pindolol fraction excreted unchanged in urine (fe) is 35%, which is 21% 
higher than that for (R)-pindolol [125]. The stereo-selective excretion of (S)-
pindolol has been successfully used to evaluate tubular cationic secretory 
function in previous studies [120, 126, 127]. Since only 35% of the (S)-pindolol is 
excreted unchanged in urine, total plasma clearance (CL/F) would not be 
expected to accurately reflect tubular cationic secretion. Therefore, both (S)-
pindolol plasma concentration data as well as urine data were used to determine 
fe. The fe was determined by; 
𝑑𝑑𝐴𝐴𝑢𝑢𝐶𝐶𝑝𝑝𝑝𝑝𝑒𝑒
𝑑𝑑𝑡𝑡
= 𝑓𝑓𝑒𝑒 ∙ 𝑘𝑘𝑒𝑒𝑡𝑡 ∙ 𝐴𝐴𝑠𝑠𝑒𝑒𝑝𝑝𝑟𝑟𝐶𝐶𝑟𝑟𝑡𝑡 
Equation 3.1 Rate of excretion of (S)-pindolol in urine. 
where, Aurine is the amount of (S)-pindolol in the urine compartment, fe is the 
fraction excreted unchanged in urine – this was estimated as a parameter in the 
model, kel is the elimination rate constant and Acentral is the amount of (S)-pindolol 
in central compartment. Note that in this case, the renal clearance of (S)-pindolol 
was not estimated directly from the urine excretion and plasma concentration 
data. The values of fe were then used to derive renal clearance of (S)-pindolol as 
follows;  
𝐶𝐶𝐶𝐶𝑅𝑅−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚 = 𝑓𝑓𝑒𝑒 ∙⁄ 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄  
Equation 3.2 Renal clearance of (S)-pindolol as a product of fraction excreted 
unchanged in urine and total plasma clearance. 
where, 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄  is total plasma clearance of (S)-pindolol and 
𝐶𝐶𝐶𝐶𝑅𝑅−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚 ∙⁄ is the renal clearance of (S)-pindolol . 
3.3.2.1. Handling data below the limit of quantification  
When < 5% of the observations were below the limit of quantification (BLQ) 
and there was no systematic trend present in the distribution of data, the BLQ 
observations were omitted. For BLQ observations > 5% but < 10% with no 
systematic trends present, the first BLQ observation was replaced with half the 
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lower limit of quantification (LLOQ) and the rest of BLQ observations were 
omitted (M6 method [128]). When > 10% of samples were BLQ likelihood-based 
method was used (M3 method [128]). The M3 method is based on simultaneous 
modelling of observations above LLOQ, which are usually continuous variable 
(e.g. plasma concentrations) and BLQ observations which are treated as 
categorical data. For observations above LLOQ, prediction of the observations 
were returned and for BLQ observations, the likelihood of the predictions being 
less than the LLOQ were returned, which creates a categorical designation for 
each BLQ observations. 
3.3.2.2. Handling missing data 
For missing continuous and categorical covariate, either multiple 
imputation or full maximum likelihood modelling method was used. The 
multiple imputation method imputes missing covariates based on a regression 
model using observed covariates (e.g. age, body weight) and individual response 
(e.g. CL). The full maximum likelihood modelling method estimates the 
relationship between observed covariates to impute the missing covariates as an 
extra parameter in the model. Both the methods are proposed to give precise and 
unbiased estimates of parameters in presence of missing data [129]. 
For a missing sample collection time the proposed sampling time in the 
study protocol was considered. Samples where the time recorded could not be 
verified and was not clearly compatible with the dosing history were omitted. 
Missing plasma concentrations were omitted from the analysis. 
3.3.2.3. Handling outliers 
Data points with a conditional weighted residuals (CWRES) > 6 were 
considered outliners. Outliers were investigated at key stage of model building. 
Outliers were not excluded as a standard approach. 
3.3.3. Population pharmacokinetic analysis 
The population pharmacokinetic analysis was conducted using the 
nonlinear mixed-effects modelling software NONMEM® Version 7.3 [130] with 
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PsN [131]. Pirana [132] was used as an interface for NONMEM®. The first-order 
conditional estimation with interaction (FOCE-I) method was implemented. The 
Laplacian estimation method was used when required e.g., when handling 
missing data using the M3 method [128]. The convergence criteria were set to 
three to four significant digits (SIG = 3 or SIG =4) and the precision of integration 
solutions was set to six to nine significant digits (TOL = 6 or TOL = 9). Outputs 
from NONMEM® were processed and plotted using R software version 3.5.1 
[133] using the Xpose package version 0.4.4 [134] and ggplot2 [135] packages. 
The software ran on a system with Intel Xenon processor, Windows Server 2012 
R2 and a GNU Fortran 95 complier. 
3.3.3.1. Model development 
The population pharmacokinetic analysis involved the development of 
three population pharmacokinetic models; (1) a population pharmacokinetic 
model for 51Cr EDTA, (2) a population pharmacokinetic model for (S)-pindolol, 
and, (3) a joint model for both 51Cr EDTA and (S)-pindolol. 
Model development for 51Cr EDTA and (S)-pindolol. Separate models were 
built for 51Cr EDTA and (S)-pindolol in the first instance. 51Cr EDTA plasma 
count data and (S)-pindolol plasma concentration as well as the amount excreted 
in the urine was used for model building. 
Here, the ADVAN 6 routine in NONMEM® was used for model 
development. ADVAN 6 allows the model to be coded as differential equations 
with a Runge-Kutta-Verner algorithm that is optimised for non-stiff differential 
equations [60].  
The between subject variability (BSV) are given by the diagonal elements 
of Ω. Each element of 𝜽𝜽𝒊𝒊, was assumed to follow a log-linear distribution and an 
exponential model was used: 
𝜽𝜽𝒊𝒊 = 𝜃𝜃 ⋅ 𝑒𝑒η𝒊𝒊 
Equation 3.3 A general form of exponential model for parameter of ith individual 
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Joint model development. A joint model including both 51Cr EDTA and (S)-
pindolol was developed. The ADVAN 6 routine in NONMEM® was used for 
model building, as above. The structural pharmacokinetic model, models for 
describing the random effects – BSVs and RUVs, covariate effect models and 
final parameter estimates from the individual models for the two probes were 
used as initial parameter estimates in the joint model. 
In the absence of a fully mechanistic model to describe the relationship 
between 51Cr EDTA clearance and (S)-pindolol renal clearance, an empirical 
nonlinear model was used. The empirical nonlinear model allowed for a non-
proportional change in (S)-pindolol renal clearance with respect to the 51Cr 
EDTA clearance (GFR) with an exponent. The empirical nonlinear model is given 
by the following equation;  
𝐶𝐶𝐶𝐶𝑅𝑅−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚 =  θ𝐶𝐶𝑟𝑟𝑒𝑒𝐶𝐶 ⋅ 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶θ𝐸𝐸𝐸𝐸𝑒𝑒 
Equation 3.4 Model for renal clearance of probe for cationic tubular secretion 
conditioned (S)-pindolol (𝐶𝐶𝐶𝐶𝑅𝑅−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚) on clearance of 51Cr EDTA (𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶) 
where, 𝐶𝐶𝐶𝐶𝑅𝑅−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚 is the apparent renal clearance of (S)-pindolol, 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 is 
the total clearance of 51Cr EDTA which is assumed to approximate GFR, 𝜃𝜃𝐶𝐶𝑟𝑟𝑒𝑒𝐶𝐶 is 
a composite of the unbound fraction and a linear coefficient describing the 
proportionality of the non-glomerular processes and 𝜃𝜃𝐶𝐶𝑒𝑒𝑝𝑝  was a composite of 
exponents that describe the divergence of various tubular processes from GFR. 
3.3.3.2. Model selection 
In all steps of the model development, models were evaluated using the 
following criteria: 
• Successful minimisation 
• Log-likelihood ratio test (LRT): The difference between objective function 
value (OFV) was used to compare nested models and to find the model 
that gives the best global fit to the data. The difference is asymptotically 
chi-squared distributed with a degree of freedom equal to the difference 
in the number of parameters between the two models. So, a reduction in 
OFV by 3.84 in model with one added parameter corresponds to 
significant improvement in the model fit (p < 0.05). 
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• Akaike information criteria (AIC): For non-nested models the AIC was 
used to evaluate differences in competing models. The model with the 
lower AIC was considered to be superior.  
• Relative standard errors (RSE): RSE of the fixed effect parameters and 
random effect parameters were expected to be < 20% and < 50%, 
respectively.  
• Shrinkage of etas and epsilons were assessed. Shrinkage was expected to 
be less than 20%. EBEs, IPRED and CWRES based diagnostics were 
interpreted with caution when etas and epsilons shrinkage were 
substantial (>20-30%) [136]. 
• Covariance between etas: The covariance between the etas were retained 
if it improved the model fit based on LRT.  
• Visual inspection of diagnostic plots: The ability of the model to describe 
the data was assessed by following diagnostic plots: 
• Population and individual predictions versus observations. 
• Conditional weighted residuals (CWRES) versus population 
predictions and versus time. 
• Individual plots comparing observed and individual predictions 
over time. 
3.3.3.3. Model evaluation  
Models were evaluated at key modelling steps using; 
1. Visual predictive checks (VPCs): One thousand data sets were simulated 
under the final model and 95% confidence intervals (CI) of the 2.5th, 50th 
and 97.5th percentiles were plotted against the same percentiles from the 
original data set. Bins were chosen to provide an even distribution of 
observations across bins. All VPC plots were created using xpose version 
0.4.4 [134] package in R software version 3.5.1 [133]. 
2. Non-parametric bootstrap: One thousand non-parametric bootstrap runs 
from the final model were used to determine the median and 95% CI of 
parameter values. These values were compared to the parameter 
estimates from the final model. 
3.3.4. Data Analysis for testing the INH 
3.3.4.1. Linear regression analysis  
A linear regression analysis was performed to explore the relationship 
between 51Cr EDTA clearance and (S)-pindolol renal clearance. The values of 51Cr 
EDTA clearance for each subject was provided as the individual empirical Bayes 
estimates (EBE) during the population analysis using NONMEM®. (S)-pindolol 
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renal clearance was derived from (S)-pindolol total plasma clearance for each 
subject (see equation 3.4) as the product of the individual EBEs of fe and 
𝐶𝐶𝐶𝐶𝑅𝑅−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚  for (S)-pindolol estimated during the population analysis. The 
analysis assumed a linear relationship between 51Cr EDTA clearance and (S)-
pindolol renal clearance and therefore is aligned with the INH. The y-intercept 
of the regression equation, including the 95% confidence interval, was 
determined. This value represented the theoretical value of (S)-pindolol renal 
clearance if 51Cr EDTA clearance was zero. In theory, if the INH is true, we would 
expect the 95% confidence interval of (S)-pindolol renal clearance to also include 
zero when 51Cr EDTA clearance is equal to zero. If the (S)-pindolol renal 
clearance was significantly different from zero, then a deviation from the INH 
and a non-linear relationship between GFR and tubular function was concluded. 
Note that non-renal clearance is not considered here. 
The linear regression analysis was conducted with subjects having 51Cr 
EDTA clearance values > 50% of normal (approximately 3.6 L/h or 60 mL/min). 
This provided the best chance of seeing a signal for a non-linear relationship 
between (S)-pindolol renal and 51Cr EDTA clearances. However, given the shape 
of the non-linear relationship proposed by Wright and Duffull [55], the deviation 
from linearity is most pronounced at GFR values < 30% of normal 
(corresponding to about 2.2 L/h or 36 mL/min). Therefore, by restricting the 
analysis to 51Cr EDTA clearance values > 50% of normal in the setting of a non-
linear relationship, we might expect that the y-intercept and 95% confidence 
interval would not include zero. For completeness, the analysis was repeated 
with all values of 51Cr EDTA clearance.  
3.3.4.2. Joint model 
The relationship between 51Cr EDTA clearance and (S)-pindolol renal 
clearance was explored using the joint model. The relationship was defined by 
an empirical nonlinear model for (S)-pindolol renal clearance (CL/F) as a function 
of 51Cr EDTA clearance (GFR) with a linear coefficient (Coef) and a nonlinear 
exponent parameter (Exp), as given by Equation 3.4. The joint model allowed 
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simultaneous estimation of pharmacokinetic parameters of both the probes as 
well as the Coef and Exp parameters. Here, the parameter of interest was Exp, 
which gave information about the nature of the relationship. A value of Exp 
where the 95% CI of the estimate includes one indicates a linear relationship. A 
value of Exp where the 95% CI of the estimate does not include one indicates a 
significant divergence from linearity.




The subjects were predominantly male (67.5%) and of New Zealand 
European ethnicity with one Maori and one Asian participant. The median 
(range) of age was 69.5 (21.0-88.0) years, weight was 75.4 (47.9-110.5) kg. The 
included subjects had a range of renal function with median (range) serum 
creatinine 89.0 (66.0-217.0) μmol/L. A summary of the subject demographic 
characteristics is shown in Table 3.1. 
Table 3.1 Demographic and clinical details of the patients included in the study 
 All Group 1a Group 2b Group 3c Group 4d 
Subjects (n) 40 10 11 10 9 
Male: Female (n) 26:14 6:4 6:5 7:3 7:2 
Age (years) 70 (21-88) 32 (21-40) 71 (65-82) 69 (66-76) 82 (73-88) 
Weight (kg) 75 (48-111) 77 (58-100) 73 (48-96) 80 (54-111) 76 (60-95) 
Height (m) 1.7(1.5-1.9) 1.7(1.6-1.9) 1.6(1.5-1.8) 1.7(1.6-1.8) 1.7 (1.5-1.8) 
Fat-free mass 
(kg) 
52 (33-69) 41 (69-86) 44 (33-63) 54 (35-66) 54 (36-61) 
Serum creatinine 
(μmol/L) 
89 (66-217) 86 (71-101) 85 (66-104) 88 (68-96) 144 
(123-217) 
All data expressed as median (range). 
a Young healthy subjects, aged 20-40 years, serum creatinine concentration less than 105 𝜇𝜇𝑚𝑚𝑑𝑑𝑙𝑙/𝐶𝐶 
b Elderly healthy subjects, aged over 65 years, serum creatinine concentration less than 105 𝜇𝜇𝑚𝑚𝑑𝑑𝑙𝑙/𝐶𝐶  
c Elderly subjects, aged over 65 years, serum creatinine concentration less than 105 𝜇𝜇𝑚𝑚𝑑𝑑𝑙𝑙/𝐶𝐶, with co-morbidities 
(hypertension, diabetes or heart disease) 
d Elderly subjects, aged over 65 years, serum creatinine concentration greater than 124 𝜇𝜇𝑚𝑚𝑑𝑑𝑙𝑙/𝐶𝐶, with co-morbidities 
(hypertension, diabetes or heart disease) 
The data used in this study included 159 plasma samples of 51Cr EDTA, 319 
plasma samples and 120 urine samples of (S)-pindolol from 40 subjects with 
varying degree of renal function. A plot of the raw 51Cr EDTA plasma count data 
is shown in Figure 3.1. (S)-pindolol plasma concentration data and amount 
excreted in urine time profile are shown in Figure 3.2. (S)-pindolol plasma 
concentration observations included 40 BLQ observations out of 319 (13%). A 
likelihood-based method (M3) [128] was used to handle the BLQ observations. 
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No other data were BLQ. There were no missing covariates, sampling times or 
concentrations. None of the data points were excluded based on outlier analysis. 
 
Figure 3.1 Time course of plasma count (cts/min) after intravenous 
administration of 2 mL of 51Cr EDTA.
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Figure 3.2 Time course of (a) plasma concentrations and (b) amount excreted in 
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3.4.1. Model for 51Cr EDTA  
A two-compartment pharmacokinetic model with first order elimination 
was the best fit for the 51Cr EDTA data. The BSV on Q was not supported by the 
data and not estimated. Covariance terms between the random effects on 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶, 𝑉𝑉2 and 𝑉𝑉1 were included in the final model. The residual variability 
was modelled as a combination of an additive and a proportional-error model 
with the additive error fixed to 0.5 mg/L. Details of the model are presented in 
Figure 3.3 and Equation 3.5. Covariates included in the final model were 
creatinine clearance and body weight on 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 and 𝑉𝑉1, respectively.  
Figure 3.3 Schematic representation of the final 51Cr EDTA pharmacokinetic 
model. Rate constants are defined in Equation 3.5.

















= 𝑘𝑘21 ∙ 𝐴𝐴(2) − 𝑘𝑘10 ∙ 𝐴𝐴(1) − 𝑘𝑘12 ∙ 𝐴𝐴(1) 
𝑑𝑑𝐴𝐴(2)
𝑑𝑑𝑡𝑡
= 𝑘𝑘12 ∙ 𝐴𝐴(1) −  𝑘𝑘21 ∙ 𝐴𝐴(2) 
Equation 3.5 Differential equations representing the final pharmacokinetic 
model for 51Cr EDTA. A(1) = the amount of 51Cr EDTA in the central 
compartment (1), A(2) = the amount of 51Cr EDTA in the peripheral 
compartment (2), 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 = 51Cr EDTA clearance, k10 = transfer rate constant 
from the central compartment (1) to the outside of the body(0), k12 = transfer rate 
constant from the central compartment (1) to the peripheral compartment (2), k21 
= transfer rate constant from the peripheral compartment (2) to the central 
compartment (1), V1 = volume of central compartment, V2 = volume of peripheral 
compartment. 
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Table 3.2 Parameter estimates and bootstrap results of the final model for 51Cr 
EDTA. 
Parameters Unit Estimate (RSE%)a 
Bootstraps  
[95% CI]b 
Fixed Effects    
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 c  L/h 6.4 (2.8) 6.4 [5.9, 6.8] 
V1 d L 15.5 (3.4) 15.6 [13.3, 17.6] 
Q L/h 2.2 (3.8) 2.1 [1.5, 2.8] 
V2 L 4.3 (5.4) 4.3 [3.1, 5.3] 
    
Random Effects BSV    
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶  CV% 19.7 (11.6) 19.1 [14.1, 23.7] 
V1 CV% 20.9 (16.6) 20.4 [14.3, 26.0] 
V2 CV% 60.4 (15.6) 68.2 [38.8, 124.1] 
Correlation 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶,𝑉𝑉1 - 0.40 0.38 [-0.04, 0.53] 
Correlation 𝐶𝐶𝐶𝐶,𝑉𝑉2 - 0.14 0.17 [-0.48, 0.34] 
Correlation 𝑉𝑉1,𝑉𝑉2 - 0.41 0.45 [-0.48, 0.74] 
    
Random Effects RUV    
𝜎𝜎𝑟𝑟𝑎𝑎𝑎𝑎   cts/min/2 mL 0.5 (FIXED) - 
CVprop % 4.5 (8.1) 4.4 [2.6, 6.7] 
    
Shrinkage    
𝜂𝜂-shrinkage    
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶  % 0.7  
V1 % 10.7  
V2 % 11.0  
𝜀𝜀-shrinkage % 35.6  
The covariate model for 51Cr EDTA 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶  was 𝜃𝜃𝐶𝐶𝐶𝐶𝐶𝐶𝑠𝑠 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 = 𝜃𝜃𝐶𝐶𝑇𝑇𝐶𝐶𝐶𝐶𝐶𝐶𝑠𝑠 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 × �
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶
6 𝐶𝐶/ℎ
� , where 𝜃𝜃𝐶𝐶𝑇𝑇𝐶𝐶𝐶𝐶𝐶𝐶𝑠𝑠 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸  is the 
population estimate for 51Cr EDTA clearance and 𝐶𝐶𝐶𝐶𝐶𝐶𝑅𝑅 is measured creatinine clearance 24 hour urine data and 
expressed as L/h. The covariate model for 51Cr EDTA 𝑉𝑉1 was 𝜃𝜃𝑇𝑇1 = 𝜃𝜃𝐶𝐶𝑇𝑇𝑇𝑇1 × �
𝑊𝑊𝐶𝐶
70 𝑘𝑘𝐴𝐴
�, where 𝜃𝜃𝐶𝐶𝑇𝑇𝑇𝑇1  is the population 
estimate for 51Cr EDTA 𝑉𝑉1 and WT is total body weight in kg 
BSV, between-subject variability; CI, confidence interval; 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 , 51Cr EDTA clearance; cts, counts; CVprop, 
coefficient of variation of a proportional residual error; Q, inter-compartment clearance; RSE, relative standard error; 
RUV, random unexplained variability; V1, volume of the central compartment, V2, volume of peripheral compartment; 
σadd, standard deviation of an additive residual error 
a RSE calculated based on asymptotic standard error of empirical Bayes estimates 
b 32.3% (n = 323) of the bootstrap runs did not minimise successfully, mainly due to rounding error. These runs were 
included in the calculating 95% of CI based on the bootstrap runs (n=1000). 
c Value of 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 is for a typical individual with 𝐶𝐶𝐶𝐶𝐶𝐶𝑅𝑅 of 6 L/h 
d Value of 𝑉𝑉1 is for a typical individual with body weight of 70 kg 
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Figure 3.4 Goodness-of-fit plots of the final model for 51Cr EDTA. Observed 51Cr 
EDTA plasma counts plotted against (a) the population predictions for 51Cr EDTA 
plasma counts and (b) the individual predictions for 51Cr EDTA; conditional 
weighted residuals plotted against (c) the population predictions for 51Cr EDTA 
plasma counts and (d) the time after dose. Note Ꜫ-shrinkage was equal to 35.6% so 











Figure 3.5 Visual predictive check of the final individual model for 51Cr EDTA. 
Closed circles represent observed data for 51Cr EDTA. Solid black lines represent 
the median of the observed data for 51Cr EDTA. Dashed black lines represent 
2.5thand 97.5th percentiles of the observed data for 51Cr EDTA. The shaded areas 
represent 95% confidence interval of the 2.5th, 50th and 97.5th percentiles of the 
simulated data for 51Cr EDTA. 
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The population pharmacokinetic parameter estimates of the final model for 
51Cr EDTA are shown in Table 3.2. The parameters were well-estimated with 
relative standard error < 6% for the fixed effect parameters and < 17% for the 
random effect parameters. The parameter estimates for the final 51Cr EDTA 
model were within the 95% CI of the bootstrap (n=1000) results. Eta shrinkage 
was reasonable for CL, V1 and V2 (0.7%, 10.7% and 11.0%, respectively). Epsilon 
shrinkage was found to be 35.6%, which can cause misleading diagnostic plots 
(based on IPRED or IWRES), either hiding the relationships or suggesting wrong 
ones [136]. The individual predictions (IPRED) in Figure 3.4 (b) are shrunk to the 
line of identity because of epsilon shrinkage. 
The goodness-of-fit plots for the final pharmacokinetic model of 51Cr EDTA 
as shown in Figure 3.4. The plots do not display any obvious systematic trends. 
The observed 51Cr EDTA plasma count (DV) versus population predicted plasma 
count (PRED) plot displayed a random distribution of data points around the 
line of identity without systematic trends. Plots of conditional weighted 
residuals (CWRES) versus time and PRED showed a random distribution of data 
points around the zero line with the majority of data between -2 and 2 (i.e., 
within 2 standard deviations). The distribution of weighted-residual values was 
acceptable with no obvious deviation for the assumption of a random normal 
distribution of CWRES.  
The VPC of the final model for 51Cr EDTA is shown in Figure 3.5. Based on 
the VPC of the final 51Cr EDTA model, the 2.5th, 50th and 97.5th percentiles of the 
observed 51Cr EDTA plasma counts were within their corresponding simulated 
95% CI demonstrating that the final model for 51Cr EDTA captures both central 
tendency and BSV of the observed data. 
Appendix A2.1 contains the NONMEM® control stream file of the final 
model for 51 Cr EDTA. The model building steps for the final model for 51 Cr 
EDTA is given in Appendix A2.2. Appendix A2.3 shows the individual plots 
comparing observed and individual predictions over time of the final model of 
51Cr EDTA.
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3.4.2. Model for (S)-pindolol 
A one-compartment model with first-order absorption with a lag-time and 
first-order elimination was the best fit for the (S)-pindolol plasma and urine data. 
The estimation of between subject variability on ka was not supported by the data 
and was not included. Covariance terms between the random effects on 
𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚 and V1/F, and 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚 and 𝑓𝑓𝑒𝑒 were included in the final 
model. The residual variability was modelled as a combination of an additive 
and a proportional error model. The additive error was not well estimated, but 
the model consistently converged with a fixed value 0.001 mg/L. Details of the 
model are presented in Figure 3.6 and Equation 3.6. Covariates included in the 
final model were creatinine clearance and body weight on 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚 and fe, 
respectively. 
All (S)-pindolol BLQ samples (13% of the samples) were measured at 24 
hours after the pindolol dose. The M3 method [128, 137] was implemented to 
account for this. All (S)-pindolol urine data were above LLOQ. 
  




Figure 3.6 Schematic representation of the final (S)-pindolol pharmacokinetic 







= −𝑘𝑘𝑟𝑟 ∙ 𝐴𝐴(1) 
𝑑𝑑𝐴𝐴(2)
𝑑𝑑𝑡𝑡
= 𝑘𝑘𝑟𝑟 ∙ 𝐴𝐴(1) − 𝑘𝑘20 ∙ 𝐴𝐴(2) 
𝑑𝑑𝐴𝐴(3)
𝑑𝑑𝑡𝑡
= 𝑓𝑓𝑒𝑒 ∙ 𝑘𝑘20 ∙ 𝐴𝐴(2) 
Equation 3.6 Differential equations representing the final pharmacokinetic 
model for (S)-pindolol. A(1) = the amount of (S)-pindolol in the gut 
compartment, A(2) = the amount of (S)-pindolol in the central compartment (1), 
A(3) = the amount of (S)-pindolol in the urine compartment (2), 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚 
= (S)-pindolol total clearance, fe = fraction excreted unchanged in urine, k20 = 
transfer rate constant from the central compartment (2) to the outside of the 
body(0), ka = absorption rate constant, V2 = volume of central compartment. 
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Table 3.3 Parameter estimates and bootstrap results for the final (S)-pindolol 
model. 
Parameters Unit Estimate  RSE (%)a 
Bootstraps  
[95% CI]b 
Fixed Effects    
𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚 c L/h 26.7 (5.7) 26.7 [23.1, 30.8] 
V2/F d L 15.2 (12.4) 15.3 [10.6, 21.5] 
ka 1/h 0.2 (5.0) 0.2 [0.2, 0.2] 
fe - 0.2 (8.5) 0.2 [0.2, 0.3] 
    
Random Effects BSV    
𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚  CV% 32.2 (9.9) 31.1 [22.3, 38.5] 
V2/F CV% 82.9 (22.1) 86.1 [48.0, 143.7] 
fe CV% 51.2 (16.7) 51.2 [31.1, 72.7] 
Correlation 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/
 𝑚𝑚,𝑉𝑉2/𝑚𝑚 
 -0.65 -0.63 [-2.5, -0.10] 
Correlation 𝑉𝑉2/𝑚𝑚,𝑓𝑓𝑒𝑒   -0.49 -0.46 [-2.7, -0.04] 
    
Random Effects RUV    
Plasma    
𝜎𝜎𝑟𝑟𝑎𝑎𝑎𝑎   mg/L 0.001 
(FIXED) 
 
CVprop % 32.0 (13.8) 31.6 [23.5, 39.7] 
Urine    
𝜎𝜎𝑟𝑟𝑎𝑎𝑎𝑎   mg 0.19 (11.8) 0.19 [0.14, 0.24] 
    
Shrinkage (%)    
𝜂𝜂-shrinkage    
𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚  % 8.3  
V2/F % 11.1  
fe % 7.4  
𝜀𝜀-shrinkage    
Plasma % 17.5  
Urine % 14.1  
The covariate model for (S)-pindolol 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄  was 𝜃𝜃𝐶𝐶𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑎𝑎𝑡𝑡−(𝑠𝑠)𝑒𝑒𝑠𝑠𝑠𝑠 𝐹𝐹⁄ = 𝜃𝜃𝐶𝐶𝑇𝑇𝐶𝐶𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑎𝑎𝑡𝑡−(𝑠𝑠)𝑒𝑒𝑠𝑠𝑠𝑠 𝐹𝐹⁄ × �
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶
6 𝐶𝐶/ℎ
� , where 
𝜃𝜃𝐶𝐶𝑇𝑇𝐶𝐶𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑎𝑎𝑡𝑡−(𝑠𝑠)𝑒𝑒𝑠𝑠𝑠𝑠 𝐹𝐹⁄  is the population estimate for (S)-pindolol total clearance and 𝐶𝐶𝐶𝐶𝐶𝐶𝑅𝑅  is measured creatinine 




�, where 𝜃𝜃𝐶𝐶𝑇𝑇𝑇𝑇2  is the population estimate for (S)-pindolol 𝑉𝑉2/𝑚𝑚 and WT is total body weight in kg 
BSV, between-subject variability; CI, confidence interval; 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚 , (S)-pindolol total clearance; CVprop, 
coefficient of variation for proportional error; fe, fraction excreted unchanged in urine; ka, absorption rate constant; 
RSE, relative standard error; RUV, random unexplained variability; V2/F, apparent volume of the central 
compartment; σadd, standard deviation for additive error, 
a RSE calculated based on asymptotic standard error of empirical Bayes estimates,  
b 35.2% (n = 352) of the bootstrap runs did not minimise successfully, mainly due to rounding error. These runs were 
included in the calculating 95% of CI based on the bootstrap runs (n=1000).  
c Value of 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚 is for a typical individual with 𝐶𝐶𝐶𝐶𝐶𝐶𝑅𝑅 of 6 L/h 
d Value of 𝑉𝑉2/𝑚𝑚 is for a typical individual with body weight of 70 kg
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Figure 3.7 Goodness-of-fit plots of the final model for (S)-pindolol. Observed (S)-
pindolol plasma concentrations plotted against (a) the population predictions for 
(S)-pindolol plasma concentrations and (b) individual predictions for (S)-pindolol 
plasma concentrations; observed (S)-pindolol amount excreted in urine plotted 
against (c) the population predictions for amount excreted in urine and (d) the 












Figure 3.8 Visual predictive check of final individual model for (S)-pindolol (a) 
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observed data. Solid black lines represent the median of the observed data. Dashed 
black lines represent 2.5thand 97.5th percentiles of the observed data. The shaded 
areas represent 95% confidence interval of the 2.5th, 50th and 97.5th percentiles of 
the simulated data. Upper panel in (a) show the lower limit of quantification of 
(LLOQ) of (S)-pindolol plasma concentration with a horizontal grey line. Lower 
panel in (a) show simulation based 95% confidence intervals for the proportion 
of BLQ samples as shaded area and the observed proportion of BLQ samples as 
dashed black line. 
 
The population pharmacokinetic parameter estimates of the final model for 
(S)-pindolol are shown in Table 3.3. All of the parameters were well-estimated 
with a relative standard error < 13% for the fixed effect parameters and < 23% 
the random effect parameters. The parameter estimates for the final (S)-pindolol 
model were within the 95% CI of the bootstrap (n=1000) results. Eta shrinkage 
was modest (< 12%) for 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚 , V2 and fe. 𝜀𝜀 -shrinkage for plasma 
concentration and urine amount data were found to be to 17.5% and 14.1%, 
respectively.  
The goodness-of-fit plots for the final pharmacokinetic model of (S)-
pindolol as shown in Figure 3.7 does not display any gross systematic trends, 
except in (b) bias is observed at high concentrations where there is little data. The 
observed (S)-pindolol plasma concentration (DV) versus PRED plot displayed a 
random distribution of data points around the line of identity without 
concerning systematic trends. Since the model for (S)-pindolol uses Laplace 
estimation method for implementing M3 method [128], weighted residual 
diagnostics (CWRES) were not calculated for categorical as well as continuous 
data in NONMEM® version 7.3.  
The VPC of the final model of (S)-pindolol (a) plasma concentrations and 
(b) amount excreted in urine is shown in Figure 3.8. Based on the VPC, the 2.5th, 
50th and 97.5th percentiles of the observed (S)-pindolol plasma concentrations 
(upper panel) and urine amounts were within their corresponding simulated 
95% CI demonstrating that the final model for (S)-pindolol captures both the 
central tendency and the BSV of (S)-pindolol pharmacokinetics in the 
participants. The observed proportion of (S)-pindolol BLQ plasma 
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concentrations (lower panel) within the simulated 95% CI indicating that the M3 
method for handling BLQ captures the probability of observations being BLQ. 
Appendix A2.4 contains the NONMEM® control stream and result files for 
the final model. The model building steps for the final model for (S)-pindolol is 
shown in Appendix A2.5. Appendix A2.6 shows the individual plots comparing 
observed and individual predictions over time of the final model of (S)-pindolol 
(a) plasma concentrations and (b) amount excreted in urine. 
3.4.3. Joint model 
The structural pharmacokinetic model, models for describing random 
effectscovariate effect models and final parameter estimates from the individual 
models of 51Cr EDTA and (S)-pindolol were used for building the joint model. 
The M3 method [128] was used to account for the BLQ samples.   
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Table 3.4 Parameter estimates and bootstrap results of the final joint model for 
51Cr EDTA and (S)-pindolol. 




    
Fixed Effects    
51Cr EDTA    
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 b L/h 6.4 (3.9) 6.4 [5.9, 6.8] 
V1 c L 15.4 (7.5) 15.3 [13.0, 17.4] 
Q L/h 2.2 (16.0) 2.2 [1.6, 2.9] 
V2 L 4.3 (13.3) 4.3 [3.1, 5.4] 
(S)-pindolol    
𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄  b L/h 26.6 (7.4) 26.6 [23.0, 30.7] 
V2/F c L 15.5 (18.0) 15.7 [10.4, 21.9] 
Ka 1/h 0.2 (5.7) 0.2 [0.2, 0.2] 
𝜃𝜃𝐶𝐶𝑟𝑟𝑒𝑒𝐶𝐶  - 1.4 (27.8) 1.4 [0.8, 2.5] 
𝜃𝜃𝐶𝐶𝑒𝑒𝑝𝑝  - 0.8 (17.8) 0.8 [0.5, 1.1] 
    
Random Effects BSV    
51Cr EDTA    
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶  CV% 19.3 (13.5) 18.8 [13.5, 23.2] 
V1 CV% 19.4 (16.8) 19.2 [12.8, 25.2] 
V2 CV% 57.2 (28.4) 63.0 [38.6, 105.4] 
Correlation 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶,𝑉𝑉1  0.38 0.35 [-0.21, 0.53] 
Correlation 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶,𝑉𝑉2  0.22 0.18 [-0.50, 0.36] 
Correlation 𝑉𝑉1,𝑉𝑉2  0.56 0.50 [-0.02, 0.16] 
(S)-pindolol    
𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄   CV% 32.0 (13.6) 31.4 [22.7, 39.4] 
V2/F CV% 81.2 (26.8) 84.2 [51.0, 139.2] 
fe CV% 42.5 (22.9) 43.1 [34.4, 62.5] 
Correlation 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄  
,  𝑉𝑉2/𝑚𝑚 
 0.21 0.17 [-0.81, 0.43] 
Correlation 𝑉𝑉2/𝑚𝑚, 𝑓𝑓𝑒𝑒  -0.52 -0.48 [-3.21, 0.08] 
    
Random Effects RUV    
51Cr EDTA (Plasma)    
σadd cts/min 0.5 
(FIXED) 
- 
CVprop % 5.0 (25.2) 4.7 [2.6, 6.8] 
(S)-pindolol (Plasma)    
σadd mg/L 0.001 
(FIXED) 
- 
CVprop % 31.9 (13.1) 31.4 [23.6, 39.5] 
(S)-pindolol (Urine)    
σadd mg 0.2 (13.4) 0.2 [0.1, 0.2] 
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Shrinkage %    
η-shrinkage (51Cr EDTA)    
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶   0.1  
V1  11.4  
V2  8.5  
Ꜫ-shrinkage (51Cr EDTA)  34.2  
η-shrinkage ((S)-pindolol)    
𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄    8.3  
V2/F  11.3  
fe  15.3  
Ꜫ-shrinkage ((S)-pindolol)    
Plasma % 17.7  
Urine % 14.9  




𝜃𝜃𝐶𝐶𝑇𝑇𝐶𝐶𝐶𝐶  is the population estimate for 51Cr EDTA or (S)-pindolol clearance and 𝐶𝐶𝐶𝐶𝐶𝐶𝑅𝑅  is measured creatinine 
clearance 24 hour urine data and expressed as L/h. The covariate model for 51Cr EDTA 𝑉𝑉1and (S)-pindolol 𝑉𝑉2/𝑚𝑚 
were 𝜃𝜃𝑇𝑇 = 𝜃𝜃𝐶𝐶𝑇𝑇𝑇𝑇 × �
𝑊𝑊𝐶𝐶
70 𝑘𝑘𝐴𝐴
�, where 𝜃𝜃𝐶𝐶𝑇𝑇𝑇𝑇  is the population estimate for 51Cr EDTA 𝑉𝑉1 or (S)-pindolol 𝑉𝑉2/𝑚𝑚 and WT is 
total body weight in kg 
BSV, between-subject variability; CI, confidence interval; 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 , 51Cr EDTA clearance; 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚 , (S)-
pindolol total clearance; Coef, linear coefficient parameter; cts, counts; CVprop, coefficient of variation for 
proportional error; Exp, nonlinear exponent parameter; fe, fraction excreted unchanged in urine; ka, absorption 
rate constant; Q, inter-compartment clearance; RSE, relative standard error; RUV, random unexplained variability; 
V1, volume of the central compartment for 51Cr EDTA, V2/F, apparent volume of the central compartment for (S)-
pindolol; V2, volume of peripheral compartment for 51Cr EDTA; σadd, standard deviation for additive error,  
a 67.5% (n = 675) of the bootstrap runs did not minimise successfully, mainly due to rounding error. These runs 
were included in the calculating RSE% and 95% of CI based on the bootstrap runs (n=1000).  
b Values of 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 and 𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝/𝑚𝑚 are for a typical individual with 𝐶𝐶𝐶𝐶𝐶𝐶𝑅𝑅 of 6 L/h 
c Values of 𝑉𝑉1 and 𝑉𝑉2/𝑚𝑚 are for a typical individual with body weight of 70 kg
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Figure 3.9 Goodness-of-fit plots of the final joint model for 51Cr EDTA and (S)-
pindolol. Observed 51Cr EDTA plasma counts plotted against (a) the population 
predictions for 51Cr EDTA plasma counts and (b) the individual predictions for 
51Cr EDTA; observed (S)-pindolol plasma concentrations plotted against (c) the 
population predictions for (S)-pindolol plasma concentrations and (d) the 
individual predictions for (S)-pindolol plasma concentrations; observed (S)-
pindolol amount excreted in urine plotted against (e) the population predictions for 
amount excreted in urine and (f) the individual predictions for amount excreted in 
urine. Note Ꜫ-shrinkage for 51Cr EDTA plasma count was 34.2%. So, the 
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The covariance step for the final run was not successful for the final model 
suggesting the model is over-parameterised. Specifically, the R matrix (i.e., 
matrix of second derivative with respect to the parameters evaluated at the final 
estimates) was singular and non-positive semidefinite. Perturbing the initial 
estimates of the parameters did not solve this issue. The joint model did not 
include new parameters except for 𝜃𝜃𝐶𝐶𝑟𝑟𝑒𝑒𝐶𝐶  and 𝜃𝜃𝐶𝐶𝑒𝑒𝑝𝑝 , which were included for 
reparameterising 𝐶𝐶𝐶𝐶𝑅𝑅−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄  as a function of 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶  (Equation 3.4). 
Additionally, none of the BSVs had high correlation coefficient.  
The population pharmacokinetic parameters of the final joint model are 
shown in Table 3.4. The RSE obtained from the bootstrap runs (n=1000) showed 
that most of the parameters were estimated precisely. RSE were < 20.0% for the 
fixed effect parameters, except for Coef parameter for the (S)-pindolol which had 
RSE of 27.8%. RSE were < 50.0% for the random effect parameters. The parameter 
estimates for the final joint model were within the 95% CI of the bootstrap 
(n=1000) results. However, about two-thirds of the bootstrap data sets did not 
minimise due to “rounding errors (error = 134)”, which is most common type of 
failure of the estimation step in NONMEM® runs [138]. This may suggest a 
model instability. 
The goodness-of-fit plots for the final pharmacokinetic model describing 
51Cr EDTA and (S)-pindolol simultaneously did not display any systematic 
trends as shown in Figure 3.9. The observed plasma concentration and amount 
excreted in urine for both the probes (DV) versus PRED plot displayed a random 
distribution of data points around the line of identity without systematic trends. 
Since the joint model uses Laplace estimation method for implementing M3 
method [128], weighted residual diagnostics (CWRES) were not calculated for 
categorical as well as continuous data in NONMEM® version 7.3. Eta shrinkage 
was modest (< 16.0%) for all pharmacokinetic parameters for both the 
compounds. Epsilon shrinkage for 51Cr EDTA plasma count, (S)-pindolol plasma 
concentration and urine amount data were equal to 34.2%, 17.7% and 14.9%, 
respectively. So, the individual predictions for 51Cr EDTA plasma count (Figure 
3.9 (b)) were shrunk to the observed data. 
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Figure 3.10 Visual predictive check of the final joint model for (a) 51Cr EDTA 
plasma counts, (S)-pindolol (b) plasma concentrations and (c) amount excreted in 
urine. (a), upper panel of (b) and (c) show simulation based 95% confidence 
interval around the 2.5th, 50th and 97.5th percentiles of the continuous data as 
shaded areas. Solid black lines represent the 50th percentile (median) of the observed 
data for respective probes. Dashed black lines represent 2.5thand 97.5th percentiles 
of the observed data for respective probes. Closed circles represent observed data for 
respective probes. Horizontal grey line in upper panel of (b) show the LLOQ of (S)-
pindolol plasma concentration. Lower panel in (b) show simulation based 95% 
confidence intervals for the proportion of BLQ samples as shaded area and the 
observed proportion of BLQ samples as dashed black line.  
  
c. 
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The VPC of the final joint model of (a) 51Cr EDTA plasma counts and (S)-
pindolol (b) plasma concentration and (c) amount excreted in urine is shown in 
Figure 3.10. Based on the VPC, the 2.5th, 50th and 97.5th percentiles of the observed 
51Cr EDTA plasma counts, (S)-pindolol plasma concentrations (upper panel) and 
amount excreted in urine were within their corresponding simulated confidence 
intervals demonstrating that the final joint model captures both the central 
tendency and the BSV of 51Cr EDTA and (S)-pindolol pharmacokinetics in the 
participants. The observed fraction of (S)-pindolol BLQ plasma concentrations 
(lower panel) were within the simulated 95% confidence interval. This indicates 
that the M3 method for handling BLQ captures the probability of observations 
being BLQ. 
Appendix A2.7 contains the NONMEM® control stream and result files of 
the final joint model that describes plasma of 51Cr EDTA and plasma and urine 
data of (S)-pindolol simultaneously. The model building steps for the final joint 
model that describe 51Cr EDTA and (S)-pindolol data simultaneously is given in 
Appendix A2.8. Appendix A2.9 shows the individual plots comparing observed 
and individual predictions over time for the final joint model. 
3.4.4. Data analysis for testing the INH 
3.4.4.1. Linear regression analysis 
The linear regression of the individual EBEs for (S)-pindolol renal clearance 
and 51Cr EDTA clearance is shown in Figure 3.11, where 51Cr EDTA clearance 
values were > 50% of normal (i.e., 3.6 L/h or 60 mL/min). The y-intercept was 
found to be 1.7 L/h (95% CI [-1.5 L/h, 4.9 L/h]). The 95% CI of the theoretical 
value of (S)-pindolol renal clearance included zero, although the confidence 
interval was very wide. 
The linear regression of the individual EBEs for (S)-pindolol renal clearance 
and 51Cr EDTA clearance is shown in Appendix A2.10, where all data were 
included regardless of 51Cr EDTA clearance values. The minimum value of 51Cr 
EDTA clearance included in the study was 1.6 L/h (or 27 mL/min). In this case, 
the y-intercept was found to be 0.8 L/h (95% CI [-1.0 L/h, 2.6 L/h]). The 95% CI 
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of the theoretical value of (S)-pindolol renal clearance included zero, similar to 
case above. 
 Figure 3.11 Linear regression between individual empirical Bayes estimates of (S)-
pindolol renal clearance and 51Cr EDTA clearance from subjects with 51Cr EDTA 
clearance ≥ 3.6 L/h. Solid line represent the linear regression line for the available 
data and dashed line represents extrapolation of the linear regression line. 
3.4.4.2. Joint model 
The parameters describing the relationship between (S)-pindolol and 51Cr 
EDTA clearance is given in Table 3.4. The 𝜃𝜃𝐶𝐶𝑟𝑟𝑒𝑒𝐶𝐶  describing the linear 
proportionality of non-glomerular processes was equal to 1.4 (95% CI [0.8, 2.5]) 
with RSE of 27.8%. The 𝜃𝜃𝐶𝐶𝑒𝑒𝑝𝑝describing the divergence of the non-glomerular 
processes was equal to 0.8 (95% CI [0.5, 1.1]) with RSE of 17.8%. The 95% CI of 
the value of 𝜃𝜃𝐶𝐶𝑒𝑒𝑝𝑝 include values close to 1 and 0.5, where former value suggests 
that the relationship between the (S)-pindolol and 51Cr EDTA clearance is linear 
and the latter value suggests a non-linear relationship. 
  




In this chapter, data from a renal drug study using 51Cr EDTA and (S)-
pindolol as probes for glomerular and tubular function, respectively, were used 
to test the assumption of the INH. The individual population pharmacokinetic 
models for 51Cr EDTA and (S)-pindolol as well as a joint population 
pharmacokinetic model for 51Cr EDTA and (S)-pindolol were successfully 
developed. The first analysis based on the linear regression of the individual 
EBEs of 51Cr EDTA clearance and (S)-pindolol renal clearance from the 
individual models showed that 95% CI of the y-intercept (the theoretical value 
of (S)-pindolol renal clearance when 51Cr EDTA clearance is equal to zero) 
included zero. The same result was observed with data restricted to values of 
51Cr EDTA clearance > 50% of normal or including all data. However, the 
precision of the y-intercept was poor, with a wide 95% CI. The second analysis 
based on the joint model showed that the Exp parameter is strictly not different 
from 1, which which means that the relationship between 51Cr EDTA clearance 
and (S)-pindolol renal clearance is essentially linear.  
The results could suggest three possible interpretations; 1) the data 
supports the INH (which in essence it does), 2) the study design was inadequate 
(i.e. lack of data in patients with poor renal function, CLcr < 30 mL/min), or, 3) 
the EBE values of (S)-pindolol renal clearance derived from this model-based 
analysis were biased and imprecise. The latter possibility was explored in a post 
hoc analysis where (S)-pindolol renal clearance determined directly from the 
urine and plasma data (using the classic 𝑈𝑈𝑉𝑉/𝑃𝑃 method i.e., ratio of urinary 
excretion rate over plasma concentration) was used to perform regression 
analysis as described in Section 3.3.4.1. The results were similar to that found 
using the EBE values of (S)-pindolol clearance i.e., the estimate of y-intercept was 
imprecise with wide 95% CI (see Appendix A2.11). Additionally, the (S)-pindolol 
renal clearance (mean ± standard deviation) determined by the 𝑈𝑈𝑉𝑉/𝑃𝑃 method 
(5.40 ± 3.51 L/h) was more variable compared to EBE values from the model-
based analysis (5.84 ± 2.87 L/h). This supports the notion that the study design 
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was not sufficient to rule out renal drug handling that follows a non-INH 
scenario. This will be explored further in the following chapters. 
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The work conducted in this thesis explores the hypothesis that the INH 
might not be a suitable model for renal drug handling for those agents cleared 
primarily by tubular secretion. As noted, there are 2 falsifiable predictions that 
can be proposed; (1) that the relationship between renal drug clearance and GFR 
will be non-linear, and, (2) that study design will impact the ability to detect this 
relationship. In the following chapter, the impact of study design to test the INH 
will be explored by evaluating the designs for renal drug studies recommended 
by the European Medicines Agency (EMA) and the United States Food and Drug 
Administration (FDA) guidelines. The studies are required for some renally 
cleared drugs in regulatory submission for new agents to evaluate the 
importance of renal disease on dose requirements.  
4.1. Introduction 
The kidneys are responsible for the elimination of many commonly 
prescribed drugs. Renal impairment would be expected to result in elevated 
plasma concentrations and an increased risk of toxicity for drugs cleared 
primarily by renal mechanisms. A dose reduction is therefore sometimes 
recommended for agents with a narrow therapeutic range when used in 
individuals with renal disease. Information about the appropriate dose to 
prescribe in this setting is provided by the manufacturer on the drug label and 
is usually derived from phase I renal drug studies, conducted during drug 
development. 
Both the EMA [86] and FDA [139] have issued guidelines outlining 
protocols and designs for conducting phase 1 pharmacokinetic studies in 
patients with renal impairment. The primary goal of these studies is to determine 
if the pharmacokinetics of a drug and/or its active metabolite are sufficiently 
altered in renal impairment to warrant dose reductions on the drug label. Both 
the EMA and FDA study designs recommend that the study cohort is stratified 
over five renal function groups, broadly covering normal to severe renal 
impairment. 
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The study designs recommended by the EMA and the FDA are assumed to 
perform well on the basis that the INH is true, i.e. there is a linear relationship 
between 𝐶𝐶𝐶𝐶𝑅𝑅and GFR. However, it is unknown how the designs will perform if 
the INH was not true, i.e. where the relationship between 𝐶𝐶𝐶𝐶𝑅𝑅and GFR is not 
proportional. It is anticipated that this situation may occur for drugs handled 
extensively by tubular processes. The discriminatory characteristics of the EMA 
and the FDA designs for distinguishing drug clearance changes under the INH 
scenario from the non-INH scenario is therefore unknown.  
4.2. Aim 
The aim of this chapter was to evaluate the study designs recommended by 
the EMA and the FDA, as a means of assessing whether renal drug handling 
conforms to the INH or not.  
  




4.3.1. General designs 
In this work, methods that are standard for phase I practice were used. The 
study used a simulation-estimation methodology for a hypothetical drug. The 
drug was assumed to be entirely renally cleared and to undergo extensive 
tubular secretion. Non-renal clearance was not considered. So, CLR is equivalent 
to total clearance (CL) in this work. 
4.3.1.1. Models 
The most commonly used model for 𝐶𝐶𝐶𝐶𝑅𝑅 assumes a linear relationship with 
GFR and hence is based on the INH [1]. This is given by Equation 4.1 below: 
𝐶𝐶𝐶𝐶𝑅𝑅 = 𝜃𝜃1 ∙ 𝑚𝑚𝑚𝑚𝐶𝐶 
Equation 4.1 A linear model for renal clearance (𝐶𝐶𝐶𝐶𝑅𝑅) of the hypothetical drug as 
a function of glomerular filtration rate (GFR) 
where, θ1 is composite of the unbound drug fraction and the linear coefficient 
describing the proportionality of the non-glomerular processes (secretion and 
reabsorption), and GFR is an estimate of glomerular filtration rate. This model 
will be referred to in this paper as ‘M1’. 
To allow for a non-INH scenario, where a change in tubular function 
relative to GFR is not proportional, a nonlinear relationship between the 𝐶𝐶𝐶𝐶𝑅𝑅 and 
GFR was used. This is given by Equation 4.2 below: 
𝐶𝐶𝐶𝐶𝑅𝑅 = 𝜃𝜃1 ∙ 𝑚𝑚𝑚𝑚𝐶𝐶𝜃𝜃2 
Equation 4.2 A non-linear model for renal clearance (𝐶𝐶𝐶𝐶𝑅𝑅 ) as a function of 
glomerular filtration rate (GFR) 
where, θ2 is a composite of exponents that describes the divergence of various 
tubular processes from GFR and other parameters are as described in Equation 
4.1. This model will be referred to as ‘M2’ in this chapter. M2 is equivalent to the 
model proposed by Wright and Duffull [55]. Here, M2 can be considered a 
general model for renal drug handling where M1 is a special case of M2 when 
the exponent θ2 = 1. 
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4.3.1.2. Study designs 
4.3.1.2.1. Simulated renal function groups 
The simulated renal function groups for this work were based on the EMA 
[86] and FDA [139] guidelines for pharmacokinetic studies in patients with 
impaired renal function. The full range of study designs recommended by both 
the EMA and FDA guidelines were tested, including patients in all renal function 
groups (Table 4.1). Subjects requiring dialysis (Group 5) were not considered. 
Additionally, the lower cut-off for GFR was conservatively assumed to be 10% 
of normal GFR, beyond which many patients will require dialysis [140].
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mGFRa (mL/min) eGFRb (mL/min) 
1 Control (normal) ≥90 ≥90 
2 Mild decrease 60 to < 90 60 to 89 
3 Moderate decrease 30 to < 60 30 to 59 
4 Severe decrease < 30 not requiring dialysis 15 to 29 
5 ESRDc < 15 requiring dialysis treatment 
< 15 not on dialysis or 
< 15 requiring dialysis 
treatment 
GFR, glomerular filtration rate; eGFR, estimated glomerular filtration; mGFR, 
measured glomerular filtration rate; ESRD, end stage renal disease 
a mGFR ranges specified in the EMA guidelines. 
b eGFR ranges specified in the FDA guidelines. 
c Subjects requiring dialysis treatment were not included in this study. 
Table adapted from FDA [139] and EMA [86] guidelines. 
4.3.1.2.2. Simulated subjects 
The number of subjects simulated under each EMA and FDA design were 
equally distributed across the four renal function groups outlined in Table 4.1 
(Groups 1-4). The number of subjects tested under each of the designs are given 
in Table 4.2. The minimum number of subjects in the whole study was four, one 
subject in each of the four GFR groups. Further simulations were conducted 
using multiples of four up to 960. 
Table 4.2 Number of subjects in each of the designs based on the FDA and the 
EMA guidelines 
Design Number of subjects 
FDA 4, 8, 12, 16, 20, 24, 32, 48, 72, 120, 240, 480, 960 
EMA 4, 8, 12, 16, 20, 24, 32, 48, 72, 120, 240, 480, 960 
4.3.2. Specific designs based on the EMA and FDA guidelines 
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A summary of study design features specific to the EMA and FDA 
guidelines is given in Table 4.3. 
Table 4.3 Summary of the models that were evaluated and suggested designs based 
(where available) from the EMA and FDA guidelines 
 EMA FDA 
Methods for GFR mGFR eGFR 
Model parameter values M1: 𝜃𝜃1 = 1 
M2: 𝜃𝜃1 = 1;𝜃𝜃2 = 0.33 
M1: 𝜃𝜃1 = 1 
M2: 𝜃𝜃1 = 1;𝜃𝜃2 = 0.43a 
Number of subjects 6 to 8 subjects per renal 
function group 
Not specified 
aSee section 4.3.2.2 for an explanation of the 𝜃𝜃2 value (0.43) used for the FDA designs 
The design aspects specific to the EMA and FDA guidelines are described 
below.  
4.3.2.1. Methods for GFR 
The EMA and FDA guidelines differ in the recommended method for 
estimating GFR. The EMA guideline recommends the use of an exogenous probe 
(e.g. inulin, 51Cr-EDTA, 99mTc-DTPA, iothalamate, iohexol) while the FDA 
recommends the use of creatinine-based methods, such as the Cockcroft-Gault 
[34] or the Modification of Diet in Renal Disease equations [36]. In this work, any 
method using a measured exogenous probe for GFR was denoted as ‘mGFR’ and 
any pre-defined equation for predicting GFR using creatinine as ‘eGFR’. 
4.3.2.2. Model parameter values 
For both M1 and M2 the linear proportional parameter 𝜃𝜃1, was set to 1. The 
𝜃𝜃1 parameter value was not changed for the EMA and the FDA designs 
regardless of whether mGFR or eGFR was used as an estimate of GFR. The EMA 
design recommends the use of mGFR so the value of 𝜃𝜃2 for M2 was set at 0.33 
based on the finding of Wright and Duffull [55]. Of note, the value of 𝜃𝜃2 reported 
in the original study [55] was 0.28, while in this study a convenient value of 0.33 
(or 1/3rd) was selected as a value that would be easier to use in practice. The 
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FDA design recommends the use of eGFR, which may give a biased estimate of 
the true GFR [76]. To account for the differences between eGFR and mGFR, a 
separate analysis was conducted to estimate an adjusted value for the 𝜃𝜃2 
exponent in the FDA design. Details are provided in Appendix A3.1. An 
adjusted 𝜃𝜃2 exponent value was found to be equal to 0.43 that accounted for the 
use of creatinine-based estimates of GFR in the FDA designs.  
4.3.2.3. Number of subjects 
The EMA recommends inclusion of 6 to 8 subjects per renal function group 
[86] while the FDA guideline suggests inclusion of approximately equal number 
of subjects in each renal function groups, but without specific guidance on 
numbers. The FDA suggests enrolling sufficient subjects to detect the level of 
renal impairment at which the dose adjustment is warranted[139]. 
4.3.3. Simulated datasets 
In keeping with EMA and FDA guidelines and common study designs in 
phase I renal handling studies [141, 142] a simulated “two-stage” approach was 
used here for the hypothetical drug. In the first stage the value of CL is estimated 
using a non-compartment approach [141, 142]. In the second stage the value of 
each individual’s estimate of 𝐶𝐶𝐶𝐶𝑅𝑅are regressed against the GFR value (either 
eGFR or mGFR). In this work, 𝐶𝐶𝐶𝐶𝑅𝑅  values were directly sampled from a log-
normal distribution. In essence, therefore only the second stage of any typical 
phase I renal drug study was considered. 
Since the purpose of this study was to evaluate the guidelines for 
identifying non-INH renal handling when it was present, M2 was considered the 
true model (for mGFR θ2 = 0.33, for eGFR θ2 = 0.42) and M1 the false model. For 
calibration of alpha (𝛼𝛼)-error, M1 was considered the true model and M2 the false 
model. 
The processes for generating individual values of 𝐶𝐶𝐶𝐶𝑅𝑅and mGFR and eGFR 
are described below: 
1. Simulation of mGFR (relevant for EMA design):  
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The values of mGFR were sampled from a random log-normal distribution 
for each of the four renal function groups (Table 4.1) centred around the mid-
point GFR value for the ith renal function group which was denoted as GFR� i. In 
this setting, values of mGFR were centred on the mid-point of the GFR range of 
a renal function group. Sampling was not uniform over the range. The purpose 
of doing this was to evaluate the performance of study designs when the values 
of mGFR between renal function groups were well separated. mGFR was 
sampled from the following equation; 
𝑙𝑙𝑛𝑛(𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶𝑝𝑝𝑖𝑖)~ 𝑁𝑁(𝑙𝑙𝑛𝑛(𝑚𝑚𝑚𝑚𝐶𝐶�𝑝𝑝),𝜎𝜎𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅2 ) 
Equation 4.3 A log-normal distribution of values of measured glomerular 
filtration rate (mGFR)  
where, mGFRij is the jth patient’s value of mGFR for the ith renal function group 
and 𝜎𝜎𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅2  is the imprecision with which mGFR is estimated. 𝜎𝜎𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅2  was set to 
the residual variance based on analysis using data from a study that estimated 
mGFR (details provided in Appendix A3.2.). The value of 𝜎𝜎𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅2 was 0.0169. 
2. Simulation of eGFR (relevant for FDA design):  
The values of eGFR were sampled from a random log-normal distribution 
for each of the four renal function groups centred around the median mGFR 
value for the ith renal function group (from step 1) which was denoted as mGFRı� . 
In this setting, values of eGFR were centred on the median mGFR of a renal 
function group. Sampling was not uniform over the range. The purpose of doing 
this was to evaluate the performance of study designs when the value of eGFR 
between renal function groups were well separated. The log-normal mean for 
the eGFR was given by 𝑓𝑓𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅�mGFRı�  ,𝛽𝛽�  and eGFR was sampled from the 
following equation; 
𝑙𝑙𝑛𝑛�𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶𝑝𝑝𝑖𝑖�~ 𝑁𝑁�𝑓𝑓𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅�𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶𝚤𝚤�  ,𝛽𝛽�,𝜎𝜎𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅2 � 
Equation 4.4 A log-normal distribution of values of estimated glomerular 
filtration rate (eGFR) 
where, eGFRij is the jth patient’s value of eGFR for the ith renal function group 
and 𝜎𝜎𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅2  is the imprecision with which eGFR is estimated. 𝜎𝜎𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅2  was set to the 
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residual variance based on analysis using data from studies that estimated both 
mGFR and eGFR (details provided in Appendix A3.2.). The value of 𝜎𝜎𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅2  was 
0.0776. 
𝑓𝑓𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅�mGFRı�  ,𝛽𝛽� gives a value of eGFR as a function of median value of 
mGFR for ith renal function group (i.e., mGFRı� ) and is given as; 
𝑓𝑓𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅�𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶𝚤𝚤�  ,𝛽𝛽� = 𝛽𝛽1 ∙ 𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶𝚤𝚤�  𝛽𝛽2 
Equation 4.5 A function defining estimated glomerular filtration rate (eGFR) 
based on values of measured glomerular filtration rate (mGFR) 
where, 𝛽𝛽1 was equal to 1 and 𝛽𝛽2 was equal to 0.77 (details provided in Appendix 
A3.1., Equation A3.2). 
3. Simulation of 𝐶𝐶𝐶𝐶𝑅𝑅 for EMA design (from mGFR):  
The values of 𝐶𝐶𝐶𝐶𝑅𝑅 for the jth person from the ith renal function group were 
sampled from a random log-normal distribution for each value of mGFRij from 
step 1 using following equation; 
𝑙𝑙𝑛𝑛 (𝐶𝐶𝐶𝐶𝑅𝑅𝑝𝑝𝑖𝑖) ~ 𝑁𝑁(𝑓𝑓𝐶𝐶𝐶𝐶𝐶𝐶,𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅�𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶𝑝𝑝𝑖𝑖 ,𝜃𝜃�,𝜔𝜔𝐶𝐶𝐶𝐶𝐶𝐶
2 ) 
Equation 4.6 A log-normal distribution of values of renal clearance (𝐶𝐶𝐶𝐶𝑅𝑅) as a 
function of measured glomerular filtration rate (mGFR) 
where, 𝜔𝜔𝐶𝐶𝐶𝐶𝐶𝐶
2  is the random variability between subjects in 𝐶𝐶𝐶𝐶𝑅𝑅from the true 𝐶𝐶𝐶𝐶𝑅𝑅, 
which was set to the variance calculated based on the mean coefficient of 
variation in 𝐶𝐶𝐶𝐶𝑅𝑅of predominantly renally cleared drugs from a published study 
[89]. The value of 𝜔𝜔𝐶𝐶𝐶𝐶𝐶𝐶
2  was equal to 0.0900. 
𝑓𝑓𝐶𝐶𝐶𝐶𝐶𝐶,𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅�𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶𝑝𝑝𝑖𝑖 ,𝜃𝜃� gives a value of 𝐶𝐶𝐶𝐶𝑅𝑅as a function of mGFRij and is 
given as (based on Equations 4.1 and 4.2); 
𝑓𝑓𝐶𝐶𝐶𝐶𝐶𝐶,𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅�𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶𝑝𝑝𝑖𝑖,𝜃𝜃� = 𝜃𝜃1 ∙ 𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶𝑝𝑝𝑖𝑖
𝜃𝜃2 
Equation 4.7 A function defining renal clearance (𝐶𝐶𝐶𝐶𝑅𝑅 ) based on values of 
measured glomerular filtration rate (mGFR) 
where, for both M1 and M2 the linear proportional parameter θ1 was set to 1. The 
value of θ2 for M1 was set 1, which reduces the Equation 4.7 to a linear model, 
and for M2 it was set to 0.33 (details provided in Section 4.3.2.2.). 
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4. Simulation of 𝐶𝐶𝐶𝐶𝑅𝑅 for FDA design (from eGFR):  
The values of 𝐶𝐶𝐶𝐶𝑅𝑅 for the jth person from the ith renal function group were 
sampled from a random log-normal distribution for each value of eGFRij from 
step 2 using following equation; 
𝑙𝑙𝑛𝑛 (𝐶𝐶𝐶𝐶𝑅𝑅𝑝𝑝𝑖𝑖) ~ 𝑁𝑁(𝑓𝑓𝐶𝐶𝐶𝐶𝐶𝐶,𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅�𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶𝑝𝑝𝑖𝑖,𝜃𝜃�,𝜔𝜔𝐶𝐶𝐶𝐶𝐶𝐶
2 ) 
Equation 4.8 A log-normal distribution of values of renal clearance (𝐶𝐶𝐶𝐶𝑅𝑅) as a 
function of estimated glomerular filtration rate (eGFR) 
where, 𝜔𝜔𝐶𝐶𝐶𝐶𝐶𝐶
2  is the random variability between subjects in 𝐶𝐶𝐶𝐶𝑅𝑅 from the true 𝐶𝐶𝐶𝐶𝑅𝑅, 
which was set to the variance calculated based on the mean coefficient of 
variation in 𝐶𝐶𝐶𝐶𝑅𝑅 of predominantly renally cleared drugs from a published study 
[89]. The value of 𝜔𝜔𝐶𝐶𝐶𝐶𝐶𝐶
2  was equal to 0.0900. 
𝑓𝑓𝐶𝐶𝐶𝐶𝐶𝐶,𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅�eGFRij,𝜃𝜃� gives a value of 𝐶𝐶𝐶𝐶𝑅𝑅 as a function of eGFRij and is given 
as (based on Equations 4.1 and 4.2); 
𝑓𝑓𝐶𝐶𝐶𝐶𝐶𝐶,𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅�𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶𝑝𝑝𝑖𝑖,𝜃𝜃� = 𝜃𝜃1 ∙ 𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶𝑝𝑝𝑖𝑖
𝜃𝜃2 
Equation 4.9 A function defining renal clearance (𝐶𝐶𝐶𝐶𝑅𝑅 ) based on values of 
estimated glomerular filtration rate (eGFR) 
where, for both M1 and M2 the linear proportional parameter θ1 was set to 1. The 
θ2 for M1 was set 1, which reduces the Equation 4.9 to a linear model, and for M2 
it was set to 0.43 (details provided in Section 4.3.2.2.). 
Finally, GFR was scaled to range from 0.1 to 1, where 1 was GFR in a normal 
adult and 0.1 was the bound, below which the patients were assumed to receive 
dialysis.  
4.3.4. Estimation 
Both M1 and M2 were fitted to the simulated data sets under each design 
and the value of 𝜃𝜃1 and 𝜃𝜃2 were estimated. Additive residual error model was 
used for both M1 and M2. There were no repeated measures. Estimation (linear 
and nonlinear regression) was performed using NONMEM® (version 7.3, ICON 
Development Solutions, Ellicott City, MD, USA). 𝛼𝛼-error was calibrated to be 
equal to 5% to define the model selection criterion (details provided in Appendix 
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A3.3.). The nested models M1 and M2 were compared based on the log 
likelihood ratio test. A decrease in objective function value by more than the 
critical value as determined during 𝛼𝛼 -error calibration for each design was 
required for a statistically significant improvement in the fit at an 𝛼𝛼 level of 0.05. 
One thousand replicates of each design were simulated and estimated.  
4.3.5. Performance evaluation 
Study power, relative standard error (RSE) and bias were calculated to 
evaluate the performance of the study designs. 
The power of a study design was calculated as the probability (expressed 
as percent) of correctly selecting the “true model” M2 over the misspecified 
model M1 under the given study design. 
The RSE was used as a measure of (im)precision. The size of the RSE was 
assumed to relate to the informativeness of a study design. RSE was expressed 
as percentage and was given by: 
𝐶𝐶𝑆𝑆𝑅𝑅 % =  
𝑆𝑆𝑡𝑡𝑒𝑒𝑛𝑛𝑑𝑑𝑒𝑒𝑟𝑟𝑑𝑑 𝑑𝑑𝑒𝑒𝑑𝑑𝑖𝑖𝑒𝑒𝑡𝑡𝑖𝑖𝑑𝑑𝑛𝑛 𝑑𝑑𝑓𝑓 𝑒𝑒𝑠𝑠𝑡𝑡𝑖𝑖𝑚𝑚𝑒𝑒𝑡𝑡𝑒𝑒𝑑𝑑 𝑝𝑝𝑒𝑒𝑟𝑟𝑒𝑒𝑚𝑚𝑒𝑒𝑡𝑡𝑒𝑒𝑟𝑟𝑠𝑠
𝑇𝑇𝑟𝑟𝑢𝑢𝑒𝑒 𝑝𝑝𝑒𝑒𝑟𝑟𝑒𝑒𝑚𝑚𝑒𝑒𝑡𝑡𝑒𝑒𝑟𝑟
× 100% 
Equation 4.10 Relative standard error expressed as percentage 
Here, the “true parameter” is the one used for simulations. 
Bias of the estimated parameter was given by mean error of the estimated 
parameter minus the “true parameter”. The relative bias was expressed as 
percent and given by: 
𝐵𝐵𝑖𝑖𝑒𝑒𝑠𝑠 (%) =  
𝑅𝑅𝑠𝑠𝑡𝑡𝑖𝑖𝑚𝑚𝑒𝑒𝑡𝑡𝑒𝑒𝑑𝑑 𝑝𝑝𝑒𝑒𝑟𝑟𝑒𝑒𝑚𝑚𝑒𝑒𝑡𝑡𝑒𝑒𝑟𝑟 − 𝑇𝑇𝑟𝑟𝑢𝑢𝑒𝑒 𝑝𝑝𝑒𝑒𝑟𝑟𝑒𝑒𝑚𝑚𝑒𝑒𝑡𝑡𝑒𝑒𝑟𝑟
𝑇𝑇𝑟𝑟𝑢𝑢𝑒𝑒 𝑝𝑝𝑒𝑒𝑟𝑟𝑒𝑒𝑚𝑚𝑒𝑒𝑡𝑡𝑒𝑒𝑟𝑟
× 100% 
Equation 4.11 Relative bias expressed as percentage 
A simulation and estimation study was conducted using MATLAB® 
(v.R2018b, The MathWorks Inc., Natick, Massachusetts, USA) for the simulations 
and NONMEM® (version 7.3, ICON Development Solutions, Ellicott City, MD, 
USA) for the estimations. The MATLAB® and NONMEM® codes used to run the 
simulation and estimation study is given in Appendix A3.4. Post-processing and 
plotting were conducted in R version 3.5.1 [133] using ggplot2 [135] and plyr 
Chapter 4: Evaluation of designs for renal drug studies based on the EMA and FDA guidelines 
117  
 
packages [143]. All software ran on a Windows Server 2012 R2 platform with a 
gfortran 4.6.0 compiler. 
  




The random variability in mGFR, eGFR and 𝐶𝐶𝐶𝐶𝑅𝑅used to simulate the data 
sets are shown in Table 4.4. 
Table 4.4 Random variability in mGFR, eGFR and 𝐶𝐶𝐶𝐶𝑅𝑅. 
Variables Estimates values 
𝜎𝜎𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅2  0.0169 




𝜎𝜎𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅2 , imprecision in estimation of mGFR;  𝜎𝜎𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅2 , imprecision in estimation of eGFR; 𝜔𝜔𝐶𝐶𝐶𝐶𝐶𝐶
2 , random 
variability between subject in 𝐶𝐶𝐶𝐶𝑅𝑅 from the true 𝐶𝐶𝐶𝐶𝑅𝑅 
The results of the power analysis of the EMA and the FDA study designs 
are shown in Figure 4.1. The designs under the EMA guidelines required ≥ 16 
subjects to achieve ≥ 80% power while the FDA designs required ≥ 48 subjects to 
achieve the same power. In order to achieve 100% power, the designs under the 
EMA guidelines required 48 subjects while those under the FDA guidelines 
required 240 subjects. 
Figure 4.1 Power of the study designs under the EMA guidelines (black circles and 
line) and the FDA guidelines (grey circles and line) to discriminate between M1 
and M2 when M2 was the “true model”. Horizontal dashed line represents 80% 
power. 
The RSE % of the parameters for designs achieving ≥ 80% power under the 
EMA and the FDA guidelines are shown in Figure 4.2. The linear coefficient θ1, 
was well estimated under both the EMA (n=16) and the FDA (n=48) guidelines, 
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where RSE% ranged from 2% to 14% and 3% to 13%, respectively. The nonlinear 
exponent θ2 was not as well estimated for the designs under both the EMA and 
the FDA guidelines, even for designs with ≥ 80% power. When the number of 
subjects was set to the minimum required by the EMA [86] i.e., 24 subjects (6 
subjects in each of the 4 renal function group), RSE % for 𝜃𝜃1 was 12% and 19%, 
and that for 𝜃𝜃2  was 36% and 65% for the designs under the EMA and FDA 
guidelines, respectively. For the estimation of the non-linear exponent 𝜃𝜃2 with 
RSE% < 25%, the designs based on the EMA and FDA guidelines required 
between 32 and 48, and 120 and 240 subjects, respectively. 
Figure 4.2 Relative standard error expressed as percentage in the estimated 
parameters using M2 under the EMA guidelines (black) and the FDA guidelines 
(grey). The circles represent the linear coefficient parameter 𝜃𝜃1 and the triangles 
represent the nonlinear exponent parameter 𝜃𝜃2. Horizontal dashed line indicates 
the boundary of 25% RSE. 
The percent relative bias for 𝜃𝜃1 and 𝜃𝜃2, for the designs with power ≥ 80% 
under the EMA and the FDA guidelines are shown in Figure 4.3. The designs 
conducted under the FDA guidelines yielded bias in the estimates of both the 𝜃𝜃1 
and 𝜃𝜃2 parameters, which were 9% to 10% and from 10% to 11%, respectively. In 
contrast, the designs under the EMA guideline gave unbiased estimates of both 
the parameters. Bias in the estimates of both the 𝜃𝜃1 and 𝜃𝜃2 parameters were only 
5% to 6%, and 1% to 2%, respectively, for the designs under the EMA guidelines. 
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Figure 4.3 Box and whiskers plot of the relative bias expressed as percentage using 
M2 under the EMA guidelines (black) and the FDA guidelines (grey). Solid box 
represents the linear coefficient parameter 𝜃𝜃1  and striped box represents the 
nonlinear exponent parameter 𝜃𝜃2. 




The renal drug study designs recommended by the EMA and FDA 
guidelines were evaluated for their ability to distinguish renal drug handling 
that follows the INH from that does not. It is envisioned that this context will be 
important for drugs predominantly handled by tubular secretion. In other 
words, to differentiate linear from nonlinear relationship between 𝐶𝐶𝐶𝐶𝑅𝑅 of a drug 
and GFR. The results from this study suggest that while study designs under the 
EMA guidelines would be adequately powered to detect a nonlinear relationship 
between 𝐶𝐶𝐶𝐶𝑅𝑅and GFR, under a standard study size of n=24, study designs under 
the FDA guidelines would require study size of n=48. However, neither 
guideline produced precise estimates of the nonlinear (non-INH) exponent for 
above mentioned study size. 
The clearance of many renally cleared drugs will not necessarily exhibit a 
non-linear relationship with GFR. Drugs that are eliminated mostly by 
glomerular filtration (gentamicin for example) might be expected to be linear in 
relation to GFR. For the purposes of this study, only compounds that were 
predominantly cleared by tubular secretion were considered. Based on the 
findings by Wright and Duffull [55], the value of the exponent (𝜃𝜃2) in the non-
linear equation is anticipated to be to be close to 0.33. It is important to note that 
the estimated value of 𝜃𝜃2 in any given experiment may be different from 0.33 
because of bias caused by insufficient study designs (e.g. too few patients with 
eGFR less than 30mL/min). Therefore, the findings of this study are considered 
only in the setting of highly secreted drugs. 
An important consideration for drug development and clinical practice is 
whether non-linearity in the relationship between renal clearance and GFR 
would impact dosing. To address this, a simulation (see Appendix A3.5.) was 
conducted to determine values of the 𝜃𝜃2  that would result in at least a 50% 
change in drug dosing compared to a linear model. A lower boundary for dose 
reduction was assumed to be a fractional GFR equal to 0.30 (corresponding to a 
GFR 30% of normal), which is commonly used as a cut-off point for changing 
drug doses. It was found that a value of 𝜃𝜃2 ≤ 0.60 provided a deviation in the 
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dose > 50%. This suggests that doses of drugs that are cleared predominantly by 
secretion might be expected to be significantly under-predicted when adjusting 
for renal impairment if a linear model is assumed. 
This study showed that the designs under the EMA guidelines would 
require fewer subjects to achieve ≥ 80% power to discriminate between a linear 
or a nonlinear relationship between 𝐶𝐶𝐶𝐶𝑅𝑅and mGFR compared to the designs 
under the FDA. This was predicated on the choice of method used to estimate 
renal function with mGFR providing a more accurate estimate of true GFR 
compared to eGFR [76]. Therefore, it is anticipated that the phase I renal drug 
studies based on the EMA guidelines have better chance of detecting the non-
linear change in renal drug handling compare to those based on FDA guidelines. 
However, the exponent 𝜃𝜃2 was imprecisely estimated under both the guidelines 
with the minimum number of subjects recommended by the EMA [86]. In 
essence, both the guidelines performed poorly for the limiting feature of the 
design i.e., parameter precision irrespective of the method used to estimate GFR. 
Another important implication of this finding is that the studies that uses eGFR 
as a method to estimate GFR and have sample size were less than 48, they would 
be underpowered to provide insights into the INH. This will include the majority 
of the renal drugs in the literature. 
Precise estimation of 𝜃𝜃2 that describes the degree of divergence of the 
relationship from linearity is expected to be important for drugs that are secreted 
extensively by the renal tubules, and that might therefore display nonlinearity 
in drug clearance. A study by Chapron et al. [144] has shown that for the drugs 
that are primarily secreted in the renal tubule, their renal clearance cannot be 
accurately described by eGFR. This raises concerns about the applicability of 
renal dosing recommendations derived from phase 1 studies where the INH is 
assumed for drugs that are extensively cleared through tubular secretion. 
For drugs that are partially cleared by both filtration and secretion (e.g. 
mirabegron, lomefloxacin [145, 146], it is expected that the relationship between 
renal clearance and GFR will approach linearity and the value of 𝜃𝜃2  will 
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approach 1. In these circumstances both EMA and FDA guidelines would be 
anticipated to perform well. 
In this study, the “two-stage” approach has been maintained that would be 
used commonly in phase 1 renal drug studies as recommended by the EMA and 
the FDA guidelines. The first stage involves calculating relevant 
pharmacokinetic parameter(s) from the clinical data using a non-compartmental 
analysis. In this work, it was assumed that the sampling design for each subject 
was sufficiently intense such that the values of CL were calculated without bias. 
The second stage of this process is to consider the relationship between CL and 
the value of mGFR or eGFR. This may overestimate the precision of the “two-
stage” approach if a less than ideal non-compartmental analysis was conducted. 
In contrast, data analysis methods that use a full population approach will yield 
a more accurate and precise estimate of parameters of interest [147] and hence 
the present work provides a conservative evaluation of power and standard 
errors when using “two-stage” approach. 
This work has some important limitations. Neither EMA nor FDA renal 
drug study guidelines were designed to evaluate the INH, therefore both are 
being extended beyond their original intention. While the comparisons made in 
this study may therefore be an unfair use of the guidelines, it can be argued that 
nonlinearity in renal drug clearance may be important for the drug label and 
therefore an assessment of the guidelines ability to detect this is reasonable. In 
the current study, simulated data is based on a hypothetical drug, which 
represents a typical drug that is predominantly renally secreted. However, the 
performance of the designs evaluated in this study will differ based on the value 
of θ2. Moreover, the power of the study designs is dependent on the fraction of 
drug excreted unchanged. For example, for drugs with a fraction excreted 
unchanged approaching one, the power of the study designs will increase but as 
the fraction excreted unchanged becomes smaller, the opposite is true. However, 
capturing the renal handling behaviour in the latter setting is also less important. 
In conclusion, study designs based on the EMA and the FDA guidelines 
have adequate power to discriminate between INH and non-INH scenarios 
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provided at least 16 and 48 subjects are enrolled, respectively. In a model-based 
analysis performed in the second stage of the “two-stage” approach, the use of 
an exponent to capture any non-linearity in the relationship between drug 
clearance and GFR should provide a flexible solution, accounting for drug 
handling that follows the INH as well as the non-INH scenario. However, the 
exponent was not precisely estimated (i.e., RSE >25%) by either the EMA or FDA 
designs at the number of subjects required for the nominal 80%-power level. The 
results from this study suggest that the renal drug studies would require 
between 48 and 240 subjects to accurately and precisely capture nonlinearity in 
renal drug handling for drugs that are predominantly cleared by secretion. 
The following chapter will use an optimal design methodology to further 
explore the study designs required to adequately capture a non-linear 
relationship between renal drug clearance and GFR. 
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Studies designed to test the INH generally do not consider optimisation of 
design factors like plasma sampling time points, values of GFR among the 
included subjects, number subjects included etc. This was evident in Chapter 2 
of this thesis where only one of the thirty studies performed a power analysis for 
detecting reduction in renal function [111] while none of the studies considered 
formal design techniques. In Chapter 4, the study designs based on EMA and 
FDA guidelines were evaluated for the purpose of testing the INH. Only EMA 
designs performed well in terms of the purpose of testing the INH while both 
performed poorly in terms of precision of the parameter that describes the 
relationship between GFR and renal clearance (CLR) of the drug of interest. The 
rationale for this work was to evaluate whether optimisation of these designs 
may potentially improve parameter precision and efficiency of the study. 
An optimal design is the best design to achieve the study goal from within 
a set of possible designs. Often in pharmacokinetic-pharmacodynamic studies 
this relates to a design that minimises parameter imprecision. In this setting an 
optimal design will result in more precise parameter estimates, than a non-
optimal design, for the same experimental effort and hence an optimal design 
will require smaller sample size to estimate the parameters with the same 
precision. In practice, this translates either to a reduced cost of a study or a more 
efficient study.  
A type of design, termed an approximate design, can be represented by:  
𝝃𝝃 = �
𝑥𝑥1, 𝑥𝑥2,⋯ , 𝑥𝑥𝑝𝑝
𝑤𝑤1,𝑤𝑤2,⋯ ,𝑤𝑤𝑝𝑝� 
Equation 5.1 An approximate design for 𝝃𝝃 with 𝑛𝑛 unique design points 𝒙𝒙𝒊𝒊 and 𝑛𝑛 
weights 𝒘𝒘𝒊𝒊 
where, 𝑥𝑥1,⋯ , 𝑥𝑥𝑝𝑝  represent the values of 𝑛𝑛  design points (e.g. blood sampling 
times) with associated design weights 𝑤𝑤1,⋯ ,𝑤𝑤𝑝𝑝, where 0 ≤ 𝑤𝑤𝑎𝑎 ≤ 1, and ∑𝑤𝑤𝑎𝑎 =
1 for 𝑑𝑑 = 1,⋯ ,𝑛𝑛. Weights of design points reflect their relative importance. The 
design is termed approximate (or statistical) to denote that each support point 
has fractional weighting which may not necessarily reflect a design that can be 
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used exactly. In contrast, an exact design, defined as one that could be conducted 
exactly, would have weights to be integer values where ∑𝑤𝑤𝑎𝑎 = n for 𝑑𝑑 = 1,⋯ , 𝑒𝑒, 
𝑤𝑤𝑝𝑝 ∈ 𝚭𝚭+ which would provide support for 𝑒𝑒 points where 𝑒𝑒 ≥ 𝑛𝑛 such that, 
𝝃𝝃 = �
𝑥𝑥1, 𝑥𝑥2,⋯ , 𝑥𝑥𝑝𝑝
𝑤𝑤1,𝑤𝑤2,⋯ ,𝑤𝑤𝑒𝑒� 
Equation 5.2 An exact design denoted by 𝝃𝝃 with 𝑛𝑛 design points 𝒙𝒙𝒅𝒅 and 𝑒𝑒 
weights 𝒘𝒘𝒅𝒅 
For instance, Equation 5.3 illustrates an example of weights in the exact 
design setting. In this design 𝑥𝑥1 and 𝑥𝑥𝑝𝑝 were given equal weighting and 𝑥𝑥2 twice 
the weighting. 
𝝃𝝃 = �
𝑥𝑥1, 𝑥𝑥2,⋯ , 𝑥𝑥𝑝𝑝
1,   2,⋯ , 1 � 
Equation 5.3 An example of exact design denoted by 𝝃𝝃 with 𝑛𝑛 design points 𝒙𝒙𝒅𝒅 
and 𝑒𝑒 weights 𝒘𝒘𝒅𝒅 
In both the approximate and exact cases there are 𝑛𝑛 support points for the 
design (i.e., 𝑛𝑛 unique dose levels or 𝑛𝑛 unique sampling times) and each support 
point is allocated an optimal weighting (either fractional or integer). An optimal 
design is therefore one in which the location of the support points (𝑥𝑥𝑎𝑎) and their 
weights (𝑤𝑤𝑎𝑎) are optimised. In this work an exact design method was used. 
It is common for optimal designs that are concerned with parameter 
precision to maximise a summary metric of the Fisher information matrix 
(explained in Appendix A4.1). The metric is based on a suitable function, called 
an optimality criterion [74, 75]. For non-linear models, the Fisher information 
matrix depends on the values of parameters denoted as 𝜽𝜽 and the information 
matrix denoted as 𝐌𝐌𝐅𝐅(𝜽𝜽, 𝝃𝝃)  [74, 75]. The most commonly used optimality 
criterion in pharmacokinetic-pharmacodynamic studies is the D-optimality 
criterion, where D denotes the determinant of the matrix, in which the 
determinant of Fisher information matrix is maximised. In pharmacokinetic-
pharmacodynamic studies, the models are inherently statistically non-linear, 
and the model parameters are generally unknown. The D-optimal design is 
therefore conditioned on prior point estimates of the values of the parameters. 
This design, however, may not be optimal if the true, but unknown parameter 
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value, deviates from the prior value. For this reason D-optimal designs are often 
called local D-optimal design [148, 149] to signify their dependence on the local 




Equation 5.4 D optimality criterion 
where, 𝐌𝐌𝐅𝐅 is the Fisher information matrix, 𝜽𝜽 is the vector of parameters, 𝝃𝝃 is a 
design (as in Equation 5.2) and |. | denotes the determinant. 
A robust design is one that is optimised in a way that it has minimal 
dependence on the prior parameter values. Robust designs are therefore 
particularly important in pharmacokinetic and pharmacodynamic studies due 
to nonlinearity of the models. A robust application of an optimal design in 
pharmacokinetic-pharmacodynamic studies should therefore account for the 
two major sources of uncertainty – (1) uncertainty in the model describing the 
system of interest and (2) uncertainty in the prior values of the parameters. For 
the purpose of this chapter, only designs dealing with uncertainty in the 
parameter space were considered. Since the two models considered in this work 
represented a full and a nested model, then the parameter space includes the 
model space in this particular case (i.e. the nest model can be constructed from 
the full model by setting one of the parameters in the full model to a null value).  
Designs that are robust to uncertainty in the parameter space summarises 
the Fisher information matrix over a prior distribution of the values of each 
parameter. Optimality criteria that are used to construct designs that are robust 
to parameter uncertainty include ED and EID [150], API [151] and the 
HyperCube ln D (HClnD) [152]. All of these criteria require maximisation of the 
determinant of the Fisher information matrix over the prior distribution of 
parameter values. The HClnD criterion was used in this work and is described 
in Section 5.3.2.3. 
In addition to parameter estimation, it is also important to discriminate 
between competing models. Commonly, T and Ds optimality criteria are used to 
optimise designs for model discrimination [73, 153]. It is usually the case that T-
optimality is used to discriminate between models that are not nested and Ds-
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optimality for models that are nested. The Ds optimality criterion was used in 
this work and is detailed in Section 5.3.2.4.  
Finally, designs that are intended for discriminating between the models 
are generally different to designs to optimise parameter precision. Indeed 
designs for model discrimination are often reported to be degenerate for 
parameter estimation and hence cannot be considered in isolation of designs to 
maximise parameter precision [154, 155]. A compound optimality criterion is 
therefore required in order to both optimise parameter precision (HClnD) and 
discriminate between models (Ds). These types of criteria have been reviewed 
by others, see for example [75, 156]. Details about the compound optimal 
criterion is given in Section 5.3.2.5. 
In this chapter, the INH was evaluated using optimal design methodology. 
A compound optimality criterion was purpose built to account for parameter 
uncertainty and model discrimination for the linear and non-linear models used 
to describe renal drug handling. The resulting compound optimality criterion 
was applied for optimising a typical phase I renal drug study. The methods used 
in this study are described in Section 5.3, which includes model structure and 
parameters, theory and criteria for the optimal design, and simulation and 
estimation techniques for evaluation of optimal design. The results and 
discussion of the chapter are given in Sections 5.4 and 5.5, respectively. 
5.2. Aim and objective 
The overall aim of this chapter was to explore the minimum requirements 
for a study design for the purpose of testing the INH. The specific objective was 
to construct a study design that served the dual purpose of being both robust for 
parameter estimation and for discrimination between models for linear and non-
linear renal drug handling for drugs that are predominantly renally secreted.




In this section a general overview of the methods used in the chapter will 
be described.  
Firstly (as in Chapter 4), the study design that is commonly used in renal 
drug studies will be described. It will be followed by a description of the 
methods used for optimisation of the design for renal drug studies. And lastly, 
the simulation and estimation method used to evaluate the purpose-built 
optimal design will be described. 
5.3.1. Study design for determining the influence of renal function on the 
pharmacokinetics of a drug 
In this chapter (and as per Chapter 4), a typical renal drug study design 
was used for the purpose of discriminating models for linear and non-linear 
renal drug handling. A two-stage method was followed that is in line with the 
regulatory guidelines [86, 139] and common practice in phase I renal drug 
studies [141, 142]. In the first stage the value of each pharmacokinetic parameter 
(e.g. 𝐶𝐶𝐶𝐶𝑅𝑅 ) is (generally) estimated using a non-compartmental approach [141, 
142]. In the second stage the value of each individual’s estimate of 𝐶𝐶𝐶𝐶𝑅𝑅  are 
regressed against the value of GFR. In this study, the values of 𝐶𝐶𝐶𝐶𝑅𝑅were sampled 
directly rather than describing a pharmacokinetic study design to estimate the 
value of 𝐶𝐶𝐶𝐶𝑅𝑅. Essentially, only the second stage of a typical renal drug study was 
considered where the independent variable was GFR and dependent variable 
was 𝐶𝐶𝐶𝐶𝑅𝑅.  
5.3.2. Design optimisation 
In this chapter, the design was optimised for the second stage of a two-stage 
population approach method of a phase I renal drug study. Therefore, the design 
in this context deals with individual level data only (i.e., no repeated measures) 
and the design space was given by the range of individual’s values of GFR. The 
response of interest was 𝐶𝐶𝐶𝐶𝑅𝑅, so a model that links 𝐶𝐶𝐶𝐶𝑅𝑅 to GFR was evaluated. 
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An optimal design was constructed using purpose-built scripts and functions in 
MATLAB® (v.R2016b, The MathWorks Inc., Natick Massachusetts, USA). 
This work considered a hypothetical drug that is entirely cleared by the 
kidneys. CLR is therefore equal to total clearance and the fraction excreted 
unchanged in urine is equal to one (as in Chapter 4). The structural models and 
model parameters considered for constructing an optimal design are described 
in the following sections. It is followed by a description of robust designs for the 
parameter space as well as model discrimination and compound designs for both 
parameter estimation and model discrimination. 
5.3.2.1. Structural models 
The models for CLR used in this chapter are the same as presented in 
Chapter 4. The most commonly used covariate model for CLR assumes a linear 
relationship with GFR and hence is based on the INH. The expected value of CLR, 
denoted as 𝑅𝑅[𝐶𝐶𝐶𝐶𝑅𝑅], is given by equation below (note a component for non-renal 
clearance was omitted from this equation): 
𝑅𝑅[𝐶𝐶𝐶𝐶𝑅𝑅] = 𝜃𝜃1 ∙ 𝑚𝑚𝑚𝑚𝐶𝐶 
Equation 5.5 Expectation of renal clearance (𝐶𝐶𝐶𝐶𝑅𝑅 ) as a linear function of 
glomerular filtration rate (GFR). 
where, θ1 is a composite of the fraction unbound and a linear coefficient 
describing the net glomerular and non-glomerular processes (e.g. reabsorption), 
GFR is measured as a clearance of an exogenous probe (e.g. inulin, 51Cr EDTA, 
99Tc DTPA) from a pharmacokinetic experiment and is represented as mGFR in 
this chapter. The model will be referred to as ‘M1’. 
In the absence of a mechanistic model to describe the change in tubular 
function relative to GFR under a non-INH scenario, a nonlinear model was used 
to model the relationship between 𝐶𝐶𝐶𝐶𝑅𝑅 and GFR. The expected value of 𝐶𝐶𝐶𝐶𝑅𝑅 is 
given by equation below: 
𝑅𝑅[𝐶𝐶𝐶𝐶𝑅𝑅] =  𝜃𝜃1 ∙ 𝑚𝑚𝑚𝑚𝐶𝐶𝜃𝜃2 
Equation 5.6 A nonlinear model for renal clearance (𝐶𝐶𝐶𝐶𝑅𝑅 ) as a function of 
glomerular filtration rate (GFR). 
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where, θ2 is a composite exponent that describes the divergence of various 
tubular processes from GFR (note the other parameters and variables are as 
described in Equation 5.5). This model will be referred to as ‘M2’ in this chapter, 
which is equivalent to the model proposed by Wright and Duffull [55]. Here, M2 
can be considered as a general model for renal drug handling where M1 is a 
nested case of M2 when the exponent 𝜃𝜃2 =  1. 
M1 and M2 are both candidate models that can be used to describe renal 
clearance of a drug that is mainly renally cleared. In this case, drugs cleared 
through glomerular process only, like gentamicin, kanamycin [106, 157, 158], are 
likely to be best described the linear model, M1. On the other hand, drugs that 
are mainly handled by tubular secretion like metformin, cimetidine, cephalexin 
[79, 80, 159], are more likely to be described by the non-linear model, M2. So, the 
study design for the purpose of this work was required to discriminate between 
M1 and M2, which represent renal drug handling under INH and non-INH 
scenario respectively. 
5.3.2.2. Model parameters 
For both M1 and M2 the initial point estimate of the linear proportional 
parameter θ1 was set to 1 (essentially the net effect is equivalent to a drug that is 
not protein bound and not reabsorbed). The value of θ2 for M2 was set to 0.33 
based on the finding of Wright et al. [55]. 
In practice, the values of the parameters (θ1 and θ2) that define the model 
for renal clearance as a function of mGFR (M1 and M2) may vary and are 
therefore essentially unknown. Hence, there will be variability and uncertainty 
in the values of θ1 and θ2. Here, the parameter values were assumed to follow a 
log normal distribution with coefficient of variation equal to 30% and 10% 
around their mean values and was given as: 
ln(𝜃𝜃1) ~𝑁𝑁(1.00, 0.09) 
ln (𝜃𝜃2)~𝑁𝑁(0.33, 0.01) 
Equation 5.7 Prior distribution for 𝜃𝜃1 and 𝜃𝜃2 
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Since variability (between individuals) and uncertainty (in terms of 
standard error of the parameters) are indistinguishable in this study it is 
assumed that this variability (from Equation 5.7) is sufficient to accommodate 
both sources.  
An additive residual error model was assumed to describe the residual 
unexplained variability (RUV) (see Appendix A4.1 for details on computation of 
the Fisher information matrix). The additive residual variance was assumed to 
be equal to 0.01 (which is relative to a normalised GFR of 0 to 1). This value was 
fixed in the optimal design since error is simply added to the prediction to 
explain the deviation from the observation and is not dependent upon the value 
of the prediction or other factors. The general form is given as: 
𝒚𝒚𝒊𝒊 = 𝒇𝒇𝑪𝑪𝑳𝑳𝑹𝑹(𝑮𝑮𝑮𝑮𝑹𝑹𝒊𝒊,𝜽𝜽) + 𝜺𝜺𝑪𝑪𝑳𝑳𝑹𝑹𝒊𝒊 
Equation 5.8 General model for renal clearance (𝐶𝐶𝐶𝐶𝑅𝑅) as a function of glomerular 
filtration rate (GFR) 
where, 𝒇𝒇𝑪𝑪𝑳𝑳𝑹𝑹(𝑮𝑮𝑮𝑮𝑹𝑹𝒊𝒊,𝜽𝜽) = 𝜃𝜃1 ∙ 𝑮𝑮𝑮𝑮𝑹𝑹𝒊𝒊
𝜃𝜃2, 𝐆𝐆𝐅𝐅𝐑𝐑𝐢𝐢 is a vector of individual values of GFR 
for 𝑖𝑖 = 1, … ,𝑛𝑛, 𝜽𝜽 is a vector of model parameters (parameters and variable are as 
described in Equation 5.5 and 5.6) and 𝜺𝜺𝑪𝑪𝑳𝑳𝑹𝑹𝒊𝒊 is a vector of individual values of 
additive residual error which is assumed to be distributed normally with mean 
zero and variance 𝜎𝜎𝐶𝐶𝐶𝐶𝐶𝐶
2  (𝜺𝜺𝑪𝑪𝑳𝑳𝑹𝑹𝒊𝒊~𝑁𝑁(0,𝜎𝜎𝐶𝐶𝐶𝐶𝐶𝐶
2 )). The details on calculating the Fisher 
information matrix for the general form of the model for renal clearance 
(Equation 5.8) is given in Appendix A4.1. 
5.3.2.3. Designs robust to parameter space 
The hypercube ln D (HClnD) optimality criterion was selected in this work 
to provide a robust design to account for uncertainty in the parameter space. 
Like all robust criteria listed in Section 5.1, this criterion considers that the 
parameters arise from a prior distribution. HClnD uses a simple 2 point 
integration over each prior parameter distribution where the points are spaced 
at the edges of the distribution. The HClnD criterion summarises the information 
across the component models by summing the log of the determinant of the 
Fisher information matrix [152] at each of these parameter sets. This criterion has 
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been shown to be 100-fold faster with similar accuracy and precision as ED and 
API optimality [160].  
The HClnD criterion constructs an optimal design at the edges of the planes 
of the parameters. Each parameter contributes two vertices. For a three 
parameter model this would yield a cube with each set of parameters at the 
vertices of the cube. Since the parameter space may exceed three parameters then 
the resulting cube will have greater than 3-dimensions (i.e. a hypercube). A 
simpler 1- and 2- dimensional representation (relevant to this work) is illustrated 
in Figures 5.1 and Figure 5.2, respectively.  
Optimisation of the resulting HClnD optimal design provides precise 
estimation of the model parameters over the region of the prior distribution of 
the parameters and therefore is robust to parameter variability (and uncertainty). 
In this work the two points were the 2.5th and 97.5th percentile of each prior 









Equation 5.9 Hypercube ln D optimality criterion 
where, 𝛹𝛹𝑃𝑃𝐶𝐶𝑡𝑡𝑝𝑝𝐶𝐶 is HClnD optimal criterion, 𝑞𝑞 is the total number of combinations 
of the 2.5th and 97.5th percentiles over the prior distributions of the parameter, 𝜽𝜽𝒓𝒓 
is the rth vector of parameter values for the rth vertex and 𝑝𝑝 is the number of 
parameters in the model.  
The nested model, M1, has only 1 parameter and hence the 2 vertices (𝑞𝑞 =
2𝑝𝑝, where 𝑝𝑝 = 1) form a line given by ln (𝜃𝜃1,𝐶𝐶) and ln (𝜃𝜃1,𝑃𝑃), with 𝐶𝐶 representing 
the low value (2.5th percentile) and 𝐻𝐻 the high value (97.5th percentile). This is 
represented in Figure 5.1. 




Figure 5.1 A 1-dimentional hypercube i.e., a line segment, with 2 vertices each 
representing a single parameter values for M1.The normal distribution of the 
natural log of 𝜃𝜃1is shown on the left of graph with arrows indicating the 2.5th and 
97.5th percentiles. 
For M2, with two model parameters (𝜃𝜃1  and 𝜃𝜃2 ), the vertices of the 
hypercube would be represented by four sets of parameters (𝑞𝑞 =  2𝑝𝑝, where 𝑝𝑝 =
2), i.e. the vertices of a square (a 2-dimensional hypercube). Again, the parameter 
sets are taken at the 2.5th and 97.5th percentiles of each prior distribution as per 
[152, 160]. Figure 5.2 shows a 2-dimensional hypercube with 4 vertices each 
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Figure 5.2 A 2-dimentional hypercube i.e., square, with 4 vertices each 
representing a sets of 2 parameter values for M2. The normal distribution of the 
natural log of 𝜃𝜃1and 𝜃𝜃2 are shown on the left and bottom of the graph, respectively, 
with arrows indicating the 2.5th and 97.5th percentiles. 
The HClnD optimality criterion can be extended to include two or more 
candidate models by combining the information across all the candidate models 
(i.e., taking sum of each candidate model’s HClnD criterion). The compound 
HClnD criterion for parameter space of more than one model is denoted as 
𝛹𝛹𝑃𝑃𝐶𝐶𝑡𝑡𝑝𝑝𝐶𝐶𝐶𝐶𝑠𝑠𝐶𝐶𝑒𝑒𝑠𝑠𝐶𝐶𝑠𝑠𝐶𝐶  and is given as: 
𝛹𝛹𝑃𝑃𝐶𝐶𝑡𝑡𝑝𝑝𝐶𝐶𝐶𝐶𝑠𝑠𝐶𝐶𝑒𝑒𝑠𝑠𝐶𝐶𝑠𝑠𝐶𝐶 = 𝑒𝑒𝑟𝑟𝑔𝑔𝑚𝑚𝑒𝑒𝑥𝑥
𝜉𝜉








Equation 5.10 Compound hypercube ln D optimality criterion 
where, 𝑙𝑙 is the number of candidate models, 𝑞𝑞𝑚𝑚 is the number of combinations 
of the 2.5th and 97.5th percentiles over the prior distributions of the parameter for 
the 𝑚𝑚𝑟𝑟ℎ model (𝑞𝑞𝑚𝑚 = 2𝑝𝑝𝐶𝐶 ), 𝜽𝜽𝒎𝒎,𝒓𝒓 is the 𝑟𝑟𝑟𝑟ℎ set of parameters of 𝑚𝑚𝑟𝑟ℎ model and 𝑝𝑝𝑚𝑚 
the total number of parameters in the 𝑚𝑚𝑟𝑟ℎ model. 
The possible combinations of parameters for M1 and M2 are provided in 



























95% 𝑐𝑐𝑑𝑑𝑛𝑛𝑓𝑓𝑖𝑖𝑑𝑑𝑒𝑒𝑛𝑛𝑐𝑐𝑒𝑒  
𝑖𝑖𝑛𝑛𝑡𝑡𝑒𝑒𝑟𝑟𝑑𝑑𝑒𝑒𝑙𝑙 𝑑𝑑𝑓𝑓 𝜃𝜃2 
ln (𝜃𝜃2) 
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Table 5.1 Combination of the 2.5th and 97.5th percentiles over the prior distribution 
of parameter values for M1 and M2. 
Model Parameter set number Parameter values 
M1  (𝜃𝜃1) 
 1 (𝜃𝜃1,𝐶𝐶) 0.56 
 2 (𝜃𝜃1,𝑃𝑃) 1.80 
M2  (𝜃𝜃1,𝜃𝜃2) 
 1 (𝜃𝜃1,𝐶𝐶 ,𝜃𝜃2,𝐶𝐶) 0.56, 0.27 
 2 (𝜃𝜃1,𝑃𝑃,𝜃𝜃2,𝐶𝐶) 1.80, 0.27 
 3 (𝜃𝜃1,𝐶𝐶 ,𝜃𝜃2,𝑃𝑃) 0.56, 0.40 
 4 (𝜃𝜃1,𝑃𝑃,𝜃𝜃2,𝑃𝑃) 1.80, 0.40 
 
For M1, the combination of the 2.5th and 97.5th percentiles over the prior 
distribution of the only one parameter (𝜃𝜃1) is equal to 2 sets of parameters (𝑞𝑞 =
 2𝑝𝑝, where 𝑝𝑝 = 1 ). Similarly, for M2 with two parameters (𝜃𝜃1  and 𝜃𝜃2 ), the 
combination of the parameters is equal to 4 sets of parameters (𝑞𝑞 =  2𝑝𝑝, where 
𝑝𝑝 = 2). 
Since M1 is nested within M2, which can be seen both in terms of the 
hypercube figures (Figures 5.1 and Figure 5.2) and in the notation (by fixing 𝜃𝜃2 =
1, Equation 5.6 reduces to Equation 5.5) then it is not necessary to consider the 
separate contribution of the HclnD hypercube for M1 as the design in M2 will 
automatically accommodate support points for M1. Therefore, the general form 
of Equation 5.10 simplifies to Equation 5.9 and it is used to construct HClnD 
optimal design that will cover both M1 and M2. 
5.3.2.4. Designs for model discrimination 
The Ds optimality criterion can be used to discriminate between nested 
models, which aligns with the case here for M1 and M2 (described in Section 
5.3.2.1). Optimisation of the Ds-criterion optimises a subset (the s of Ds) of the 
Fisher information matrix. If the information matrix for the full model is 
considered, then some elements of the matrix will represent information 
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common to both the full and nested models (i.e. 𝜃𝜃1) and some elements will be 
relevant to the full model only (i.e., 𝜃𝜃2 ). The goal of this optimisation is to 
optimise the design for elements related to 𝜃𝜃2  in order to distinguish the full 
model from the nested model (since the nested model does not contain this 
parameter). Hence the design region chosen will be one that provides maximal 
information about 𝜃𝜃2  and minimal information about 𝜃𝜃1 . The Ds optimality 
criterion is constructed by creating sub-matrices (of the information matrix) that 
consist of parameters of interest i.e., 𝜃𝜃2 and the rest of the parameters i.e., 𝜃𝜃1. The 
Fisher information matrix for M2, consists of 4 elements, representing each 
parameter and the interaction between parameters:  
𝐌𝐌𝐅𝐅(𝜽𝜽, 𝝃𝝃) = �
𝐌𝐌𝐅𝐅(𝜽𝜽𝟏𝟏,𝟏𝟏, 𝝃𝝃) 𝐌𝐌𝐅𝐅(𝜽𝜽𝟏𝟏,𝟐𝟐, 𝝃𝝃)
𝐌𝐌𝐅𝐅(𝜽𝜽𝟐𝟐,𝟏𝟏, 𝝃𝝃) 𝐌𝐌𝐅𝐅(𝜽𝜽𝟐𝟐,𝟐𝟐, 𝝃𝝃)
� 
Equation 5.11 Elements of the Fisher information matrix (2 × 2) 
where, 𝐌𝐌𝐅𝐅(𝜽𝜽𝟏𝟏,𝟏𝟏, 𝝃𝝃) and 𝐌𝐌𝐅𝐅(𝜽𝜽𝟐𝟐,𝟐𝟐, 𝝃𝝃) are the elements that relate to the information 
about 𝜃𝜃1 and 𝜃𝜃2 and 𝐌𝐌𝐅𝐅(𝜽𝜽𝟏𝟏,𝟐𝟐, 𝝃𝝃) and 𝐌𝐌𝐅𝐅(𝜽𝜽𝟐𝟐,𝟏𝟏, 𝝃𝝃) are the interaction terms. In the 
absence of interaction terms, it would simply be a matter of optimising the 
information content in the single term 𝐌𝐌𝐅𝐅𝟐𝟐,𝟐𝟐. However, due to these interaction 
terms, the Ds optimality criterion is given as the ratio of the full matrix to the 







Equation 5.12 Ds optimality criterion 
The Ds optimality criterion provides a design that maximises parameter 
precision for a subset of parameters. If the chosen subset are the parameters that 
are present in M2 only then this will maximise the ability to distinguish M2 from 
M1. It is anticipated that designs that arise under this criterion while good for 
discrimination will perform poorly for estimating parameters for M1. 
5.3.2.5. Designs for parameter estimation and model discrimination 
In the current work, the study design is required to be optimal for both 
model discrimination and parameter estimation. It is expected however, and 
shown by others, that designs that are optimal for parameter estimation perform 
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poorly for model discrimination and vice versa [154, 155]. It is therefore required 
that a compound design is formed which comprises both techniques.  
A compound design criterion can be defined as a non-negatively weighted 
linear combination of ℎ design criteria defined on a common design variable 
space [75, 156] and is written as: 
𝛹𝛹𝑠𝑠𝑟𝑟𝑚𝑚𝑝𝑝𝑟𝑟𝑢𝑢𝑝𝑝𝑎𝑎 = arg max
𝜉𝜉




Equation 5.13 A general compound optimality criterion for a set of component 
optimality criteria 
where, 𝛹𝛹𝑠𝑠𝑟𝑟𝑚𝑚𝑝𝑝𝑟𝑟𝑢𝑢𝑝𝑝𝑎𝑎 is the compound design criterion, 𝜳𝜳𝒔𝒔 (𝐌𝐌𝐅𝐅(𝜽𝜽, 𝝃𝝃)), (𝑠𝑠 = 1, … ,ℎ) 
is a vector of ℎ  design criteria, 𝜶𝜶𝒔𝒔 , (𝑠𝑠 = 1, … , ℎ ) is a vector of non-negative 
weights. 
The HClnD and Ds optimality criteria described in Section 5.3.2.3. and 
Section 5.3.2.4., respectively, were combined to form a compound optimality 
criterion. The resulting compound optimality criterion optimises the design for 
both parameter estimation and model discrimination. This compound criterion 
is denoted HClnD⸱Ds and combines the information across the designs by 
summing the log of the determinants at their allocated equal weights (given by 











(1−𝛼𝛼) ��  
Equation 5.14 Compound Hypercube D-Hypercube Ds optimality criterion 
The MATLAB® code for constructing the Fisher information matrices and 
compound optimal design criterion (Equation 5.14) are given in Appendix A4.2. 
The compound optimal design criterion was maximised using simulated 
annealing algorithm implemented in MATLAB®. The details of the variables 
used in this algorithm can be found in paper by Duffull et al.[161]. The values of 
the core variables of the algorithm that were used in these analysis were, initial 
temperature = 103, initial step size for each design point = difference between 
upper and lower bound of a design space (1 and 0.1 mGFR units in this study) 
Chapter 5: Evaluation of the intact nephron hypothesis using optimal design methodology 
 140 
 
and the algorithm was set up to stop at when the step size had reduced to less 
than 10-2. 
5.3.3. Simulation and estimation study 
The optimal design constructed for the purpose of evaluating the INH in 
this chapter was assessed by conducting a simulation and estimation study, 
using MATLAB® for simulation and NONMEM® (version 7.3, ICON 
Development Solutions, Ellicott City, MD, USA) for estimation. The simulation 
and estimation study performed in this chapter is same as that in Chapter 4. The 
components of the simulation and estimation study – simulated subjects, 
simulations, estimations and performance evaluation are that differ from 
Chapter 4 will be noted in following sections: 
5.3.3.1. Simulated mGFR values 
The simulated mGFR values were based on the composite design points 
described in Section 5.4.1. The lower cut-off for mGFR was conservatively 
assumed to be 10% of normal GFR value based on suggestion by Cooper et al. 
[140]. The mGFR was scaled to range from 0.1 to 1, same as in Chapter 4, where 
1 was mGFR in normal adult (corresponding to 120 mL/min) and 0.1 
(corresponding to 12 mL/min) was the bound below which the patients were 
assumed to receive dialysis. 
5.3.3.2. Simulated subjects 
The number of subjects tested under each of the designs are same as in the 
Chapter 4 (Section 4.3.2.3.) and are given in Table 5.2. Four patients were 
considered for the smallest study. This would represent a value of 𝑒𝑒 = 4 (as per 
Equation 5.2). When the study was conducted for multiples of 4 subjects the 
design was expanded proportionally.  
From a design perspective the minimal design would be found where the 
number of design points = 𝑝𝑝 (the number of parameters), assuming any additive 
residual error component is fixed. If the number of subjects is greater than 𝑝𝑝 then 
one of the design points would be repeated (e.g. of the number of subjects = 𝑝𝑝 +
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 1 then one design point would have weighting = 2 and the remainder weighting 
= 1. The replicated design point has twice the weight and corresponds to a 
design where two patients would be enrolled at the particular GFR value.  
The minimum number of subjects included in the study was equal to 4. 
Further simulations were conducted with up to 960 subjects equally distributed 
among the design points. In case the number of subjects mentioned in Table 5.2 
were not exact multiple of the number of design points, subjects remaining after 
equally distributing among the design points were randomly allocated to one of 
the design points. 
Table 5.2 Number of subjects in each of the tested optimal designs 
Design Number of subjects 
Optimal design 4, 8, 12, 16, 20, 24, 32, 48, 72, 120, 240, 480, 960 
 
5.3.3.3. Simulated datasets 
The simulation step for this chapter was similar to that in Chapter 4. The 
difference being 1) the values of mGFR were the composite design points as 
described in Section 5.4.1, where no variability in mGFR values were considered 
and 2) the simulations with eGFR were not considered. The processes for 
generating individual values of 𝐶𝐶𝐶𝐶 are described in Chapter 4, Section 4.3.3. 
5.3.3.4. Estimation 
The estimation step for this chapter was same as in Chapter 4 (Section 
4.3.4.). 
5.3.3.5. Performance evaluation 
The performance of the optimal designs were evaluated by calculating 
study power, relative standard error (RSE) and bias. Each of the performance 
evaluation tool are described in Chapter 4 (Section 4.3.5.).




5.4.1. Optimal design for parameter estimation and model discrimination 
The optimal design points for Ds, HClnD and compound HClnD⸱Ds 
optimal design were found to be the same. The optimal design based on three 
design points were:  
𝝃𝝃 = �0.1, 0.82, 1 � 
Equation 5.15 Ds, HClnD and compound HClnD⸱Ds optimal deisgn based on 
three design points 
And the optimal design based on four design points were: 
𝝃𝝃 = �0.1, 0.73, 1 � 
Equation 5.16 Ds, HClnD and compound HClnD⸱Ds optimal deisgn based on 
four design points 
The optimal designs consisted of two unique design points with a 
repetition of one of the design points. It is not possible to provide an exact 
interpretation of the reason for the repeated sample at 0.1 mGFR units (note this 
is the lower bound of the search space) other than this would appear to be 
important for both parameter estimation and discrimination. 
The support points, 0.1, 0.7 and 0.8, corresponds to mGFR values of 12, 84 
and 96 mL/min. The simulations here were based on the design shown in 
Equation 5.15. Based on the EMA and FDA guidelines [86, 139], 15 mL/min is 
considered to be the cut-off for end stage renal disease, below which it is difficult 
to enrol the subjects in a study. Therefore, one of the design points was adjusted 
to be above the cut-off for end stage renal disease. That means, the optimal 
design points that were used in this study were, 0.10, 0.13 and 0.80 
(corresponding to 12 [the original optimal design point], 16 [a value that is just 
greater than the lower bound by EMA & FDA] and 96 mL/min). This revised 
design is called a composite design (as it comprises both the original optimality 
criteria and limitations imposed by guidances). 
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The percentage RSE for 𝜃𝜃1 and 𝜃𝜃2 were computed for the composite design 
evaluated at nominal parameter values equal to the mean of the prior 
distribution (Equation 5.7) with a sample size of n = 24. For this computation, 8 
subjects were enrolled at each of the three measures of mGFR. The sample size 
corresponds to that recommended by the EMA guideline (only including 
subjects from four renal function groups as described in Chapter 4) [86]. The 
results are shown in Table 5.3. For M1, 𝜃𝜃1 was predicted to be estimated well 
with RSE equal to 4.33%. For M2, both the parameters were predicted to be well 
estimated where RSE was 3.06% for 𝜃𝜃1 and 9.93% for 𝜃𝜃2. Note these values are 
less than the values from the simulation-estimation study (from Figure 5.4).  
Table 5.3 Percentage relative standard error of the estimated parameters for M1 
and M2 evaluated using the composite design with 24 subjects 
Parameters Relative standard error (n = 24) 
For M1  
𝜃𝜃1 4.33% 
For M2  
𝜃𝜃1 3.06% 
𝜃𝜃2 9.93% 
Note: The nominal parameter values for M1 and M2 were equal to the mean 
of the prior distribution (Equation 5.7) and total sample size n = 24, where 8 
subjects were enrolled each of the three design points. 
5.4.2. Evaluation of optimal design 
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The composite design for both parameter estimation and model 
discrimination achieved 90% power with 8 subjects and reached 100% with ≥ 12 
subjects. The results of the power analysis of the composite designs are shown 
in Figure 5.3. 
Figure 5.3 Power of the composite study designs (solid circles) to discriminate 
between M1 and M2 when M2 was the true model. Horizontal dashed line 
represents 80% power. 
The linear coefficient θ1 was estimated with good precision (RSE = 2% to 
18%) for the composite designs with ≥ 12 subjects. The non-linear exponent θ2 
was estimated with good precision (RSE% = 20% to 3%) for the composite 
designs with ≥ 24 subjects. With standard sample size of 24 subjects (6 subjects 
in each of the 4 renal function groups) both the parameters were precisely 
estimated where RSE% of θ1 was 13% and θ2 was 20%. The RSE% of the θ1 and θ2 
parameters for the composite designs achieving >80% power are shown in 
Figure 5.4. 
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Figure 5.4 Relative standard error expressed as percentage in the estimated 
parameters using M2 under the composite designs. Circles represent the linear 
coefficient parameter θ1 and triangles represent the non-linear exponent parameter 
θ2. Horizontal dashed line indicates the boundary of 25% relative standard error. 
 
The composite designs with > 80% provided unbiased estimates of both the 
θ1 and θ2 parameters. The mean bias ranged from 6% to 5% for 𝜃𝜃1 and from 2% 
to 0.03% for 𝜃𝜃2 under the composite designs. The percent relative bias for the θ1 
and θ2 parameters for the composite designs with power > 80% are shown in 
Figure 5.5. 
Figure 5.5 Box and whiskers plot of relative bias expressed as percentage using M2 
under the composite designs. Dark grey boxes represent the linear coefficient 
parameter 𝜃𝜃1 and light grey box represent the non-linear exponent parameter 𝜃𝜃2. 




A study design that is robust for both parameter estimation and 
discrimination between models for linear and non-linear renal drug handling 
was successfully developed. The revised design that accommodated both the 
compound HClnD∙Ds optimality criterion and limitation imposed on values of 
GFR by the guidances was termed a composite design in this study. Only mGFR 
was considered as method for determining the GFR for the purpose of this work. 
So, the outcomes from this study can be compared to the EMA design only, 
which also recommends use of mGFR.  
The performance of the composite designs were better in terms of power, 
precision and efficiency compared to the EMA designs (in Chapter 4). The 
composite design with 8 subjects acquired 90% power to distinguish between a 
linear or a non-linear relationship between 𝐶𝐶𝐶𝐶𝑅𝑅  and mGFR, where the EMA 
design required 16 subjects to achieve same study power. The composite design 
performed better in terms of parameter estimation as well with RSE% of 𝜃𝜃2 equal 
to 20% (based on the simulations) for a sample size of n = 24. Whereas the EMA 
designs with the same sample size performed less well (RSE = 36%) for 
estimating 𝜃𝜃2. Moreover, the composite design improved the efficiency of design 
where inclusion of subjects from only 3 renal function groups (Group 1, 4 and 5) 
was sufficient while the EMA designs recommends inclusion of subjects from 5 
renal function groups. In practice, this results in easier recruitment of subjects 
and reduction in cost. 
Precise estimation of 𝜃𝜃2 is critical for drugs that are primarily secreted by 
the renal tubules. These drugs are most likely to show nonlinearity in renal drug 
clearance. Implementation of the composite design for phase I renal drug studies 
will improve the accuracy of renal dosing recommendations for drugs that are 
secreted by the renal tubules. Implication of this finding to drug development 
and regulatory agencies is that the proposed optimal design can used to reliably 
calculate renal doses in renal impairment patients with standard study size of 24 
subjects. Of note is that both the EMA and FDA designs fail to achieve the same 
as shown in Chapter 4 of this thesis. 
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This is the first study that has applied design optimisation techniques for a 
phase I renal drug study. In this work, the two-stage method was maintained 
that is in-line with phase I renal drug studies based on the EMA and FDA 
guidelines (same as that described in Chapter 4, Section 4.5). The results 
indicated that the composite design would be sufficiently powered to detect a 
nonlinear relationship between renal drug clearance and mGFR with 8 subjects 
at minimum i.e., less than a standard sample size n=24 subjects recommended 
by the EMA guidelines. Moreover, the optimal design estimated the nonlinear 
(non-INH) exponent parameter (𝜃𝜃2) precisely for the aforementioned standard 
sample size. However, it should be noted that this study did not address the 
influence of the practicality of enrolling subjects only at these (exact) GFR values 
(discussed in more detail in the limitations). 
Of interest, it is generally found that designs that are optimised for model 
discrimination are degenerate for parameter estimation and hence cannot be 
considered in isolation of designs to maximise parameter precision [154, 155]. A 
compound optimality criterion is therefore required in order to both optimise 
parameter precision (e.g. ED, API, HClnD optimality) and discriminate between 
models (e.g. T, Ds optimality). These types of criteria have been reviewed by 
others, see for example [75, 156]. Details about the compound optimal criterion 
is given in Section 5.3.2.5. However, in this study the optimal designs to optimise 
(1) parameter precision (HClnD optimal design), (2) discrimination between 
models (Ds optimal design) and (3) both of these criterion (HClnD⸱Ds optimal 
design) were found to be the same. Although, it is not possible to give an exact 
reason, it seems probable that one of the design points is informative for both 
discrimination and estimation. 
There are a number of limitations of this study.  
(1) The variability in the exponent (non-INH) parameter 𝜃𝜃2  were 
conservatively set to a 10% coefficient of variation. Low variability of 𝜃𝜃2  was 
considered because this study focused on the drugs that are predominantly 
cleared by tubular secretion and the value of 𝜃𝜃2 is anticipated to be close to 0.33 
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based on the findings by Wright and Duffull [55]. Consequently, the findings of 
this study are valid for highly secreted drugs only.  
(2) The assumption of an additive residual unexplained variability in the 
design. An additive error model is used generally used when the range of values 
of the dependent variable is relatively small (i.e., less than order of magnitude), 
which is also the case in this study (i.e., renal clearance scaled to range from 0.1 
to 1) [162]. However, in case the range of renal clearance is larger than an order 
of magnitude, a combined additive and proportional error model may be more 
appropriate than additive residual error model [162]. For example, drugs that 
are predominantly secreted may have renal clearance that range more than one 
order of magnitude like metformin, beta lactam antibiotics. To learn about the 
appropriate residual error model, analysis of residuals should be performed. It 
is important to note that the choice of error models will affect the 
informativeness of the design [74].  
(3) The proposed composite design is based on the assumption of non-INH 
scenario being true i.e., the relationship between renal drug clearance and mGFR 
is non-linear. So, the composite design provides minimum requirements for the 
purpose of testing the INH only when the non-INH scenario is true. For the INH 
scenario, where the relationship between renal drug clearance and GFR is linear, 
a design with all subjects equally allocated at the two ends of the physiologically 
possible values of mGFR would be sufficient. Note in this study this would yield 
an optimal design of 0.1 and 1.0. 
(4) The implementation of the composite design in this work did not 
consider variability in GFR values based on recruitment of patients. In a clinical 
study, it is not possible to enrol subjects with mGFR that conform exactly to the 
composite design i.e., 12, 16 and 96 mL/min. In such case the design will be sub-
optimal. This limitation does not apply to Chapter 4 so, in theory, the results 
from this study are not directly comparable to that in Chapter 4. In order to apply 
the composite design in a clinical study, a marginal window around each mGFR 
design points can be created [163]. The marginal windows for the three design 
points based on the composite design were 0-0.13, 0.10-0.35 and 0.75-1.00. The 
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marginal windows provide a region in which some level of difference in values 
of mGFR of enrolled subjects will have minimal effect on the performance of the 
design [74]. 
Overall, the optimal design performed better and had superior efficiency 
compared to the comparable design recommended by the EMA. Under the 
optimal design, 90% power was achieved with at least 8 subjects enrolled in the 
study, which is 3-fold smaller than the standard study size recommended by the 
EMA guideline. The standard study size was adequate to precisely estimate the 
exponent used to define a non-linear (non-INH) relationship between renal drug 
clearance and mGFR. Additionally, the optimal design was comparatively 
efficient design than both the EMA and FDA designs where former design 
require inclusion of subjects from only 3 renal function groups while latter 
designs require subjects from 5 renal function groups. The optimal design 
proposed here can provide a more cost effective and efficient design alternative 
to the existing phase I renal drug studies, which can be used to develop dose 
recommendations more reliably. 
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Renal drug studies, such as those recommended for regulatory submission 
by the FDA and EMA (explored in Chapter 4), were not designed to test the INH. 
Rather, the studies were designed to test the need for dose adjustment in renal 
impairment and the INH is implicitly assumed to be true. As argued elsewhere 
in this thesis, the INH may not hold for the drugs that undergo extensive tubular 
secretion. Studies that are purposely designed to test the INH involve a variety 
of study types including in vitro experiments, animal models, in silico and in vivo 
experiments (see Chapter 2). The following chapter concerns only the latter, i.e. 
in vivo clinical pharmacology studies in humans using drugs or probes for GFR 
and renal tubular handling. Often these studies will include probes for GFR and 
tubular drug clearance and, therefore, if optimally designed can provide a means 
of testing the usefulness of the INH to describe renal drug handling and to 
predict appropriate dosing. 
6.2. Aim and objectives 
The overarching aim of the work summarised here is to explore different 
approaches for analysing the plasma and urine data generated by clinical 
pharmacology studies as a means of testing the INH. There are three specific 
objectives; (1) to describe different approaches for analysing data generated by 
clinical pharmacology studies that might inform the INH, (2) to identify a study 
design criterion for each approach to maximise the ability to distinguish a linear 
from a non-linear relationship between GFR and tubular clearance, and, (3) to 
explore the utility of each experimental approach to test the INH. 
The work presented in this chapter is based on simulated data. Virtual 
subjects with a range of renal function were considered and pharmacokinetic 
parameters of interest were determined. Further details follow. 
6.3. Chapter layout 
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The chapter does not follow a typical layout for an experimental analysis. 
Following an outline of the general methods, study designs and models used in 
the chapter to generate data, the work is summarised under three broad 
headings, aligned with the stated aims above; 
1. Description of approaches for analysing plasma and/or urine data to 
test the INH  
2. Identification of study design criterion for testing the INH 
3. Exploration of the utility of each approach for testing the INH 
6.4. General methods 
The general methods described here were used to generate data for the 
subsequent analyses described in this chapter.  
6.4.1. Measure of renal function 
Virtual subjects were simulated across a wide range of GFR values. Here, 
the values of GFR were assumed to be determined as measured GFR (mGFR) i.e., 
calculated as the clearance of an exogenous probe (e.g. 51Cr ETA, 99mTc DTPA, 
inulin) from a pharmacokinetic study. The values of GFR were scaled to range 
from 0 to 1, where 0 is corresponds to no renal function and 1 corresponds to 
value of GFR in a healthy adult. 
The patient cohorts were stratified by renal function based on the EMA 
guideline for pharmacokinetic studies in patients with impaired renal function 
[86]. The renal function groups are shown in Table 6.1.
Chapter 6: Approaches for analysing data from renal drug studies 
 154 
 
Table 6.1 Classification of renal function groups based on EMA guidelines 
Group GFR description mGFR (mL/min) 
1 Normal GFR ≥ 90 
2 Mild GFR 60-89 
3 Moderate GFR 30-59 
4 Severe GFR <30 not requiring dialysis 
5 Kidney failure <15 requiring dialysis treatment 
6.4.2. Renal drug clearance 
For the purpose of the work conducted in this chapter, a hypothetical drug 
was considered that was assumed to be entirely cleared renally and 
predominantly by tubular secretion. The non-renal clearance was equal to zero. 
This hypothetical drug will be referred to as the “drug” in this chapter. Note here 
total clearance (𝐶𝐶𝐶𝐶) is equivalent to 𝐶𝐶𝐶𝐶𝑅𝑅. 
Two models for 𝐶𝐶𝐶𝐶𝑅𝑅  were used to simulate data; 1) assuming a linear 
relationship between mGFR and CLR (the INH scenario) and 2) assuming a non-
linear relationship between mGFR and CLR (the non-INH scenario). The values 
of mGFR and subsequently CLR were scaled to range from 0 to 1. 
The linear (INH) model. The linear model is given by Equation 6.1 below;  
𝐶𝐶𝐶𝐶𝑅𝑅 =  𝜃𝜃1 ∙ 𝑚𝑚𝑚𝑚𝐶𝐶 
Equation 6.1 Renal drug clearance as a linear function of GFR (M1). 
where, CLR is the renal clearance of the drug, θ1 is a composite of the fraction 
unbound and the linear coefficient describing the net glomerular and non-
glomerular processes, and GFR is the clearance of an exogenous drug for GFR 
drug i.e., mGFR. This model will be referred to in this chapter as ‘M1’. 
The non-linear (non-INH) model. The nonlinear model was given by Equation 
6.2 below; 
𝐶𝐶𝐶𝐶𝑅𝑅 =  𝜃𝜃1 ∙ 𝑚𝑚𝑚𝑚𝐶𝐶𝜃𝜃2 
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Equation 6.2 Renal drug clearance as a non-linear function of GFR. 
where, θ2 is a composite of exponents that describe the divergence of various 
tubular processes from GFR. This model will be referred to as ‘M2’ in this 
chapter. M2 is equivalent to the model proposed by Wright and Duffull [55]. 
Here, M2 can be considered to be a general model for renal drug handling. 
Where M1 is a special case of M2 when the exponent θ2 = 1. For both M1 and M2 
the linear proportional parameter θ1, was set to 1. The θ2 was set to 0.33 for M2 
based on the finding of Wright and Duffull [55]. 
6.4.3. Pharmacokinetic model 
The plasma concentration or urine amount data for the hypothetical drug 
were simulated assuming a one-compartment model with first order elimination 
and an intravenous bolus dose. The pharmacokinetic parameters used for 
simulation were – volume of distribution (𝑉𝑉1) = 1𝐶𝐶, dose = 1𝑚𝑚𝑔𝑔 and 𝑓𝑓𝑒𝑒 = 1. The 
values of 𝐶𝐶𝐶𝐶𝑅𝑅 used were calculated based on either M1 or M2. 
6.5. Identification of approaches for analysing plasma and/or urine data to 
test the INH 
In this section, data analysis approaches to test the INH are described. Here, 
the approaches are intended for data arising from a clinical pharmacology 
studies in humans where relevant drugs or probes are used to estimate GFR and 
renal tubular function. 
6.5.1. Approach 1 
Approach 1 is same as that described in Chapter 3, 4 and 5, adapted from 
the Phase I renal drug studies recommended by regulatory guidelines [86, 139]. 
The guidelines recommend constructing a mathematical model using a 
regression approach to establish the relationship between estimated renal 
function (e.g. mGFR or eGFR) and relevant pharmacokinetic parameter(s) (e.g. 
CLR, CL, AUC). 
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Type of data required. Approach 1 can be used with either plasma data only or 
both plasma and urine data collected from a clinical pharmacological study to 
estimate 𝐶𝐶𝐶𝐶 and 𝐶𝐶𝐶𝐶𝑅𝑅, respectively. It is important to note that for drugs that are 
mainly cleared through the kidneys, 𝐶𝐶𝐶𝐶 determined using only plasma data may 
closely represent 𝐶𝐶𝐶𝐶𝑅𝑅. However, for drugs with a smaller fraction of drug cleared 
through the kidneys, urine data are required to estimate 𝐶𝐶𝐶𝐶𝑅𝑅. 
Methods for data analysis. This approach compares relative change in values of 
mGFR and 𝐶𝐶𝐶𝐶 or CLR as the renal function declines. Here, a non-linear regression 
model (as described in Equation 6.2) was assumed to be the true model. If the 
relationship between mGFR and 𝐶𝐶𝐶𝐶  or 𝐶𝐶𝐶𝐶𝑅𝑅  is best described by a non-linear 
regression model, then it indicates support of non-INH scenario. On the other 
hand, if the same relationship is best described by a linear regression model 
(Equation 6.1), then it supports an INH scenario. 
6.5.2. Approach 2 
This approach is designed to show that simple linear regression of CLR 
against GFR can only support the INH if the y-intercept includes zero. This 
approach was described in Chapter 3 and may be useful when data with a 
limited range of mGFR are available. 
Type of data required. The types of data required and conditions for their use in 
Approach 2 is same as that described for Approach 1.  
Methods for data analysis. This approach is based on a linear regression analysis 
that assumes a linear relationship between CLR of the drug and mGFR, therefore 
aligns with the INH. The linear regression model is given below: 
𝐶𝐶𝐶𝐶𝑅𝑅 =  𝜃𝜃1 ∙ 𝑚𝑚𝑚𝑚𝐶𝐶 + 𝜃𝜃0 
Equation 6.3 Renal drug clearance as a linear function of GFR with 𝜽𝜽𝟎𝟎 
representing the y-intercept. 
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where, the value of the 𝜃𝜃0 represents a deviation of the intercept from the true 
value of zero (which would have been 𝐶𝐶𝐶𝐶𝑁𝑁𝑅𝑅  in the case where 𝐶𝐶𝐶𝐶𝑁𝑁𝑅𝑅  > 0). In 
simulations 𝐶𝐶𝐶𝐶𝑁𝑁𝑅𝑅 is set to zero.  
Using the linear regression model (Equation 6.3), the y-intercept is 
determined under this approach. Theoretically, if the INH holds true (a linear 
relationship between CLR and mGFR), the y-intercept is expected to be zero. If 
the y-intercept is not equal to zero, then it can be concluded that the data suggest 
significant deviation from the INH (a nonlinear relationship between CLR and 
mGFR). 
6.5.3. Approach 3 
Approach 3 is relatively novel and uses the time course of drug 
accumulation in the urine to test the INH.  
Type of data required. Approach 3 requires urine data, collected from a clinical 
pharmacological study to determine 𝐴𝐴𝑒𝑒. It is acknowledged that the collection of 
urine data alone would be unlikely in a practical setting.  
Methods for data analysis. This approach compares the time course of Ae under 
the INH and non-INH scenario at different values of mGFR. Here, similar 
cumulative drug amount-time profiles for two subjects with similar mGFR 
values under the INH and non-INH scenarios indicate support for the INH. 
While any significant difference in time profile of Ae indicate significant 
deviation from the INH. 
6.6.  Identification of study design criterion for testing the INH 
In this section, the criterion for testing the INH will be proposed and the 
study design features required for satisfying the criterion will be identified. In 
this context, the “criterion” means the condition that increases the chance of 
distinguishing between linear and non-linear relationship between 𝐶𝐶𝐶𝐶𝑅𝑅  of the 
drug and mGFR i.e., testing the INH. The only study design component explored 
for this part of work was mGFR. For each of the approaches identified in Section 
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6.5., the proposed criterion, the method used to explore the study design and the 
identified study design feature are described below. 
6.6.1. Approach 1 
Proposed criterion. For approach 1, the criterion for testing the INH is to 
maximise the difference between 𝐶𝐶𝐶𝐶𝑅𝑅  estimated based on non-INH scenario 
(M2) and INH scenario (M1) for a given value of mGFR. 
Methods. A single deterministic simulation was performed to estimate CLR as a 
function of mGFR using M1 and M2, and parameter values described in Section 
6.4.2. The values of 𝐶𝐶𝐶𝐶𝑅𝑅 were estimated directly based on M1 or M2 rather than 
estimating the parameters using simulated data from the pharmacokinetic 
model described in Section 6.4.3. The values of mGFR ranged from 0.00 and 1.00 
and were sampled at the interval of 0.01. 
Identified study design feature. A plot of CLR of the drug versus mGFR under 
INH and non-INH scenario is shown in Figure 6.1. The plot shows that under 
the non-INH scenario, CLR does not decrease proportionally with mGFR, while 
the decrease is proportional under the INH scenario. It was found that the 
maximum absolute difference between the CLR of the drug under the INH 
(𝐶𝐶𝐶𝐶𝑅𝑅 = 0.20) and non-INH scenario (𝐶𝐶𝐶𝐶𝑅𝑅 = 0.59) occurred at mGFR of about 
20% of normal GFR and it was equal to 0.39, which corresponds to a difference 
of 200%. The results suggest that the criterion for testing the INH can be achieved 
by including subjects with lower values of mGFR, i.e. around 20% of normal 
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GFR. This is because the maximum deviation of the relationship between mGFR 
and CLR from linearity is observed among subjects with lower values of mGFR. 
Figure 6.1 Plot of renal clearance (CLR) of the drug versus measured glomerular 
filtration rate (mGFR) under INH (black line) and non-INH (pink line) scenario. 
6.6.2. Approach 2 
Proposed criterion. For the approach 2, the criterion is a y-intercept that is 
significantly different from zero based on the linear regression analysis. 
Methods. Deterministic simulations were conducted and involved calculation of 
values of CLR as a function of mGFR using M2 i.e., under a non-INH scenario. 
The simulated values of mGFR and 𝐶𝐶𝐶𝐶𝑅𝑅  were used to perform the linear 
regression analysis. The y-intercept (Equation 6.3) was determined under four 
mGFR values aligned to the lower limits of the EMA renal groups 1-4 (see Table 
6.1). The values of mGFR used were 0.75, 0.5, 0.25 or 0.13. 
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Figure 6.2 Linear regression of renal clearance of the drug (CLR) versus glomerular 
filtration rate drug clearance (mGFR) simulated under non-INH scenario with 
lower cut-off values of mGFR at (a) 0.75, (b) 0.50, (c) 0.25 and (d) 0.13. Regression 
line for available estimated values of CLR are shown as a solid line and linear 
extrapolation of the regression line is shown as a dashed line. The values of y-
intercepts are indicated in the graph. 
Identified study design. Plots of a linear regression of CLR of the drug and mGFR 
with four different cut-off values are shown in Figure 6.2. The y-intercept was 
estimated to be 0.64, 0.60, 0.55 and 0.51 for each renal group. At a practical level, 
the results suggest that linear regression of CLR and GFR for a drug that is cleared 
mainly by the tubules is able to identify an assumed non-linearity in CLR 
compared to GFR. Note that this result is suggestive only because uncertainty in 
the y-intersect was not considered (this will be explored in Section 6.7.3.2. 
below). 
6.6.3. Approach 3 
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Proposed criterion. For this approach, the criterion is to maximise the difference 
between Ae under INH and non-INH scenario. 
Methods. A deterministic simulation was performed to calculate the time course 
of Ae based on M1 and M2 at different values of mGFR. The 𝐴𝐴𝑒𝑒 was calculated 
based on the pharmacokinetic model described in Section 6.4.3. The maximum 
difference in Ae was calculated at values of mGFR equal to 0.20, 0.40, 0.60 and 
0.80. 
Identified study design. The plots of time course of Ae four different values of 
mGFR are shown in Figure 6.3. The maximum difference between Ae was 
observed at values of mGFR equal to 0.2 (about 20% of normal GFR), where the 
absolute difference in amount was 0.38 mg. The differences were lower at mGFR 
equal to 0.4, 0.6 and 0.8. The results show that the difference in Ae under INH 
and non-INH scenario was maximal at about 20% of normal GFR. Similar to 
approach 1, these results also indicate the importance of inclusion of subjects 
with lower values of mGFR for the purpose of discriminating linear and non-
linear renal drug handling. 
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Figure 6.3 Plots of amount excreted in urine (Ae) of the drug versus time under 
INH (black line) and non-INH (pink line) scenario at values of measured 
glomerular filtration rate (mGFR) equal to 0.2, 0.4, 0.6 and 0.8. 
6.7.  Exploring the utility of each approach for testing the INH 
A simulation of data followed by analysis of the data was done in this 
chapter to explore the utility of the identified approaches for the purpose of 
testing the INH. The study design used was adapted from a standard phase I 
renal drug study design. This study design was fixed i.e., only single design was 
implemented, and no further designs were explored. The simulation and 
analysis of the simulated data for each identified approach are summarised in 
Figure 6.4. The approaches are described in the following subsections.




Figure 6.4 A flow diagram for simulation and analysis of the simulated data sets 
based on the three identified approaches.  
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All simulations, data analysis and plotting were performed in MATLAB® 
(v.R2016b, The MathWorks Inc., Natick, Massachusetts, USA). The MATLAB® 
codes for simulating data sets is given in Appendix A5.1. The non-
compartmental analysis was conducted using PKNCA package (version 0.9.1) 
[164] in R (version 3.5.3) [133]. For the approach 1, the linear and non-linear 
regression using M1 and M2 were done in NONMEM® (version 7.3, ICON 
Development Solutions, Ellicott City, MD, USA) with gfortran version 4.6.0 
compiler (same as in Chapter 4 and 5). For the approach 2, the linear regression 
was performed in MATLAB®. For the approach 3, Ae(t) was directly used, no 
further analysis was required. All software ran in a system with Intel Xenon 
processor, Windows Server 2012 R2 and a GNU Fortran 95 compiler. 
6.7.1. Simulation 
6.7.1.1. Renal function groups 
The patient cohorts were defined based on renal function groups given by 
the EMA guideline for pharmacokinetic studies in patients with impaired renal 
function (Table 6.1) [86]. In this study, mGFR values were used to categorise 
renal function groups, as recommended by the EMA guideline. The lower cut-
off for mGFR was conservatively assumed to be 10% of the mGFR (normal 
healthy subjects) since subjects with mGFR below that level generally require 
dialysis [140]. Therefore, the subjects categorised as Group 5 requiring dialysis 
were not considered in the simulation study.  
One thousand replications of the study design were simulated. Each 
approach was applied to each replication of 100 subjects. Since approach 2 had 4 
cut-off values for GFR then this represented only 25 subjects in group 1 (GFR cut 
off value equal to 0.75), 50 subjects in group 2 (GFR cut off value equal to 0.50), 
75 subjects in group 3 (GFR cut off value equal to 0.25) and 100 subjects in group 
4 (GFR cut off value equal to 0.13). For the other two approaches the complete 
data set of 100 subjects were available. 
6.7.1.2. Pharmacokinetic model and sampling design 
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The simulations were performed using a one-compartment 
pharmacokinetic model and parameters as described in Section 6.4.3 following 
a single intravenous dose of the drug. 
A fixed rich sampling time points were selected for plasma and urine 
samples to ensure that the pharmacokinetic parameters can be estimated with 
adequate precision and acceptable bias. The sampling points for plasma and 
urine samples are given in Table 6.2. 
Table 6. 2 Number of subjects in the study design. 
Sample Time points (hours after dose) 
Plasma 0,0.1,0.2, 0.5,1,1.5,2,3,4,6,8,12,18,24,36 
Urine 0, 0.2,0.5,1,2,4,8,12,24,36 
6.7.1.3. Simulated datasets 
The same simulated data sets were used for data analysis using approach 
1, 2 and 3. The process of simulating plasma concentration and amount excreted 
in urine data is described in Appendix A5.2. In brief, mGFR was divided into 
four renal function groups (as per Table 6.1). The mid-point mGFR value of each 
renal function group was chosen to be the centre values of mGFR and 
subsequently 𝐶𝐶𝐶𝐶𝑅𝑅. In this study, the values of mGFR and 𝐶𝐶𝐶𝐶𝑅𝑅were sampled from 
a log-normal distribution. These sampled values of 𝐶𝐶𝐶𝐶𝑅𝑅  were used in the 
pharmacokinetic model and sampling design described above to simulate 
plasma concentration and urine amount data sets. The simulations were 
performed in two instances using M1 and M2 that give two sets of simulated 
data sets. This is equivalent to two different covariate effect of mGFR on CLR. 
The residual variability for plasma concentration and urine amount data were 
described using combined i.e., additive plus proportional, and additive error 
model, respectively. 
The mGFR values were scaled to range from 0.1 to 1, where 1 was mGFR in 
a normal adult and 0.1 was the bound below which we assume that the patient 
would receive dialysis [140]. 
6.7.2. Analysis 
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For approach 1 and 2 the analysis was based on an initial NCA approach 
to calculate CLR, and then the CLR was regressed against GFR in a second step. 
For approach 3 the variable of interest Ae was available directly from the NCA 
calculation.  
Two sets of parameters were calculated using data sets simulated based on 
M1 and M2. This step was common for all of the three approaches of data 
analysis explored (see Figure 6.4). Following this, individual values of the 
parameters were used for the analysis as described in Section 6.7.3. below. 
One thousand replicates of each design were simulated, and data analysis 
done for each of them. 
6.7.3. Data analysis 
6.7.3.1. Approach 1 
Data analysis method. Analysis of the data involved regression analysis to 
establish a relationship between individual values CLR and mGFR. This is the 
same approach of data analysis used in Chapter 3, 4 and 5. The individual values 
of CLR from data sets simulated under a non-INH scenario was used along with 
corresponding values of mGFR. The linear and nonlinear regression models, M1 
and M2, were fitted to these individual values of CLR and mGFR. Additive 
residual error model was used for both M1 and M2. This was implemented using 
the $PRED block in the NONMEM®, which allows manual specification of a 
model, and the first order (FO) method. Each simulated subject yielded a single 
value of CLR i.e., there were no repeated measures. Therefore, FO method in 
NONMEM® was suitable for modelling data with single level of random 
variability. 
The model comparison was based on a log likelihood ratio test with a 
significance level of a P value of 0.05. Here, M1 is nested under M2. The 
difference between the objective function values from two nested models (M1 
and M2) were assumed to follow a chi-square distribution with a degree of 
freedom equal to the number of additional parameters in the largest of the two 
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models. A model associated with 1 degree of freedom would require a decrease 
in the objective function value of at least 3.84 to achieve statistically significant 
improvement. 
Under the non-INH scenario, the relationship between CLR and mGFR is 
non-linear. So, M2 is expected to perform better than M1 as M2 can capture the 
non-proportional change in CLR with respect to mGFR, which is reflected by the 
exponent parameter 𝜃𝜃2. The power of the study was calculated as the probability 
(expressed as percent) of correctly selecting the true model M2 over the 
misspecified model M1. The precision and bias of the parameters were also 
calculated. 
Results. For each of the simulated data sets, individual CLR and mGFR values 
from all subjects (n=100) were used for regression analysis using M1 and M2. 
Under the Approach 1, 100% power was achieved to correctly identify the non-
INH scenario. Precision of both the parameters were acceptable – relative 
standard error (RSE) for θ1 and θ2 were 6% and 17%, respectively. Both the 
parameters were unbiased under the current study deign. The median (95% 
confidence interval (CI)) value of θ1 was 1.05 (0.94, 1.18) and θ2 was 0.33 (0.22, 
0.45). The 95% CI of both θ1 and θ2 included the true values i.e., 1 and 0.33, 
respectively. The median and 95% CI of estimated values of θ1 and θ2 using the 
M2 are shown in Figure 6.5. 
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Figure 6.5 Plot of median (solid circle) and 95% confidence interval (vertical bar) 
of values of (a) θ1 and (b) θ2 using the M2 (Approach 1). Horizontal dashed line 
represents true values for θ1 and θ2, which were 1.00 and 0.33, respectively. 
6.7.3.2. Approach 2 
Data analysis method. In approach 2, a linear regression was performed with 
individual values of CLR against corresponding mGFR values. Here, the range of 
renal function that would provide the best chance of distinguishing a linear 
relationship from a non-linear relationship between CLR of the drug and mGFR 
was explored. The data sets simulated under only M2 i.e., non-INH scenario 
were used for estimating the CLR of the drug. The analysis was performed with 
four patient cohorts with different cut-off values of mGFR. The lower cut-off 
values for four patient cohort were same as that described in Section 6.6.2. i.e., 
0.75, 0.50, 0.25 and 0.13, which represents the lower end of renal function group 
1, 2, 3 and 4. Since each renal function group included 25 subjects, the patient 
cohorts with lower cut-off corresponding to renal function group 1, 2, 3 and 4 
included 25, 50, 75 and 100 subjects, respectively. 
The y-intercepts were determined based on the regression analysis using 
Equation 6.3. The ‘polyfit’ function was used to perform the linear regression in 
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MATLAB®. This function provides a best fit for the data by minimising the sum 
of the squares of the residuals. The analyses were performed separately for each 
cohort. Each simulated study provided an estimate of the y-intercept – a value 
that represents the theoretical value of CLR when mGFR is equal to zero. In 
theory, when the INH is true, the 95% CI of the values of y-intercept from the 
replicated studies is expected to include zero. However, given the proposed 
shape of the non-linear relationship established by Wright and Duffull [55], the 
deviation of linearly is most pronounced at mGFR values less than about 30% of 
normal GFR. So, by restricting the analysis to lower cut-off values of mGFR equal 
to 0.75, 0.5, 0.25 or 0.13 the y-intercept and 95% confidence interval would not be 
expected to include zero (shown in Figure 6.2). In this approach, the value y-
intercept significantly different from zero (95% confidence interval does not 
include zero) provides evidence against the assumption of INH and vice versa. 
Results. The estimated y-intercept and 95% CI based on the regression analysis 
is shown in Figure 6.6. The median (95% CI) values of the y-intercept estimated 
from the linear regression for patient cohort with lower cut-off corresponding to 
renal function group 1, 2, 3 and 4 were 0.74 (-1.15, 2.36), 0.64 (0.18, 1.18), 0.59 
(0.39-0.79) and 0.53 (0.42-0.64), respectively. The 95% CI of the median values of 
y-intercept did not include zero for patient cohort with lower cut-off 
corresponding to renal function group 2, 3 and 4, while it included zero for that 
with lower cut-off at renal function group 1. The result suggests that this 
approach can be used to test the INH for patient cohorts with GFR values starting 
from the renal function group 1 with lower cut-off corresponding to lower end 
of the renal function group 2, 3 or 4. 
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Figure 6.6 Plot of median (solid circle) and 95% confidence interval (vertical bar) 
of y-intercept determined from the linear regression. Patient cohorts with lower 
cut-off corresponding to renal function group 1, 2, 3 and 4 are represented by G1, 
G2, G3 and G4, respectively. Horizontal dashed line represents y-intercept = 0. 
6.7.3.3. Approach 3 
Data analysis method. In approach 3, the data analysis involved comparison of 
time profile of Ae under INH and non-INH scenario. The data sets simulated 
from both the INH and non-INH scenario were used for determining the time 
course of Ae at different values of mGFR. Here, each patient yields a time course 
of Ae(t), which was obtained from the urine data of the drug. The maximum 
difference in Ae between subjects simulated under INH and non-INH scenario 
with similar value of mGFR was determined. Since the simulated data sets for 
INH and non-INH scenario were obtained from two separate instances of 
stochastic simulation, an exact match of values of mGFR for comparison of Ae 
were not available. For each simulated subject under the INH and non-INH 
scenario, two individuals with the closest match in the values of mGFR were 
paired for comparison. Subjects with values of mGFR corresponding to the renal 
function group 1, 2, 3 and 4 were grouped and the median and 95% CI of the 
differences in Ae were reported. Each renal function group included 25 subjects. 
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For two subjects with similar values of mGFR simulated under INH and 
non-INH scenario, time profile of Ae may be comparable as long as values of CLR 
are not significantly different between the subjects, where other pharmacokinetic 
parameters (V and fe) remain relatively constant. The maximum difference in Ae 
in this case may not be significantly different from zero (i.e., 95% CI of Ae 
includes zero). This supports the assumption of INH i.e., linear relationship 
between CLR and mGFR. If the time profiles of Ae deviate from each other, the 
maximum difference may be significantly different from zero (i.e., 95% CI of Ae 
does not include zero). This occurs because Ae for a given value of mGFR, values 
of CLR are significantly different between the subjects, where other 
pharmacokinetic parameters (V and fe) remain relatively constant. This indicates 
that the relationship between CLR and mGFR significantly deviate from linearity 
i.e., non-INH scenario.  
Results. The values of maximum difference in Ae under INH and non-INH 
scenario for different renal function groups is shown in Figure 6.7. The median 
(95% CI) value of maximum difference in Ae under INH and non-INH scenario 
for subjects in renal function groups 1, 2, 3 and 4 were 0.03 mg (-2.54×10 -11-0.24), 
0.11 mg (2.15×10-4-0.30), 0.23 mg (0.04-0.41) and 0.39 mg (0.20-0.54), respectively. 
The 95% CI of the median values of maximum difference in Ae did not include 
zero for subjects in all renal function group 3 and 4 only. So, the approach can be 
used to test the INH when data from subjects corresponding to renal function 
group 2, 3 or 4 are available. 
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Figure 6.7 Plot of median (solid circle) and 95% confidence interval (vertical bar) 
of maximum difference in amount excreted unchanged between subjects simulated 
with similar value of measured glomerular filtration rate (mGFR) under INH and 
non-INH scenario. Horizontal dashed line represents difference in amount excreted 
unchanged = 0 mg. 




In this chapter, three approaches were identified for analysing data 
generated by clinical pharmacology studies. Each identified approach required 
different study design criterion for discriminating a linear and a non-linear 
relationship between GFR and renal clearance of the drug. Furthermore, their 
utility to test the INH was explored using simulated data followed by its 
analysis. The three approaches used either plasma and/or urine samples, which 
are typically collected in a renal drug study.  
The approach 1 showed that under a non-INH scenario, the maximum 
absolute deviation of CLR from mGFR occurs at about 20% of normal mGFR. This 
signifies the importance of inclusion of subjects with lower values of mGFR, 
especially below 20% of the normal value of mGFR, when the aim is to 
characterise the non-proportional change in CLR of the drug with respect to 
mGFR. The results showed that the study design had 100% power to correctly 
identify a non-INH scenario when it exists. The estimates of model parameters 
were precise and unbiased. Therefore, the Approach 1, is adequate for the 
purpose of evaluating the INH. This is applicable when data are available from 
a full-range design for phase I renal drug study recommended by the regulatory 
agencies [86, 139]. The inferences from this result can be extended for 
recommendation of renal dose adjustment. Precise and unbiased estimates of 
linear coefficient θ1 and non-linear exponent θ2 can be used to estimate CLR based 
on the value of mGFR in a patient with renal impairment. Value of CLR can then 
be used to calculate the maintenance dose rate of drug that are mainly cleared 
through tubular processes [165]. 
Under the approach 2, the value of y-intercept determined from the linear 
regression was dependent on the lower cut-off value of mGFR in the study. The 
results showed that the y-intercept was significantly different from zero for 
patient cohort with renal function groups 2, 3 and 4, and above. This indicates 
that for this approach, at minimum subjects with values of mGFR corresponding 
to renal function group 1 and 2 (i.e., 50% of the normal value and higher) and 
samples size of n=50 subjects should be included for the purpose of testing the 
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INH. Furthermore, inclusion of subjects with even lower values of mGFR 
corresponding to renal function group 1 to 4 (i.e., 13% of the normal values and 
higher) and larger number of subjects (n=100) further improved precision of the 
y-intercept. This would increase the chance of observing the y-intercept 
significantly greater than zero. This approach is useful for testing the INH when 
the data does not include subject with lower values of GFR, where a many renal 
drug studies do not include subjects with mGFR below 30% of the normal value 
of GFR. 
Based on the approach 3, maximal absolute difference between Ae for 
subjects simulated under INH and non-INH scenario was observed at 20% of the 
normal mGFR. This indicates the importance of inclusion of subjects with lower 
values of mGFR for detection of difference in time profile of Ae under INH and 
non-INH scenario. The results from this study showed that the maximum 
difference between Ae in INH and non-INH scenario was significantly different 
from zero for subjects with mGFR corresponding to renal function groups 3 and 
4. This indicates the deviation of the relationship between CLR and mGFR from 
linearity. Therefore, approach 3 can also be used to identify a non-INH scenario 
when it exists. Besides, using the urine data only, the elimination half-life can 
also be calculated by linear regression of the semi-logarithmic plot of the rate of 
excretion versus the midpoint of the urine collection time. Half-life can be used 
to guide dosing interval for chronic multiple dosing scenario [166, 167]. 
An important limitation of this study is the use of large sample size. The 
sample size was larger than that in a typical renal drug study. This was done to 
ensure that the precision of calculated parameters were adequate, based on the 
outcome from Chapter 4. Similar or better performance can be expected from an 
optimal design proposed in Chapter 5. However, this was not tested in this 
thesis. 
The initial exploration of the three approaches using deterministic 
simulations indicated that each approach required different criterion to test the 
INH. The identified criterion can inform about the future study regarding the 
requirement of subjects with minimum values of mGFR to be included in the 
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study for testing the INH. Each of the three approaches could be used to 
successfully test the INH. The approach 1 has been routinely used in a typical 
phase I renal drug study. The other two approaches have not been used 
previously outside of this thesis for the purpose of evaluating the INH. These 
approaches provide alternatives to the reference approach that already exists. 
Overall, the three approaches indicate the importance of inclusion of subjects 
with lower values of mGFR (approximately < 30 mL/min) of the normal value 
of mGFR, for studies evaluating assumption of the INH. 
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7.1. Synopsis of the thesis 
In this thesis, the usefulness of the INH as a general model for renal drug 
handling and dose prediction for drugs predominantly secreted by tubular 
secretion was explored. The following two falsifiable predictions were 
investigated; 1) that the relationship between renal drug clearance and GFR is 
expected to be non-linear for drugs that are secreted by tubular processes, and, 
2) that renal drug study design is expected to play an important role in whether 
non-linearity can be observed. 
The literature has not been reviewed for evidence-base to support the INH 
as a model for renal drug handling. In Chapter 2, a systematic literature review 
was conducted to explore the studies that were specifically designed to test the 
INH. Additionally, the study design features of the included studies were 
accessed using a bespoke strength of evidence score. The majority of studies did 
not support the INH and these studies were more robust in some design features 
in comparison to those supporting the INH. This supports the idea that the INH 
may not be a suitable general model for renal drug handling, especially for drugs 
with predominant tubular secretion. This suggests that the first prediction about 
non-linear drug handling holds true. 
In Chapter 3, two model-based analyses were performed to test the INH 
using concentration time data of probes used to measure glomerular (i.e. 51Cr 
EDTA) and tubular function (i.e. (S)-pindolol). Unfortunately, the analyses could 
not establish whether renal drug handling followed the INH or not, most likely 
because of limitations of the study design. This notion was explored further in 
the subsequent chapters. The findings in this study was not able to conclude 
anything about the first prediction. 
The published studies that aimed to test the INH generally did not make 
any prior consideration about components of the study design - this was evident 
from the literature review in Chapter 2. In Chapter 3, the phase I renal drug 
study designs recommended by the EMA and FDA were explored as a means of 
distinguishing renal drug handling that followed the INH from handing that did 
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not. The designs based on the EMA guidelines required a less number of subjects 
(n = 16) than those recommended by the FDA (n = 48) to achieve sufficient study 
power to distinguish non-linearity in renal drug handling (non-INH scenario) 
from linear (INH scenario). This outcome was predicated on the recommended 
method for determining GFR, where the EMA recommended the use of mGFR 
(the gold standard method) as opposed to eGFR, which was recommended by 
the FDA. Importantly, when standard sample sizes for renal drug studies were 
considered (i.e., n = 24; 6 subjects each in 4 renal function groups), neither study 
design produced precise parameter estimates (RSE % for EMA was 12% to 36% 
(for 𝜃𝜃1 and 𝜃𝜃2) and that for FDA was 19% to 65% (for 𝜃𝜃1 and 𝜃𝜃2)). It is important 
to note that the precise estimation of parameters is crucial for determining the 
true relationship between renal drug clearance and GFR (either eGFR or mGFR), 
and, ultimately in renal dose adjustment. This work showed support for the 
second prediction where the method used to determine GFR and the number of 
subjects included in the renal drug studies are critical components for 
distinguishing between linear and non-linear renal drug handling. 
A study design robust for both parameter estimation and for distinguishing 
between models for linear (INH) and non-linear (non-INH) renal drug handling 
was built. An optimal design methodology was used for this purpose and the 
proposed study design was called the composite design. The performance of the 
composite designs was superior in comparison to the study designs proposed by 
the EMA and FDA where only 8 subjects were required to achieve 90% study 
power. More importantly, the model (M2) parameters were estimated with 
adequate precision (RSE % = 13% and 20 % for 𝜃𝜃1 and 𝜃𝜃2, respectively ) when 
using the standard sample size (n = 24). This would in turn improve the 
estimation of renal drug clearance based on GFR value and hence allow for more 
accurate dose prediction in renal impairment patients. Moreover, the finding 
that the optimal study design included mGFR values of 12, 16 and 96 mL/min 
in the composite design indicates the importance of enrolling subjects with a 
range of GFR values, including lower values (< 30 mL/min) in renal drug 
studies. This is because the maximum deviation of renal drug handling for 
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highly secreted drugs from linearity was found to occur at lower values of 
mGFR. The findings in this work suggest that the mGFR values of the enrolled 
subjects are critical for determining the true relationship between renal drug 
clearance and GFR. 
Three different approaches were identified and explored as a means of 
testing the INH. In addition to the commonly used approach i.e., the standard 
phase I renal drug study, two new approaches were proposed. The second 
approach was based on linear regression of renal drug clearance against GFR 
and the third approach used the time course of drug accumulation in the urine 
to test the INH. The utility of the three approaches to test the INH were 
successfully established. The results indicated the importance of enrolling 
subjects with lower values of mGFR (approximately < 30 mL/min) for studies 
evaluating the INH for all three approaches. 
7.1.1. Importance for clinical practice and drug development 
In clinical practice, there are two major concerns with dosing renally 
cleared drugs in patients with renal impairment: 1) an increased risk of toxicity 
for drugs with a narrow therapeutic range when standard doses are used (e.g. 
gentamicin, vancomycin), and, 2) a risk of under-dosing in some patients groups 
with increased (or augmented) renal clearance (e.g. the obese or critically unwell) 
if the standard doses are prescribed (e.g. beta-lactam in critically unwell 
patients).  
It is acknowledged that this thesis does not explicitly explore the clinical 
implication of non-linearity in renal drug handling on drug dosing. In other 
words, this thesis did not conclude anything about specific drugs or clinical 
conditions where INH versus non-INH renal drug handing might be important 
for dose selection. It is argued here that the clinical impact of the non-linearity in 
renal drug handling could not be explored without knowledge of the study 
designs required to capture non-linearity in renal drug handling. In this thesis, 
the impact of the components of the study design (i.e. type of probe used to 
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determine GFR, number of subjects and range of GFR) on the ability to capture 
this non-linearity were explored. 
It should also be stated that not all drugs would be expected to exhibit non-
linearity in the relationship between renal clearance and GFR. Drugs that are 
mainly cleared by glomerular filtration (e.g. gentamycin, vancomycin) are 
expected to demonstrate a linear relationship. In this thesis, only drugs that are 
predominantly cleared by tubular secretion are considered, where it is proposed, 
and supported by data in the literature, that a non-linear relationship between 
renal clearance and GFR exists [55, 106, 111, 116]. The impact of this non-linearity 
on renal drug dosing was explored in Chapter 4 (Appendix 3.5). A simulation-
based analysis showed that for drugs that are mainly cleared by glomerular 
filtration the dose predicted and adjusted for renally impaired patients is not 
significantly affected (< 50%). This was under the assumption that the linear 
(INH) model held true. Therefore, although incorrect, the INH could be applied 
without anticipating major clinical issues. On the other hand, for drugs that are 
cleared predominantly via tubular secretion the renal dose adjustment may be 
significantly under-predicted (> 50%) if the linear INH model is assumed. So, in 
this setting, a clinically significant impact (i.e., treatment failure due to under-
dosing) under prediction of dose, may be anticipated when the INH is applied. 
In drug development, Phase 1 renal drugs studies are performed for new 
drugs for which the kidney is the major organ for elimination (≥30%) [139]. The 
renal drug study designs proposed by the EMA and FDA guidelines assume a 
linear relationship between the renal clearance of a drug and GFR i.e., INH is 
true. However, it was shown (in Chapter 4) that both the study designs did not 
perform well in determining the non-linear relationship between the renal 
clearance of a drug and GFR when the standard number of subjects were 
enrolled (n =24). This may have clinically significant implications for drugs that 
are predominantly cleared by tubular secretion, where dose may be significantly 
under-predicted (> 50%) if the linear relationship i.e., INH is assumed (see 
Chapter 4, Appendix 3.5). Therefore, there appears to be a case for new drugs 
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with tubular secretion as a primary route of elimination to be tested for non-
linearity. In this setting, the clinical implications on dosing should be explored. 
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7.2. Thesis limitations 
The work presented here needs to be interpreted in light of some important 
limitations. It was not possible to conduct a meta-analysis nor determine a 
summary effect size for the studies reviewed Chapter 2. This limits the ability to 
draw inferences from the results. Unfortunately, and not unexpectedly for the 
types of studies reviewed, the studies used a variety of different methods, in 
different settings (in vitro, animal models etc.) to assess the relationship between 
tubular function and GFR. Therefore, the results from the reviewed studies were 
not directly comparable.  
In Chapter 4, 5 and 6 of this thesis model-based approaches were used to 
explore the renal drug study designs for their ability to capture non-linearity in 
renal drug handling. It is important to note that the current work was based on 
in silico simulation-estimation experiments. The simulations performed in this 
work were based on the empirical non-linear model (M2) for renal drug 
clearance and study designs recommended by the EMA and FDA or purpose-
built study designs. Therefore, the simulated data represent, while not 
equivalent, that collected from a well-designed renal drug study. The outcomes 
from this work provide evidence to indicate the requirement for the study 
designs to test the INH. The outcomes presented in this work represent a step 
towards a better understanding of the components of study designs required for 
capturing non-linearity in the relationship between renal drug clearance and 
GFR.  
An important limitation of the work performed in Chapter 4 was that both 
the EMA and FDA renal drug study guidelines were not designed to evaluate 
the INH. Therefore, both were being extended beyond their original intention. 
The comparisons that were made may be an unfair use of the guidelines. 
However, it can be argued that non-linearity in renal drug handling may be 
important information on drug labels and therefore an assessment of the 
guidelines ability to detect this is reasonable. Another limitation was that the 
simulation-estimation experiment evaluating the performance of the study 
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designs (EMA, FDA and composite design) conducted in Chapter 4 and Chapter 
5 did not consider design for plasma and/ or urine sampling times for renal drug 
studies. This was done because the sampling design was assumed to be adequate 
for determining the renal clearance of drug without bias.
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7.3. Future work 
An interesting proposition that could be explored in a systematic literature 
review, is that published renal drug studies may inadvertently provide 
information about the INH. Renal drug studies may be intended to explore dose 
requirements, or to determine the pharmacokinetic changes in renal impairment, 
by investigating the change in renal drug clearance with respect to a change in 
mGFR or eGFR. A review of these studies, with a focus on drugs handled by 
tubular secretion, could support the hypothesis addressed in this thesis that the 
INH will not provide a reasonable model for drug handling when tubular 
secretion dominates. In general, these types of studies are limited by two issues; 
1) many studies do not include or have small number of subjects with GFR < 30 
mL/min, which are likely to limit the chance of observing a non-linear renal 
drug handling (see Chapter 6), and, 2) most studies estimate renal function using 
creatinine based eGFR, which may confound the relationship between renal 
drug clearance and GFR due to the fact that creatinine is secreted by tubules. 
Future research intended to establish the true relationship between GFR 
and tubular function i.e., to test the INH, should be specifically designed to 
capture non-linearity for drugs that are predominantly secreted. It is important 
to carefully consider the design of future renal drug studies. A standard phase I 
renal drug study can be used where pharmacokinetic study is conducted in 
subjects with a range of renal function while considering following component 
of study design: 1) exogenous probes should be used to determine GFR i.e., 
mGFR method, 2) subjects with low GFR values (< 30 mL/min) as well as those 
with normal values of GFR (≥ 90 mL/min) should be enrolled in the study, and, 
3) at least 24 subjects should be enrolled with equally distribution within the 
range of GFR. 
Determining the clinical impact of dosing renally cleared drugs requires 
further work not covered in this thesis. This may be important for drugs that are 
predominantly cleared by tubular secretion. Dose adjustment assuming a linear 
relationship between GFR and tubular clearance may result in an under-
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prediction of dose by as much as 50% for patients with severe renal impairment 
(GFR < 30mL/min) according to the models used in this work (see Chapter 4). 
Future studies are required to replicate this this under-prediction in vivo and to 
explore any clinical implications. 
Future studies are warranted to explore the study design requirements for 
the second and third approach proposed in Chapter 6. The second approach is 
based on a linear regression model. According to optimal design theory, for a 
linear model, the allocation of subjects at the upper and lower cut-off for mGFR 
values would provide optimal design points [74]. The third approach compares 
the time profile of amount excreted unchanged in urine to test the INH, which is 
described by a non-linear model. For this approach, the optimal design points 
based on values of mGFR to be included in the study should be determined using 
an optimal design methodology. A separate simulation-estimation based study 
is required to determine the number of subjects required to estimate the model 
parameters with adequate precision and accuracy for both approaches. 
 




The INH has been investigated as a general model for renal drug handling 
and renal study designs have been evaluated for the purpose of testing the INH. 
The evidence-base as reported in published studies suggest that the INH 
may not be a suitable model for renal drug handling. Moreover, the studies that 
did not support the INH were robust in terms of some design features compared 
to those supporting the INH. However, the two model-based analyses using data 
from a renal drug study using probes for glomerular and tubular function were 
not adequate to evaluate the INH. Further analysis of the data from a specifically 
designed study to test the INH is warranted. 
The standard phase I renal drug study design based on the EMA guideline 
performed better when compared to the FDA guideline for the purposes of 
testing the INH. However, both of the study designs performed poorly in terms 
of parameter precision when using the standard sample size (n = 24). The 
composite design constructed using optimal design methodology showed an 
adequate performance with standard sample size (n = 24) to test the INH, 
including parameter precision. Parameter precision is crucial for predicting renal 
clearance based on GFR, which is in turn used to calculate the maintenance dose 
in patients with renal impairment. 
Three approaches for analysing data from a renal drug study were explored 
to test the INH. The first approach was based on the standard phase I renal drug 
study, whilst the other two approaches were newly introduced in this thesis. The 
latter two approaches provide an alternative means for testing the INH in 
addition to the first method that is currently routinely used. The utility of the 
three approaches for testing the INH were established successfully. 
The evidence-base in literature suggest that the INH may not be a suitable 
general model for renal dug handling. An empirical non-linear model can be 
used to account for both non-linear (non-INH) and linear (INH) renal drug 
handling. An appropriately designed study for testing the INH will provide a 
means for accurately predicting the change in renal drug clearance based on 
renal function and hence the required maintenance dose. The work conducted in 
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this thesis provides a framework for the safe and effective use of medicines in 
patients with renal impairment.
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A1.1. Literature search strategy based on learning-based approach 
Table A1.1 MeSH terms, number of possible combinations and the number of 
hits in each iteration for the learning based approach 
Iteration MeSH terms used No. of 
possible 
combinations 
No. of hits 





2 exp chronic disease 
exp kidney function tests 
exp nephrectomy 
exp kidney disease  
exp aminohippuric acid 
exp kidney 
exp potassium dichromate 
exp inulin 
70 2341 
3 (1 or 2) - 2696 
4 Limit 3 to English language only - 2117 
MeSH, medical subject heading; exp, “exploded”
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A2.1. NONMEM® control file of the final individual model for 51Cr EDTA. 
;; 1. Based on: 15 
;; 2. Description: Cr EDTA plasma data   
;; x1. Author: user 
$PROBLEM    Cr EDTA plasma data 
;; 3. Label: 
;; Final model 
;; 4. Structural model: 
;; Two compartment model 
;; 5. Covariate model: 
;; CRCL on CL, WT on V1 
;; 6. Interindividual variability: 
;; CL, V 
;; 7. Interoccasion variability: 
;; 8. Residual variability: 
;; Combined additive and proportional 
;; 9. Estimation: 
;; FOCE+I 
$INPUT      ID STUDYID=DROP TIME DV AMT DNAMT RATE MDV CMT EVID 
BLQ 
            AGE WT HT SEX CRCL 
$DATA      credta_new.csv IGNORE=# 
 ; 
$SUBROUTINE ADVAN6 TRANS1 TOL=9 
$MODEL      COMP=(PLASMA) COMP=(PERIP) 
$PK    












 ; SCALE CONCENTRATIONS 
 S1=V1 
 





$DES    
 DADT(1)=-K10*A(1)-K12*A(1)+K21*A(2) 





$ERROR    
 IPRED = A(1)/V1 
 W = SQRT(IPRED**2*THETA(5)**2 + THETA(6)**2) 
 Y = IPRED + W * EPS(1) 
 
$THETA  (0,6.24484397479647) ; CL 
 (0,14.537374634867) ; V1 
 (0,2.17580990814084) ; Q 
 (0,3.95754900838559) ; V2 
 (0,0.0455818947721371) ; RUV_PROP 
 (0,0.5) FIX ; RUV_ADD 
$OMEGA  BLOCK(3) 
 0.0469827600959663  ; BSV_CL 
 0.0156201894627819 0.0553200806058742  ; BSV_V1 
 0.0139443205457727 0.0519317059843638 0.390114678553887  ;BSV_V2 
$SIGMA  1  FIX 
$ESTIMATION MAX=9999 SIG=4 PRINT=10 METHOD=COND INTER NOABORT  
$COVARIANCE PRINT=E 
$TABLE      ID TIME CMT IPRED CWRES CIWRES NOPRINT ONEHEADER 
FILE=sdtab17 
$TABLE      ID CL V1 Q V2 ETAS(1:LAST) NOPRINT ONEHEADER 
FILE=patab17 
$TABLE      ID SEX NOPRINT ONEHEADER FILE=catab17 
$TABLE      ID AGE WT HT SEX CRCL NOPRINT ONEHEADER FILE=cotab17 
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A2.2. The development of the 51Cr EDTA model 
Table A2.1 Model building steps for 51Cr EDTA 
Run 
number 







model; BSV on all 
parameters; combined 
proportional and 
additive residual errors 
1192.89 
(6) 
- Bias in CWRES 
versus time after 
dose 






increment in OFV 
6 Two-compartment 
model; BSV on all 
parameters; 
proportional and 
additive residual errors 
1085.80 
(10) 
2 Reduction in AIC  
(-99.091); no bias in 
CWRES versus time 
after dose; BSV on Q 
equal to 0.30 % 
7 Same as run 6; BSV on 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶, V1, and V2 
1085.90 
(9) 
6 No significant 
change in OFV  
8 Same as run 7; additive 





increment in OFV  
9 Three-compartment 
model; BSV on all 
parameters; 
proportional and 
additive residual errors 
1085.01 
(14) 
6 Increase in AIC 
(7.213) 
11 Same as run 7; 
creatinine clearance 
effect on 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 
1013.07 
(9) 
7 Significant reduction 
in OFV; BSV on 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 reduced 
from 54% to 20% 
12 Same as run 11; BW 
effect on V1 
1003.79 
(9) 
11 Significant reduction 
in OFV; BSV on V1 
reduced from 25% to 
22% 
13 Same as run 12; 
variance-covariance 
matrix with co variance 
estimated between 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶, V1 and V2 
995.23 
(12) 
12 Significant reduction 
in OFV; no 
successful 
convergence 
17 Same as run 13; additive 





convergence; RSE of 




parameters ≤ 21% 
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A2.3. Individual plots from the final 51Cr EDTA model  
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Figure A2.1 Individual plots for the time course of 51Cr EDTA counts data. Closed 
circles represent the observed data; solid and dotted lines represent the individual and 
population predictions from the final 51Cr EDTA model, respectively. 
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A2.4. NONMEM® control file of the final individual model for (S)-pindolol. 
;; 1. Based on:  
;; 2. Description: S-pindolol plasma data   
;; x1. Author: user 
$PROBLEM    S-pindolol plasma and urine data 
;; 3. Label: 
;; Final model 
;; 4. Structural model: 
;; One compartment model 
;; 5. Covariate model: 
;; CRCL on F0; WT on V2 
;; 6. Interindividual variability: 
;; CL, V, F0 
;; 7. Interoccasion variability: 
;; 8. Residual variability: 
;; Combined additive and proportional 
;; 9. Estimation: 
;; LAPLACIAN 
 
$INPUT      ID STUDYID=DROP TIME DV AMT MDV CMT EVID UVOL=DROP 
BLQ AGE 
            WT HT SEX CRCL 
$DATA      pindolol_plasma_urine_new.csv IGNORE=# 
$SUBROUTINE ADVAN6 TRANS1 TOL=9 
$MODEL      COMP=(GUT) COMP=(PLASMA) COMP=(URINE) 
$PK        






 ; MODEL FOR RANDOM BETWEEN SUBJECT VARIABILITY 



















$ERROR        
 IF (CMT.EQ.2.AND.BLQ.EQ.0) THEN 
 IPRED = A(2)/V2 
 W=SQRT(IPRED**2*THETA(5)**2 + THETA(6)**2) 




 IF (CMT.EQ.2.AND.BLQ.EQ.1) THEN 
 F_FLAG=1 
 IPRED=A(2)/V2 
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 IF (CMT.EQ.3) THEN 
 IPRED = A(3) 
 W = THETA(7) 




 (0,28.59) ; CL 
 (0,12.56) ; V2 
 (0,0.19) ; KA 
 (0,0.28) ; F0 
 (0,0.39) ; RUV_PROP_PLASMA 
 (0,0.001) FIX ; RUV_ADD_PLASMA 
 (0,0.22) ; RUV_ADD_URINE 
 
$OMEGA  BLOCK(3) 
 0.12  ;     BSV_CL 
 -0.07 0.27  ;     BSV_F0 
 0 -0.154 0.55  ;      BSV_V 
 
$SIGMA   
 1  FIX 
 1  FIX 
 
$ESTIMATION MAX=9999 SIG=3 PRINT=10 METHOD=COND INTER LAPLACIAN 
            NUMERICAL SLOW NOABORT MSFO=msf25 
$COVARIANCE PRINT=E 
$TABLE      ID TIME CMT IPRED CWRES CIWRES NOPRINT ONEHEADER 
            FILE=sdtab25 
$TABLE      ID CL V2 KA F0 ETAS(1:LAST) NOPRINT ONEHEADER 
            FILE=patab25 
$TABLE      ID SEX NOPRINT ONEHEADER FILE=catab25 
$TABLE      ID AGE WT HT SEX CRCL NOPRINT ONEHEADER FILE=cotab25 
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A2.5. The development of the (S)- pindolol model 
Table A2.2 Model building steps for the final model for (S)-pindolol 
Run 
number 







model; BSV on all 
parameters; combined 
proportional and 
additive residual errors 
-2990.21 
(8) 
- Bias in CWRES 
versus time after 
dose; BSV on Ka 
estimated close to 
zero 
4 Same as run 1; BSV on 
𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄  and 
V2/F; additive residual 
errors fixed to 0.001 
-2990.21 
(6) 
1 No significant 
change in OFV; bias 
in CWRES versus 
time after dose 
11 Two-compartment 
model; BSV on 
𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄ , V2/F; 
combined proportional 
and additive residual 
errors (fixed to 0.001) 
-2992.18 
(8) 
4 No significant 
reduction in OFV; 
decrease in AIC by 
2.03; bias remains in 
CWRES versus time 
after dose 
17 Three-compartment 
model with ALAG; 
BSV on 
𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄ , V2/F; 
proportional and 
additive residual errors 
(fixed to 0.001) 
-2992.18 
(10) 
11 Increase in AIC 
(4.000) 
18 Same as run 1; inclusion 
of urine data and 
addition of fe; BSV on 




1 Bias remains in 
CWRES versus time 
after dose 
19 Same as run 18; 
creatinine clearance 
effect on fe 
-3184.32 
(9) 
18 Significant reduction 
on OFV; BSV on fe 
reduced from 52% to 
44%; bias remains in 
CWRES versus time 
after dose 
20 Same as run 19; 




19 Bias remains in 
CWRES versus time 
after dose  
21 Same as run 20; 
variance-covariance 
matrix with co variance 
-3199.38 
(11) 
20 Significant reduction 
in OFV; bias remains 




𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄ , V2/F, 
and fe 
in CWRES versus 
time after dose 
22 Same as run 21; 
variance-covariance 
matrix with covariance 
estimated between 
𝐶𝐶𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄ and fe, 
V2/F and fe 
-3198.71 
(10) 
21 Significant reduction 





remains in CWRES 
versus time after 
dose 
25 Same as run 22; M3 







and RSE all ≤ 14%; 
no bias in CWRES 
versus time after 
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A2.6. Individual plots from the final (S)-pindolol model 
a. 
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Figure A2.2 Individual plots for the time course of (S)-pindolol (a) plasma concentration 
and (b) amount excreted in urine. Closed circles represent the observed data; solid and 
dotted lines represent the individual and population predictions from the final (S)-
pindolol model, respectively. 
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A2.7. NONMEM® control file of the final joint model for 51Cr EDTA and (S)-
pindolol. 
;; 1. Based on: run124 
;; 2. Description: Cr EDTA and S-pindolol data   
;; x1. Author: user 
$PROBLEM    Cr EDTA and S-pindolol joint model 
;; 3. Label: 
;; Final model 
;; 4. Structural model: 
;; Two compartment model - Cr EDTA; One compartment model - (S)-
pindolol 
;; 5. Covariate model: 
;; CRCL on CL; WT on V 
;; 6. Interindividual variability: 
;; Cr EDTA - CL, V1, V2; (S)-pindolol CL, V2, F0 
;; 7. Interoccasion variability: 
;; 8. Residual variability: 
;; Combined additive and proportional 
;; 9. Estimation: 
;; LAPLACIAN 
 
$INPUT      ID STUDYID=DROP TIME DV AMT DNAMT RATE MDV CMT EVID 
            UVOL=DROP BLQ AGE WT HT SEX CRCL 
$DATA      combined_plasma_urine_new.csv IGNORE=# 
$SUBROUTINE ADVAN6 TRANS1 TOL=9 
$MODEL      COMP=("EDTA_CEN") ; 1 
            COMP=("EDTA_PER") ; 2 
            COMP=("PIN_GUT") ; 3 
            COMP=("PIN_CEN") ; 4 
            COMP=("PIN_URI") ; 5 
 
;; _1 indicates compartments and parameters for CrEDTA and _2 
indicates those for S-pindolol 
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$PK                                  





























 ; REPARAMETERISATION 
 ; For CrEDTA 
 K10=CL_1/V1_1 










$DES                                  









$ERROR                                  
 ; FOR CrEDTA 
 IF (CMT.EQ.1) THEN 
 IPRED = A(1)/V1_1 
 W = SQRT(IPRED**2*THETA(10)**2 + THETA(11)**2) 
 Y = IPRED + W*EPS(1) 
 ENDIF 
 
 ; For (S)-pindolol 
 IF (CMT.EQ.4.AND.BLQ.EQ.0) THEN 
 F_FLAG=0 
 IPRED = A(4)/V2_2 
 W=SQRT(THETA(12)**2*IPRED**2 + THETA(13)**2) 
 Y = IPRED + W*EPS(2) 
 ENDIF 
 





 IF (CMT.EQ.4.AND.BLQ.EQ.1) THEN 
 F_FLAG=1 
 IPRED = A(4)/V2_2 






 IF (CMT.EQ.5) THEN 
 IPRED = A(5) 
 W = THETA(14) 
 Y = IPRED + W*EPS(3) 
 ENDIF 
 
$THETA   
 ; FOR CrEDTA 
 (0,7.56) ; CL_1 
 (0,15.70) ; V1_1 
 (0,1.52) ; Q_1 
 (0,3.15) ; V2_1 
 
 ; For (S)-pindolol 
 (0,29.13) ; CL_2 
 (0,13.85) ; V2_2 
 (0,0.20) ; KA_2 
 (0,1.17) ; COEF_2 
 (0,0.90) ; EXP_2 
 
 ; FOR CrEDTA 
 (0,0.04) ; RUV_PROP_1 
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 (0,0.5) FIX ; RUV_ADD_1 
 
 ; For (S)-pindolol 
 (0,0.36) ; RUV_PROP_PLASMA_2 
 (0,0.001) FIX ; RUV_ADD_PLASMA_2 
 (0,0.16) ; RUV_ADD_URINE_2 
 
 ; FOR CrEDTA 
$OMEGA  BLOCK(3) 
 0.036  ;   BSV_CL_1 
 0.010 0.03  ;   BSV_V1_1 
 0.03 0.11 0.70  ;   BSV_V2_1 
 
;For S-pindolol 
$OMEGA  BLOCK(3) 
 0.11  ;   BSV_CL_2 
 0.02 0.13  ;   BSV_F0_2 
 0 -0.16 0.58  ;    BSV_V_2 
 
$SIGMA  1  FIX 
 1  FIX 
 1  FIX 
 
$ESTIMATION MAX=9999 SIG=3 PRINT=10 METHOD=COND INTER LAPLACIAN 
NUMERICAL SLOW NOABORT MSFO=msf4 
$COVARIANCE PRINT=E SLOW 
$TABLE ID TIME CMT IPRED CWRES CIWRES NOPRINT ONEHEADER 
FILE=sdtab4 
$TABLE ID CL_1 V1_1 Q_1 V2_1 CL_2 KA_2 F0_2 ETAS(1:LAST) NOPRINT 
ONEHEADER FILE=patab4 
$TABLE ID SEX NOPRINT ONEHEADER FILE=catab4 
$TABLE ID AGE WT HT CRCL NOPRINT ONEHEADER FILE=cotab4 
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A2.8. The development of the joint model for 51Cr EDTA and (S)-pindolol 
Table A2.3 Model building steps for the final joint model that simultaneously describes 










1 Same as individual 





- Parameter estimates 
similar to those 
estimated by the 
individual models 
for 51Cr EDTA and 
(S)-pindolol 
4 Same as run1; 
𝐶𝐶𝐶𝐶𝑅𝑅−(𝑠𝑠)𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚⁄ of (S)-
pindolol estimated as a 
function of 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 of 
51Cr EDTA as given in 
Equation 3.4 
-1669.40 1 RSE (determined 
based on 1000 
bootstrap runs) in all 
fixed effect 
parameters were < 
20% (except Coef , 
RSE = 28%) and all 
random effect 
parameters were < 
50%; shrinkage in all 
parameters were 
below 18% (except 𝜀𝜀-
shrinkage for 51Cr 
EDTA = 34%) 
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A2.9. Individual plots from the final joint model of 51Cr EDTA and (S)-
pindolol.  
a. 






































Figure A2.3 Individual plots for the time course of (a) 51Cr EDTA counts data and (S)-
pindolol (b) plasma concentration and (c) urine amount data. Closed circles represent 
the observed data; solid and dotted lines represent the individual and population 
predictions from the final joint model for 51Cr EDTA and (S)-pindolol, respectively. 
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A2.10. Linear regression analysis of (S)-pindolol renal clearance and 51Cr 
EDTA clearance 
Figure A2.4 Linear regression between individual empirical Bayes estimates of (S)-
pindolol renal clearance and 51Cr EDTA clearance from all subjects. Solid line represents 
the linear regression line for the available data and dashed line represents extrapolation 
of the linear regression line 
Note: Minimum value of 51Cr EDTA clearance was equal to 1.6 L/h
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A2.11. Comparison of (S)-pindolol renal clearance determined by empirical 
Bayes estimate values and classical UV/P method 
The individual parameter estimates in population model-based analysis 
are estimated using the Bayesian methodology, and they are referred to as an 
empirical Bayes estimates (EBEs).  





Equation A2.1 Equation for determining renal clearance using urine and plasma 
data 
where, U is the concentration of a drug in urine, V is the volume of urine 
collected over a period of time and P is the concentration of a drug in urine. 
Mean ± standard deviation of (S)-pindolol renal clearance values 
determined as EBEs and using Equation A2.1 were 5.84 ± 2.87 L/h and 5.40 ± 
3.51 L/h, respectively. 
The linear regression as described in Chapter 3 (Section 3.3.4.1.) was 
repeated with the individual values of (S)-pindolol renal clearance determined 
using UV/P method and EBEs for 51Cr EDTA clearance. The plots of the linear 
regression are shown in Figure A2.5 and A2.6. The y-intercept was found to be 
0.5 L/h (95% CI [-3.8 L/h, 4.8 L/h]) where 51Cr EDTA clearance values were > 
50% of normal (approximately 3.6 L/h or 60 mL/min). When all data were 
included regardless of 51Cr EDTA clearance values (minimum value was 1.6 L/h 
or 27 mL/min), the y-intercept was found to be -0.2 L/h (95% CI [-2.5 L/h, 2.2 
L/h]). In both the cases the 95% CI of the theoretical value of (S)-pindolol renal 
clearance included zero, while the confidence interval was very wide. 
 




Figure A2.5 Linear regression between individual values of (S)-pindolol renal 
clearance determined by UV/P method and empirical Bayes estimates of 51Cr 
EDTA clearance from subjects with 51Cr EDTA clearance ≥ 3.6 L/h. Solid line 
represent the linear regression line for the available data and dashed line represents 
extrapolation of the linear regression line. 
  
Figure A2.6 Linear regression between individual values of (S)-pindolol renal 
clearance determined by UV/P method and empirical Bayes estimates of 51Cr 
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EDTA clearance from all subjects. Solid line represents the linear regression line 
for the available data and dashed line represents extrapolation of the linear 
regression line.
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A3.1. Relationship between mGFR and eGFR 
For determining the relation between eGFR and mGFR data was taken from 
five different studies that reported eGFR and mGFR from a total of 393 
individuals. Dr. Mark Marshall generously provided data from a previously 
published study [168], which consisted of 178 individuals. From the remaining 
four studies, data were extracted from the publications as individual level data 
(number of subjects = 55) [169, 170] or they were extracted from graph (number 
of subjects = 160) [171, 172]. For all the studies, eGFR was estimated using 
Cockcroft Gault equation [34] and mGFR was measured using an isotopic GFR 
probe (51Cr EDTA, 99mTc DTPA or 125I-iothalamate). Note some, marginal 
differences were seen in the nonlinear coefficients for different estimating 
equations for GFR (shown below). 
In this setting, we considered eGFR to be the dependent variable and mGFR 
the predictor variable. A nonlinear model, same as M2, was fitted to the 
combined data mentioned above. 
 
Figure A3.1 Plot of eGFR vs mGFR. Open circles represent data from an 
individual with corresponding mGFR and eGFR values. Solid line represents the 
line of best fit that describes the relation between eGFR and mGFR (Equation 
A3.1). 
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A plot of the data with the line of best fit is shown in Figure A3.1 and the 
relationship between eGFR and mGFR is given by; 
𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶 = 2.30 ∙ 𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶0.77 
Equation A3.1 A non-linear model for eGFR as a function of mGFR 
We take the linear coefficient to be equal to 1 to scale the range of eGFR and 
mGFR to be equal, so the Equation A3.1 becomes (for the Cockcroft and Gault 
equation); 
𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶 = 𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶0.77 
Equation A3.2 A non-linear model for eGFR as a function of mGFR, where linear 
coefficient is equal to 1 
Bias was also observed when eGFR calculated based on MDRD and CKD-
EPI. Following relationships between eGFR and mGFR were seen: 
Using MDRD-equation: 𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶 = 𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶0.82 
Equation A3.3 A non-linear model describing the relationship between eGFR and 
mGFR, where eGFR is calculated based on MDRD-equation 
Using CKD-EPI equation: 𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶 = 𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶0.88 
Equation A3.4 A non-linear model for eGFR as a function of mGFR, where eGFR 
is calculated based on CKD-EPI-equation 
The exponents describing the relationship between eGFR and mGFR when 
using MDRD (Equation A3.3) and CKD-EPI (Equation A3.4) are closer to 1 
compared to that when using Cockcroft and Gault equation. This suggest that 
MDRD and CKD-EPI might be less biased than the Cockcroft and Gault 
equation. 
Rearranging Equation A3.2, we can estimate mGFR as a function of eGFR 
and the relation is given by; 
𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶 = 𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶1.30 
Equation A3.5 A non-linear model for mGFR as a function of eGFR, where linear 
coefficient is equal to 1 
Now, when we substitute mGFR from Equation A3.5 to M2 under the EMA 
design where θ1 = 1, θ2 = 0.33; 
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𝐶𝐶𝐶𝐶 = 1 ∙ (𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶1.30)0.33 
𝐶𝐶𝐶𝐶 = 1 ∙ 𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶0.43 
Equation A3.6 A non-linear model for CL as a function of eGFR, where linear 
coefficient is equal to 1 
Equation A3.6 represents M2 under the FDA design where θ1 = 1 and 
adjusted θ2 = 0.43.
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A3.2. Random variability in mGFR and eGFR 
1. The imprecision with which mGFR is estimated was set to the residual 
variance based on analysis using data from a study that estimated mGFR. In 
the original study, it is assumed that mGFR is an unbiased but imprecise 
measure of GFR, therefore the imprecision represents deviation of an 
individual’s value of mGFR from their true GFR. The original study involved 
n = 40 patients, stratified into groups based on renal function [45]. The 
residual variance was estimated in following steps: 
i. Empirical Bayes Estimates (EBEs) of 51Cr EDTA clearance from a published 
population pharmacokinetic model [45] were available where, each EBEs 
provided an individual estimate of mGFR and we denote it as mGFR’. These 
values were considered an independent variable in this work. 
ii. Estimates of 51Cr EDTA clearance, determined using a traditional slope-
intercept method [24] were available from the same dataset described above 
[45], which provided an individual estimate of mGFR and we denote it as 
mGFR’’. These values were considered to be dependent variable in this work. 
iii. A linear model was used to estimate 𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶′′ as a function of 𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶′, given 
by following equation;  
𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶′′ = 𝑓𝑓𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅′′(𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶′, 𝛾𝛾) + 𝜀𝜀𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅;  𝜀𝜀𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅~ 𝑁𝑁(0,𝜎𝜎𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅2 ) 
Equation A3.7 A model for mGFR determined using a traditional slope-intercept 
method (𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶′′) as a function of mGFR determined using a published population 
pharmacokinetic model (𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶′) 
where, 𝜎𝜎𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅2  is the residual variability of the linear model (Equation A3.7) 
and it gave the imprecision with which mGFR is estimated for this work. The 
value of 𝜎𝜎𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅2 was 0.0169 and; 
𝑓𝑓𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅′′(𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶′, 𝛾𝛾) = 𝛾𝛾1 ∙ 𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶′ 
Equation A3.8 A function (𝑓𝑓𝑚𝑚𝑚𝑚𝐹𝐹𝑅𝑅′′) describing mGFR determined using a 
traditional slope-intercept method (𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶′′) as a function of mGFR determined 
using a published population pharmacokinetic model (𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶′) 
where, 𝛾𝛾1 was equal to 3.13. 
2. The imprecision with which eGFR is estimate was set to the residual variance 
based on analysis using data from studies that estimated both mGFR and 
eGFR. For the calculation of the residual variance, data were taken from five 
different studies that included a total of 393 individuals and available data 
were either individual level data [168-170] or extracted from graph [171, 172]. 
For all the studies, eGFR was estimated using Cockcroft Gault equation [34] 
and mGFR was estimated using an isotopic GFR probe (51Cr EDTA, 99mTc 
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DTPA or 125I-iothalamate). The residual variance was estimated in following 
steps: 
i. Individual clearance values of an isotopic probe provided an individual 
estimate of mGFR. These values were used as an independent variable. 
ii. Individual eGFR values, derived using the Cockcroft and Gault equation, 
from the same published data were used as the dependent variable [168]. 
iii. A nonlinear model was used to estimate eGFR as a function of mGFR, given 
by following equation;  
𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶 =  𝑓𝑓𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅(𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶,𝜃𝜃) +  𝜀𝜀𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅;  𝜀𝜀𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅 ~(0,𝜎𝜎𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅2 ) 
Equation A3.9 A model for eGFR derived using a creatinine based equation (𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶) 
as a function of mGFR measured as a clearance of an isotopic probe (𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶) 
where, 𝜎𝜎𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅2  is the residual variability of the nonlinear model (Equation 
A3.9) and it gave the imprecision with which eGFR is estimated for this work. 
The value of 𝜎𝜎𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅2  was 0.0776 and; 
𝑓𝑓𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅(𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶,𝛽𝛽) = 𝛽𝛽1 ∙ 𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶𝛽𝛽2 
Equation A310 A function (𝑓𝑓𝑒𝑒𝑚𝑚𝐹𝐹𝑅𝑅) describing eGFR derived using a creatinine 
based equation (𝑒𝑒𝑚𝑚𝑚𝑚𝐶𝐶) as a function of measured as a clearance of a isotopic probe 
(𝑚𝑚𝑚𝑚𝑚𝑚𝐶𝐶) 
where, 𝛽𝛽1was equal to 2.30 and 𝛽𝛽2 was equal to 0.77.
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A3.3. Calibration of alpha error 
Alpha (𝛼𝛼)-error is a probability of rejecting the null hypothesis given that it 
is true. Generally, 𝛼𝛼-error is set to 5% implying that it is acceptable to have a 5% 
chance of incorrectly rejecting the null hypothesis. Simulations were conducted 
to calibrate 𝛼𝛼-error. Under these simulations the true model was set to M1 and 
the alternative (incorrect) model was set to M2. Simulations were conducted 
under the EMA and the FDA guidelines and were the same as described in the 
methods section. 
The 𝛼𝛼 -error was calculated as the probability (expressed as percent) of 
incorrectly selecting the misspecified model M2 over the “true model” M1 under 
the given study design (Figure A3.2). For the designs under the EMA guidelines, 
𝛼𝛼-error was < 25% for the designs with ≥ 8 subjects. This can be attributed to use 
of mGFR, which provides an unbiased measure of GFR [76] such that the relation 
between CL and mGFR is strictly linear under the M1. On the other hand, 𝛼𝛼-error 
was inflated for the designs under the FDA guidelines where it increased with 
increasing number of subjects and approached 100% for the designs with 1080 
subjects. This can potentially be due to use of a biased estimate of GFR i.e., eGFR 
[76]. 
Figure A3.2 𝛼𝛼-error (%) of the study designs for given number of subjects under the 
EMA guidelines (black circles and line) and the FDA guidelines (grey circles and line). 
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The value of the difference in two successive objective function values of 
NONMEM® (the objective function is proportional to minus twice the log-
likelihood) was then calibrated to the level of 5% error (Figure A3.3). The 
calibrated value is termed the critical value. 
Figure A3.3 Critical value of log likelihood ratio test statistics of the study designs 
for given number of subjects under the EMA guidelines (black circles and line) and 
the FDA guidelines (grey circles and line) that resets 𝛼𝛼-error to 5%
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A3.4. MATLAB® and NONMEM® codes for simulation and estimation 
study 
MATLAB® codes 
Main file to run simulations (run_simulation.m) 
%This file calls 3 different files to simulate and estimated 





%% Design variables 
  
%design - 1 = FDA deisgn; 2 = EMA design  
design = 2; 
if design == 1 
    DESIGN = 'FDA'; 
else 
    DESIGN = 'EMA'; 
end 
  
%model 1 = Linear model (M1); 2 = Non-linear model (M2) 
model = 2; 
  
%vec_subjects - vector of number of subjects to be included in a 
design 
vec_subjects = [4 8 12 16 20 24 32 48 72 120 240 480 960]; 
  
%iter - number of times the simulation is iterated 
iter = 1000; 
  
%% Call files to simulate, estimate and read in a sequence 
%run call_simulate.m file in parallel 
parfor i = 1:length(vec_subjects) 
    subjects = vec_subjects(i); 
     
    call_simulate(design, DESIGN, model, iter, subjects); 
end 
  
%run call_estimate.m file in parallel 
parfor i = 1:length(vec_subjects) 
    subjects = vec_subjects(i); 
  
    call_estimate(DESIGN, model, iter, subjects) 
end 
  
%run call_read.m file in parallel 
parfor i = 1:length(vec_subjects) 
    subjects = vec_subjects(i); 
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File for simulating data sets (call_simulate.m) 
function[] = call_simulate(design, DESIGN, model, iter, 
subjects) 
%%This file simulates data files in format that can be read by 
NONMEM 
  
%create directory to store data files 




for j = 1:iter 
  
    if design == 1     
        % Renal function groups based on eGFR (ml/min/1.73m2 or 
ml/min) -  
        % FDA guideline 2010 
        DESIGN_POINTS = [0.1875; 0.3750; 0.6250; 0.8750]; 
         
        %GFR_SD - standard deviation of distribution of eGFR 
        GFR_SD_PROP = sqrt(0.272^2 + 0.13^2); 
        GFR_SD_ADD = sqrt(0.060^2 + 0.00001^2); 
         
        %CL_SD - standard deviation of distribution of CL 
        CL_SD_BSV = 0.30; 
         
        if model == 1 
            %COEF - linear proportional coefficient for M1 
            COEF = 1; 
            %PWR - non-linear exponential coefficient for M1 
            PWR = 0.77; 
        else  
            %COEF - linear proportional coefficient for M2 
            COEF = 1;         
            %PWR - non-linear exponential coefficient for M2 
            PWR = 0.33; 
        end 
         
    else 
        % Renal function groups based on mGFR (ml/min) -  
        % EMA guideline 2014 
        DESIGN_POINTS = [0.1875; 0.3750; 0.6250; 0.8750]; 
         
        %GFR_SD - standard deviation of distribution of mGFR 
        GFR_SD_PROP = 0.13; 
        GFR_SD_ADD = 0.00001; 
  
        %CL_SD - standard deviation of distribution of CL 
        CL_SD_BSV = 0.30; 
         
        if model == 1 
            %COEF - linear proportional coefficient for M1 
            COEF = 1; 
            %PWR - non-linear exponential coefficient for M1 
            PWR = 1; 
        else  
            %COEF - linear proportional coefficient for M2 
            COEF = 1;         
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            %PWR - non-linear exponential coefficient for M2 
            PWR = 0.33; 
             
        end 
         
    end 
     
    %ID - number of subjects in a data set 
    ID = [1:subjects]';   
     
    %CL - estimated clearance of all individuals 
    CL = []; 
  
    %GFR - measured clearance of all individuals 
    GFR = []; 
     
    for i = 1:length(DESIGN_POINTS) 
  
        for k = 1:subjects/length(DESIGN_POINTS) 
             
            %generate random number based on number of design 
points, i, j 
            %and number of subjects for: 
             
            %randgfr - random number for generating distribution 
of GFR 
            seedgfr = [length(DESIGN_POINTS),i,j,subjects]; 
            randn('seed',str2num(strrep(num2str(seedgfr(:)'),' 
',''))); 
            randgfr = randn(subjects/length(DESIGN_POINTS),2); 
  
            %randcl - random number for generating distribution 
of CL 
            seedcl = [subjects,j,i,length(DESIGN_POINTS)]; 
            randn('seed',str2num(strrep(num2str(seedcl(:)'),' 
',''))); 
            randcl = randn(subjects/length(DESIGN_POINTS),1); 
  
            %LNGFRi - individual GFR (mGFR or eGFR) in log scale 
            LNGFRi = log(DESIGN_POINTS(i)) + 
GFR_SD_PROP*DESIGN_POINTS(i)... 
                *randgfr(k,1) + GFR_SD_ADD*randgfr(k,2); 
         
            %GFRi - individual GFR (mGFR or eGFR) in normal 
scale 
            GFRi = exp(LNGFRi); 
             
            if GFRi < 0 
                GFRi = 0; 
            else 
                GFRi = GFRi; 
            end 
             
            CL_SD_BSV_POOLED = sqrt(CL_SD_BSV^2 + 
(GFR_SD_PROP*GFRi)^2 ... 
                + GFR_SD_ADD^2); 
                         
            %LNCLi - individual clearance in log scale 
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            LNCLi = log(COEF*(GFRi ^ PWR)) + 
CL_SD_BSV_POOLED*randcl(k,1); 
  
            %CLi - individual clearance in normal scale 
            CLi = exp(LNCLi); 
  
            CL = [CL; CLi]; 
            GFR = [GFR; GFRi]; 
        end 
  
    end 
  
    DV = CL; 
    GFR = GFR; 
  
    %TABLE1 - table containing data items as required in for the 
data file 
    TABLE1 = table(ID,GFR,DV); 
  
    %filename - file name for data file for j subjectslicates; 
all files are stored 
    %in folder 'data_files' 
    filename = sprintf('%s_M%d_n%d_data%d.csv',DESIGN, model, 
subjects, j); 
  
    %write data files for j subjectslicates with file names 
specified by 'filename' 




%format data file for NONMEM run 
for data = 1:length(1:iter) 
    datafile = sprintf('%s_M%d_n%d_data%d.csv',DESIGN, model, 
subjects, data); 
    input = fileread(datafile); 
  
    %subjectslace header 'ID' with '#ID' 
    input = regexprep(input, 'ID', '#ID'); 
  
    %subjectslace 'NaN' with '.' 
    input = regexprep(input, 'NaN', '.'); 
  
    fid = fopen(datafile,'w'); 
    fwrite(fid,input); 
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File for estimating using model (call_estimate.m) 
function[] = call_estimate(DESIGN, model, iter, subjects) 
%This file estimate parameters based on the given model 
(run0.ctl) 
  
%create control stream file (.ctl) based on a given template 
(run0.ctl)  
%for each data sets 
%run - number of NONMEM runs i.e., number of data sets and .ctl 
files 
  
for m = model 
         
    %go to directory for the model (M1 or M2)   
    dir = sprintf('%s_M%d_n%d_data_files', DESIGN, model, 
subjects); 
    cd (dir) 
     
    %create .ctl file for M1 
    for run = 1:iter 
         
        %input_1 = read the control stream file for M1 
        input_1 = fileread('..\M1_run0.ctl'); 
         
        %datafile - name of old data file in the templete .ctl 
file that  
        %is to be replaced in '$DATA' record with new data file  
        %name 
        datafile = 'data0.csv'; 
  
        %newfile - name of new data file that is to be written 
in "$DATA" 
        %record replacing the old data file name 
        newfile = sprintf('%s_M%d_n%d_data%d.csv',DESIGN, model, 
subjects, run); 
  
        %replace old data file name with new data file name in 
'$DATA' record  
        %in new .ctl file 
        input_1 = regexprep(input_1, datafile, newfile); 
  
        %newrun - name of new .ctl file 
        newrun = sprintf('%s_M1_n%d_run%d.ctl',DESIGN, subjects, 
run); 
        fid = fopen(newrun,'w'); 
        fwrite(fid,input_1); 
        fclose(fid); 
    end 
  
    %create .ctl file for M2 
    for run = 0:length(1:iter)-1 
        
        %input_2 = read the control stream file for M2 
        input_2 = fileread('..\M2_run0.ctl'); 
  
        %datafile - name of old data file in the templete .ctl 
file that  
        %is to be replaced in '$DATA' record with new data file  
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        %name 
        datafile = 'data0.csv'; 
  
        %newfile - name of new data file that is to be written 
in "$DATA" 
        %record replacing the old data file name 
        newfile = sprintf('%s_M%d_n%d_data%d.csv',DESIGN, model, 
subjects, 1+run); 
  
        %replace old data file name with new data file name in 
'$DATA' record  
        %in new .ctl file 
        input_2 = regexprep(input_2, datafile, newfile); 
  
        %newrun - name of new .ctl file 
        newrun = sprintf('%s_M2_n%d_run%d.ctl',DESIGN, subjects, 
1+run); 
        fid = fopen(newrun,'w'); 
        fwrite(fid,input_2); 
        fclose(fid); 
    end 
end 
  
%call NONMEM to run all .ctl files 




for nm = 1:length(1:iter) 
    
    %runfile - name of .ctl file to be executed by NONMEM 
    runfile = sprintf('%s_M1_n%d_run%d.ctl',DESIGN, subjects, 
nm); 
     
    %nmcommand - command to call nonmem  
    nmcommand = ['C:\nm73g64\wfn7\bin\wfn.bat gf & nmgo 
',runfile]; 




for nm = 1:length(1:iter) 
  
    %runfile - name of .ctl file to be executed by NONMEM 
    runfile = sprintf('%s_M2_n%d_run%d.ctl',DESIGN, subjects, 
nm); 
     
    %nmcommand - command to call nonmem  
    nmcommand = ['C:\nm73g64\wfn7\bin\wfn.bat gf & nmgo 
',runfile]; 
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File for reading result files (call_read.m) 
function[] = call_read(DESIGN, model, iter, subjects) 




%%Selecting directory depending on the selection of model (M1 or 
M2) as  
%true model 
%go to directory for the model (M1 or M2)   
dir = sprintf('%s_M%d_n%d_data_files', DESIGN, model, subjects); 
cd (dir) 
     
%% For M1 
  
%(PARAMETER) - 0-by-0 matrix to store all i individual 
parameters 
OBJ = []; 
MIN = []; 
COV = []; 
  
COEF = []; 
  
ERR_EXP = []; 
  
for read = 1:length(1:iter) 
  %go to directory of different NONMEM runs 
  cd (sprintf('%s_M1_n%d_run%d.nm7',DESIGN, subjects, read)); 
   
  %read smy file  
  smyfile = sprintf('%s_M1_n%d_run%d.smy',DESIGN, subjects, 
read); 
   
  %copy smy file and make dat file 
  datfile = sprintf('%s_M1_n%d_run%d.dat',DESIGN, subjects, 
read); 
  copyfile (smyfile,datfile); 
  input = fileread(datfile); 
  
  %replace header 8X'.'  with '' 
%   input = regexprep(input, '\t\.\t\.\t\.\t\.\t\.\t\.\t\.\t\.', 
'\t\.'); 
  input = regexprep(input, '\t\.\t\.\t\.\t\.\t\.\t\.', ''); 
  input = regexprep(input, '\t\.\t\.\t\.\t\.\t\.', ''); 
  input = regexprep(input, '\t\.\t\.\t\.\t\.', ''); 
  input = regexprep(input, '\t\.\t\.\t\.', ''); 
  input = regexprep(input, '\t\.\t\.', ''); 
  input = regexprep(input, '\t\.', ''); 
  
  fid = fopen(datfile,'w'); 
  fwrite(fid,input); 
  fclose(fid); 
   
  %read dat file 
    A = 
readtable(datfile,'Delimiter','tab','ReadVariableNames',false); 
    A = A(1,1:15); 
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  %extract (PARAMETER) values   
        iOBJ = (A.Var2(1)); 
        iMIN = (A.Var4(1)); 
        iCOV = (A.Var5(1)); 
        iCOEF = (A.Var14(1)); 
        iERR_EXP = (A.Var15(1)); 
      
    cd .. 
     
    OBJ = [OBJ;iOBJ]; 
    MIN = [MIN;iMIN]; 
    COV = [COV;iCOV]; 
     
    COEF = [COEF;iCOEF]; 
   
    ERR_EXP = [ERR_EXP;iERR_EXP]; 
  
end 
     
  
%ITERATION - number of NONMEM runs 
ITERATION = (1:length(1:iter))'; 
  
%TABLE1 - table containing estimated (PARAMETERS) from each 
iterations  
TABLE1 = table(ITERATION,OBJ,MIN,COV,COEF,ERR_EXP); 
  
%write data files containing estimated (PARAMETERS) from each 
iterations 




%% For M2 
  
%(PARAMETER) - 0-by-0 matrix to store all i individual 
parameters 
OBJ = []; 
MIN = []; 
COV = []; 
  
COEF = []; 
PWR = []; 
  
ERR_EXP = []; 
  
for read = 1:length(1:iter) 
  %go to directory of different NONMEM runs 
  cd (sprintf('%s_M2_n%d_run%d.nm7',DESIGN, subjects, read)); 
   
  %read smy file  
  smyfile = sprintf('%s_M2_n%d_run%d.smy',DESIGN, subjects, 
read); 
   
  %copy smy file and make dat file 
  datfile = sprintf('%s_M2_n%d_run%d.dat',DESIGN, subjects, 
read); 
  copyfile (smyfile,datfile); 
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  input = fileread(datfile); 
  
%   %replace header '.' with '' 
%   input = regexprep(input, '\t\.\t\.\t\.\t\.\t\.\t\.\t\.\t\.', 
'\t\.'); 
  input = regexprep(input, '\t\.\t\.\t\.\t\.\t\.\t\.', ''); 
  input = regexprep(input, '\t\.\t\.\t\.\t\.\t\.', ''); 
  input = regexprep(input, '\t\.\t\.\t\.\t\.', ''); 
  input = regexprep(input, '\t\.\t\.\t\.', ''); 
  input = regexprep(input, '\t\.\t\.', ''); 
  input = regexprep(input, '\t\.', ''); 
   
  fid = fopen(datfile,'w'); 
  fwrite(fid,input); 
  fclose(fid); 
   
  %read dat file 
    A = 
readtable(datfile,'Delimiter','tab','ReadVariableNames',false); 
    A = A(1,1:16); 
     
  %extract (PARAMETER) values   
        iOBJ = (A.Var2(1)); 
        iMIN = (A.Var4(1)); 
        iCOV = (A.Var5(1)); 
        iCOEF = (A.Var14(1)); 
        iPWR = (A.Var15(1)); 
        iERR_EXP = (A.Var16(1)); 
      
    cd .. 
     
    OBJ = [OBJ;iOBJ]; 
    MIN = [MIN;iMIN]; 
    COV = [COV;iCOV]; 
     
    COEF = [COEF;iCOEF]; 
    PWR = [PWR;iPWR]; 
   
    ERR_EXP = [ERR_EXP;iERR_EXP]; 
end 
     
  
%ITERATION - number of NONMEM runs 
ITERATION = (1:length(1:iter))'; 
  
%TABLE2 - table containing estimated (PARAMETERS) from each 
iterations  
TABLE2 = table(ITERATION,OBJ,MIN,COV,COEF,PWR,ERR_EXP); 
  
%write data files containing estimated (PARAMETERS) from each 
iterations 




%% Power calculation 
delta_OBJ = []; 
for i = 1: length(TABLE1.OBJ) 
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    idelta_OBJ = str2double(TABLE2.OBJ(i)) - 
str2double(TABLE1.OBJ(i)); 
    delta_OBJ = [delta_OBJ; idelta_OBJ];    
end 
  
if model == 1 
    power = length(find(delta_OBJ < 399.34))/iter*100; 
else 
    power = length(find(delta_OBJ > 0))/iter*100; 
end 
  
fprintf(fopen('result.txt', 'w'), 'Power = %d%% with %d 
subjects.\r\n', power, subjects); 








Model file for linear model (M1) (M1_run0.ctl) 
;; 1. Based on:  
;; 2. Description: A LINEAR MODEL FOR RENAL CLEARANCE (M1) 
;; x1. Author:  
$PROB A LINEAR MODEL FOR RENAL CLEARANCE (M1) 
$INPUT ID GFR DV 
$DATA data0.csv 
$PRED 
    COEF = THETA(1) 
    CL = COEF * GFR 
    Y = CL + ETA(1) 
$THETA 
(1) ; COEF 
  
$OMEGA  
 0.01 ; RUV_ADD 
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Model file for linear model (M1) (M1_run0.ctl) 
;; 1. Based on:  
;; 2. Description: A NON-LINEAR MODEL FOR RENAL CLEARANCE (M2) 
;; x1. Author:  
$PROB A NON-LINEAR MODEL FOR RENAL CLEARANCE (M2) 
$INPUT ID GFR DV 
$DATA data0.csv 
$PRED 
    COEF = THETA(1) 
    PWR = THETA(2) 
    CL = COEF * GFR ** PWR 
    Y = CL + ETA(1) 
$THETA 
(1) ; COEF 
(0.33) ; PWR 
  
$OMEGA  
 0.01 ; RUV_ADD 
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A3.5. Impact of value of exponent parameter(M2) on dose calculation 
Here, an exploratory analysis was conducted to determine how different 
values of the exponent (𝜃𝜃2) would affect the dose calculated based on the non-
linear model (M2) and linear model (M1). A 50% difference in drug dosing based 
on M2 compared to M1 was considered to be significant. The comparison of dose 
calculation based on M1 and M2 was considered at a fractional GFR equal to 0.30 
that corresponds to 30% of the GFR in normal healthy adult. This value of GFR 
is commonly used as a standard cut-off for changing drug dose. 
The equation to calculate the maintenance dose rate based on the renal 
clearance of drug (𝐶𝐶𝐶𝐶𝑅𝑅) and target average steady state concentration (𝐶𝐶𝑝𝑝,𝑠𝑠𝑠𝑠,𝑟𝑟𝑎𝑎𝑒𝑒) 
is given below: 
𝑀𝑀𝑒𝑒𝑖𝑖𝑛𝑛𝑡𝑡𝑒𝑒𝑛𝑛𝑒𝑒𝑛𝑛𝑒𝑒𝑐𝑐𝑒𝑒 𝑑𝑑𝑑𝑑𝑠𝑠𝑒𝑒 𝑟𝑟𝑒𝑒𝑡𝑡𝑒𝑒 = 𝐶𝐶𝐶𝐶𝑅𝑅 ∙ 𝐶𝐶𝑝𝑝,𝑠𝑠𝑠𝑠,𝑟𝑟𝑎𝑎𝑒𝑒 
Equation A3.11 Equation to calculate maintenance dose rate 
For simplicity, the target 𝐶𝐶𝑝𝑝,𝑠𝑠𝑠𝑠,𝑟𝑟𝑎𝑎𝑒𝑒 was considered to be 1 (mass/volume). 
For calculation of 𝐶𝐶𝐶𝐶𝑅𝑅, M1 (Equation 4.1) and M2 (Equation 4.2) were used. The 
linear coefficient (𝜃𝜃1) was considered to be equal to 1 for both M1 and M2, while 
different values of 𝜃𝜃2 ranging from 0.1 to 1 were considered. 
The relative percent difference in dose calculated based on M2 and M1 are 
given in Table A3.1 was calculated as: 
𝐶𝐶𝑒𝑒𝑙𝑙𝑒𝑒𝑡𝑡𝑖𝑖𝑑𝑑𝑒𝑒 𝑝𝑝𝑒𝑒𝑟𝑟𝑐𝑐𝑒𝑒𝑛𝑛𝑡𝑡 𝑑𝑑𝑖𝑖𝑓𝑓𝑓𝑓𝑒𝑒𝑟𝑟𝑒𝑒𝑛𝑛𝑐𝑐𝑒𝑒 =
𝐷𝐷𝑑𝑑𝑠𝑠𝑒𝑒 𝑝𝑝𝑒𝑒𝑠𝑠𝑒𝑒𝑑𝑑 𝑑𝑑𝑛𝑛 𝑀𝑀2 − 𝐷𝐷𝑑𝑑𝑠𝑠𝑒𝑒 𝑝𝑝𝑒𝑒𝑠𝑠𝑒𝑒𝑑𝑑 𝑑𝑑𝑛𝑛 𝑀𝑀1
𝐷𝐷𝑑𝑑𝑠𝑠𝑒𝑒 𝑝𝑝𝑒𝑒𝑠𝑠𝑒𝑒𝑑𝑑 𝑑𝑑𝑛𝑛 𝑀𝑀1
× 100% 
Equation A3.12 Equation to calculate relative percentage difference in dose 
The fractional dose calculated based on M1 is 0.30 and is independent of 
value of 𝜃𝜃2. The difference in dose was found to be > 50% when the value of 𝜃𝜃2 
was ≤ 0.60.
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Relative difference in dose 
based on M2 and M1 (%) 
0.30 0.10 0.89 195.52 
0.30 0.20 0.79 162.00 
0.30 0.33 0.67 124.04 
0.30 0.40 0.62 105.93 
0.30 0.50 0.55 82.57 
0.30 0.60 0.49 61.86 
0.30 0.70 0.43 43.50 
0.30 0.80 0.38 27.23 
0.30 0.90 0.34 12.79 
0.30 1.00 0.30 0.00 
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A4.1. Fisher information matrix 
The Fisher information matrix is explained in this appendix. Here, the general 
model for 𝐶𝐶𝐶𝐶 as a function of GFR (Equation 5.8) is used as an example. Note, the 
Fisher information computed here is for individual level data as there are no repeated 
measures in this analysis. 
The Fisher information matrix is denoted by 𝐌𝐌𝐅𝐅 and is written as: 
𝐌𝐌𝐅𝐅 = 𝐉𝐉T𝚺𝚺−1𝐉𝐉 
Equation A4.1 Fisher information matrix 
where, 𝐉𝐉 is a 𝑛𝑛 (number of design points) × 𝑝𝑝 (number of parameters) Jacobian matrix, 
T is the transpose of the matrix and 𝚺𝚺 is a 𝑛𝑛 × 𝑛𝑛 residual variance matrix which is equal 
to the product of variance of the residual error (𝜎𝜎2) and identity matrix (𝐈𝐈)of dimension 
𝑛𝑛. 
The Jacobian matrix is given by the sensitivity of the predicted response variable 
(renal clearance: 𝐶𝐶𝐶𝐶𝑅𝑅) to all parameters at all values of GFR. The sensitivity is given by 
the first partial derivative of the model with respect to a model parameter. 
The model is given by 
𝒚𝒚𝒊𝒊 = 𝒇𝒇𝑪𝑪𝑳𝑳𝑹𝑹(𝑮𝑮𝑮𝑮𝑹𝑹𝒊𝒊,𝜽𝜽) + 𝜺𝜺𝑪𝑪𝑳𝑳𝑹𝑹𝒊𝒊 
(as per Equation 5.8 from the Chapter 5) 

























Equation A4.2 Jacobian matrix (𝐉𝐉) for the general model for renal clearance (𝐶𝐶𝐶𝐶𝑅𝑅) 
The residual variability was an additive model and therefore the residual 
variance matrix of size 𝑛𝑛 × 𝑛𝑛 can be written as: 
𝚺𝚺 = 𝜎𝜎𝐶𝐶𝐶𝐶𝐶𝐶
2 ∙ 𝐈𝐈𝐧𝐧 
where 𝐈𝐈𝐧𝐧 is the identity matrix of dimension 𝑛𝑛 × 𝑛𝑛. 
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A4.2. MATLAB® code for construction of Fisher information matrix and the 
optimal design 
Main file to run (run_ HClnD_Ds.m) 





%% Parameters and other user inputs for robust HClnD.Ds-optimal design 
  
[theta_combi, GFR_num, alpha] = inputs_HClnD_Ds_v3; 
  
%% Simulated annealing 
  
% Setting initial value, lower and upper bounds 
LB = [0.1 * ones(GFR_num,1)]; 
UB = [1 * ones(GFR_num,1)]; 
X = LB + (UB - LB).* rand(GFR_num,1); 
 
% Setting options for simulated annealing function (Written by T. H.  
% Waterhouse, Nov 2007 (C) copyright 
% vmin - minimum change in step size (stop when this value is reached) 




disp('Starting search across design space...') 
  
% Calling function - anneal 
[X, FVAL] = anneal(@HClnD_Ds_v3, X, LB, UB, options, theta_combi, 
alpha); 
  
if alpha == 1 
    disp('HClnD-optimal design points: ') 
    disp(X) % Display output X from simulated annealing i.e., optimal 
design  
    % points 
elseif alpha == 0.5  
    disp('HClnD.Ds-optimal design points: ') 
    disp(X) % Display output X from simulated annealing i.e., optimal 
design  
    % points 
elseif alpha == 0 
    disp('Ds-optimal design points: ') 
    disp(X) % Display output X from simulated annealing i.e., optimal 
design  
    % points 
end 
  
% Display output from simulated annealing i.e., objective function 
value 
fprintf('Objective function value: %d \n', FVAL); 
  
toc
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Compute Fisher information matrix and optimal design criterion (HClnD_Ds.m) 
%% HClnD.Ds-optimal criteria (function) 
% Model: Non-linear model for clearance (CL = THETA(1) * GFR^THETA(2)) 
  
function [HClnDDs_value] = HClnD_Ds_v3(X, theta_combi, alpha) 
    %% calculus variables 
    % h - a smalle value 
    h = 1e-10;  
  
    %% setting design variables 
    % GFR -any values of GFR of interest 
    GFR = X; 
  
    %% parameterisation 
    % sd - residual error 
    sd = 0.01 ; 
     
    % SIGMA - N by N residual variance matrix which only has diagonal  
    % elements equal to 'sd^2' (N - number of deisgn points,  
    % here number of GFR mesurements) 
    SIGMA = sd^2*eye(length(GFR)); 
     
    % Setting lower boundary for search 
    if any(X < 0.1)  
        HClnDDs_value = -1e+10; 
    else 
         
        %% Hypercube ln D-optimal criterion 
        % Jacobian Matrix for non-linear model: CL = THETA(1)*GFR^THETA(2) 
  
        [r c] = size(theta_combi); 
  
        for loop_1 = 1 : r 
            d_theta_HClnD = theta_combi(loop_1,:); 
            for loop_2 = 1 : c  
                d_theta_HClnD(loop_2) = theta_combi(loop_1,loop_2) + i*h; % 
Small change (h) in value of a 
                % one parameter at a time  
                d_cl_HClnD = d_theta_HClnD(1)*(GFR.^d_theta_HClnD(2)); 
                jacob_HClnD(:,loop_2) = imag(d_cl_HClnD)/h; % Jacobian 
matrix - N by P matrix 
                % complex step differential method 
            end 
            jacob_HClnD_all(:,:,loop_1) = jacob_HClnD; 
            FIM_HClnD(:,:,loop_1) = jacob_HClnD_all(:,:,loop_1)'*SIGMA^-
1*jacob_HClnD_all(:,:,loop_1); % FIM 
            D_value_HClnD(loop_1) = det(FIM_HClnD(:,:,loop_1)); % 
Determinant of FIM 
        end  
        HClnD_OF = sum(log(D_value_HClnD.^(alpha/2))); 
  
        %% Local D-optimal criterion for M2 
        % Jacobian matrix for non-linear model: CL = THETA(1)*GFR^THETA(2) 
        % theta_num - number of parameters in non-linear model i.e., equal 
to 2 
  
        d_theta_M2 = [1 0.33]; 
        for loop_3 = 1 : 2  
            d_theta_M2(loop_3) = d_theta_M2(loop_3) + i*h; % Small change 
(h) in value of a 
            % one parameter at a time  
            d_cl_M2 = d_theta_M2(1)*(GFR.^d_theta_M2(2)); 
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            jacob_D_M2(:,loop_3) = imag(d_cl_M2)/h; % Jacobian matrix - N by 
P matrix 
            % complex step differential method 
        end 
        FIM_D_M2 = jacob_D_M2'*SIGMA^-1*jacob_D_M2; % FIM 
  
        D_M2 = det(FIM_D_M2); % Determinant of FIM 
  
        %% Local D-optimal criterion for M1 
        % Jacobian matrix for linear model: CL = THETA(1)*GFR 
        % theta_num - number of parameters in linear model i.e., equal to 1 
  
        d_theta_M1 = [1]; 
        d_theta_M1(1) = d_theta_M1(1) + i*h; 
        d_cl_M1 = d_theta_M1(1)*GFR; 
        jacob_M1 = imag(d_cl_M1)/h; 
        FIM_M1 = jacob_M1' * SIGMA^-1 * jacob_M1; 
        D_M1 = det(FIM_M1); 
         
        %% Ds optimal criterion 
        DS_OF = (D_M2/D_M1)^(1-alpha); 
        %% HClnDDs optimal criterion 
        HClnDDs_value = HClnD_OF + log(DS_OF); 
    end          
end 
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Inputs parameter values (inputs_HClnD_Ds.m) 
%% Parameters and other user inputs for HClnD.Ds-optimal criteria  
  
function [theta_combi, GFR_num, alpha] = inputs_HClnD_Ds_v3 
    %% setting parameters 
    % theta - theta_1 and theta_2 parameters 
    theta = [1 0.33]; 
  
    % 2.5th and 97.5th percentiles (extreme values) of all parameters 
    sd_theta = [0.3 0.1]; 
    for i = 1:length(theta) 
        theta_extrema(i,:) = exp([(log(theta(i))-1.96*sd_theta(i)) 
(log(theta(i))+1.96*sd_theta(i))]);  
    end 
  
    % Combinations of extreme values of all parameters 
    theta_combi = combvec(theta_extrema(1,:), theta_extrema(2,:))'; 
  
    %% Requesting a numeric input for the number of design variable GFR 
to be 
    % searched across the GFR space 
    prompt1 = 'Enter the number of design varaiable GFR to be explored: 
'; 
    GFR_num = input(prompt1); 
  
    %% Requesting a numeric input for weighting variable, 'alpha' 
    % reverseStr - number of backspaces to be entered after each 
invalid  
    % number entry 
    reverseStr = [];  
    while 1 
        % prompt2 - input depending on the desired optimal design 
        prompt2 = sprintf('\n For D-optimal design enter "1" \n For 
D.Ds-optimal design enter "0.5" \n For Ds-optimal design enter "0" \n 
Enter a value: '); 
         
        alpha = input(prompt2);  
        if (alpha == 0 || alpha == 0.5 || alpha == 1) 
            break; 
        end 
         
        % reverseStr - number of backspaces to be entered after each  
        % invalid number entry 
        reverseStr = repmat(sprintf('\b'), 1, length(prompt2 + count)); 
         
        %printing backspaces 
        fprintf([reverseStr]); 
         
        % printing error message if entered value is other than 0, 0.5 
or 1 
        fprintf('\n Not a valid number. Please try again. \n');  
end 
 






























A5.1. MATLAB® codes for simulation estimation study 
Main file to run simulations (run_simulation.m) 
%% This file calls files to simulate data sets and estimate 






% model - 1 is linear model (M1)  and 2 is nonlinear model (M2)  
model = 2; 
 
% subjects - number of subject in each design 
subjects = 100; 
 
% iteration - number of times the simulation is iterated 
iteration = 1:1000; 
 
% Making directory to store files 




%% Call files to simulate, estimate and read in a sequence 
%run call_simulate.m file in parallel 
poolobj = gcp; 
addAttachedFiles(poolobj, 'call_simulate.m'); 
 
parfor i = 1:length(iteration) 
    iter = iteration(i); 
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File for simulating data sets (call_simulate.m) 
% This file simulates data files in format that can be read by 
NONMEM 
 function[] = call_simulate(iter, model, subjects) 
%Create directory to store data files 
% mkdir data_files  
    
    %iID - number of subjects in a data set 
    iID = (1:subjects); 
     
    %iTIME - sampling time points 
    iTIME = [0.1,0.2,0.5,1,1.5,2,3,4,6,8,12,18,24,36]'; 
     
    %ID - iID repeated to match the sampling time points 
    ID = repelem((iID),length(iTIME))'; 
  
    %TIME - iTIME repeated to match the number of iID 
    TIME = repmat(iTIME,length(iID),1); 
  
    % AMT - Dose in the first row followed by '.' for remaining 
entries for 
    % the same individual 
    A = {'.'}; 
    dot = repmat(A,1,14); 
    DOSE = 1; 
    AMT = [DOSE dot]; 
    AMT = repmat(AMT,1,length(iID))'; 
     
    % MDV - Logical variable to inform whether or not the value in 
%DV field 
    % is missing 
    MDV = [1, (repelem(0,14))]; 
    MDV = repmat(MDV,1,length(iID))'; 
  
    % DESIGN_POINTS based on renal function groups KDIGO guideline 
    DESIGN_POINTS = [0.1875; 0.3750; 0.6250; 0.8750]; 
  
    %GFR_SD - standard deviation of distribution of mGFR 
    GFR_SD_PROP = 0.13; 
    GFR_SD_ADD = 0.00001; 
  
    %CL_SD - standard deviation of distribution of CL 
    CL_SD_BSV = 0.30; 
  
    if model == 1 
        %COEF - linear proportional coefficient for M1 
        COEF = 1; 
        %PWR - non-linear exponential coefficient for M1 
        PWR = 1; 
    else  
        %COEF - linear proportional coefficient for M2 
        COEF = 1;         
        %PWR - non-linear exponential coefficient for M2 
        PWR = 0.33; 
    end 
         
    %SD_ETA_(PARAMETER) - standard deviation (SD) of random effect  
    %parameters 




    SD_ETA_V = 0.50; 
     
    %TV(PARAMETER) - typical value (TV) of fixed effect paramteres  
    TVV = 1; 
    TVfe = 1; 
         
    %SD_EPS1 - standard deviation (SD) of proportional residual 
%error 
    SD_EPS1 = 0.10; 
     
    %TVAUC - TV of area under the concentration curve (AUC) 
    TVAUC = DOSE/1; 
     
    %C_AVG - average plasma concentration 
    C_AVG = TVAUC/max(iTIME); 
     
    %SD_EPS2 - SD of additive residual error 
    SD_EPS2 = 0.01*C_AVG; 
     
    all_PDV = []; 
    all_UDV = []; 
     
    all_GFR = []; 
    all_CL =[]; 
    all_V = []; 
    all_fe = []; 
     
    for i = 1:length(DESIGN_POINTS) 
     
    %nDV - 0-by-0 matrix to store individual DV from all i 
%individuals 
    nPDV = []; 
    nUDV = []; 
     
    %n(PARAMETERS) - 0-by-0 matrix to store all i individual 
%parameters 
    nGFR = []; 
    nCL = []; 
    nV = []; 
    nfe = []; 
     
    for k = 1:subjects/length(DESIGN_POINTS) 
  
        %LNGFRi - individual GFR in log scale 
        LNGFRi = log(DESIGN_POINTS(i)) + 
(DESIGN_POINTS(i)*GFR_SD_PROP... 
            *randn(1)) + GFR_SD_ADD*randn(1); 
         
        %GFRi - individual GFR 
        GFRi = exp(LNGFRi); 
  
        if GFRi < 0 
            GFRi = 0; 
        else 
            GFRi = GFRi; 
        end 
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        CL_SD_BSV_POOLED = sqrt(CL_SD_BSV^2 + (GFR_SD_PROP*GFRi)^2 
... 
            + GFR_SD_ADD^2); 
  
        %LNCLi - individual clearance in log scale 
        LNCLi = log(COEF*(GFRi ̂  PWR)) + CL_SD_BSV_POOLED*randn(1); 
  
        %CLi - individual clearance in normal scale 
        CLi = exp(LNCLi); 
  
        %Vi - individual volume of distribution 
        Vi = TVV*exp(0+SD_ETA_V.*randn(1)); 
  
        %fei - individual fraction excreted unchanged in urine (0 
%to 1); it 
        %is fixed to 1 
        fei = 1; 
  
        %Ci - estimated plasma concentration of ith individual at 
%sampling  
        %time points w/o residual variability 
        Ci = []; 
        Ui = []; 
  
        for d = 1:length(iTIME) 
  
            %Ct - plasma concentration at sampling time points 
%(iTIME) 
            Ct = (DOSE/Vi)*(exp((-CLi/Vi)*(iTIME(d,1)))); 
            Ci = [Ci; Ct]; 
             
            %Ut - cumulative amount excreted in urine at sampline 
%time  
            %point (iTIME) 
            Ut = (fei*DOSE)*(1-(exp((-CLi/Vi)*(iTIME(d,1))))); 
            Ui = [Ui; Ut]; 
        end 
         
  
            iPDV = []; 
            iUDV = [];             
            for d = 1:length(iTIME) 
                EPS1 = 0 + SD_EPS1.*randn(1,1); 
                EPS2 = 0 + SD_EPS2.*randn(2,1); 
  
                C_obs = Ci(d,1)+(Ci(d,1)*EPS1) + EPS2(1); 
                U_obs = Ui(d,1) + EPS2(2); 
                iPDV = [iPDV; C_obs]; 
                iUDV = [iUDV; U_obs];                
            end 
             
        %nDV - individual DV from all i individuals 
        nPDV = [nPDV; iPDV];    
        nUDV = [nUDV; iUDV]; 
         
        %nParameters - individual parameters froma all i 
%individuals 
        nGFR = [nGFR; repelem(GFRi,length(iTIME))']; 
        nCL = [nCL; repelem(CLi,length(iTIME))']; 




        nV = [nV; repelem(Vi,length(iTIME))']; 
        nfe = [nfe; repelem(fei,length(iTIME))']; 
         
        end 
        all_PDV = [all_PDV; nPDV]; 
        all_UDV = [all_UDV; nUDV]; 
         
        all_GFR = [all_GFR; nGFR]; 
        all_CL = [all_CL; nCL]; 
        all_V = [all_V; nV]; 
        all_fe = [all_fe; nfe]; 
    end 
  
    DVs = 
table(ID,TIME,all_PDV,all_UDV,all_GFR,all_CL,all_V,all_fe); 
    n_count = iID(1); 
    %TABLE1 - table containing data items as required in for the 
%data file 
    TABLE = [];  
    DOT = {'.'}; 
    var_name = 
{'ID','TIME','AMT','DV','MDV','CMT','EVID','GFRi','CLi',... 
        'Vi','fei'}; 
     
    TABLE = [TABLE; table((n_count),0, 1, DOT, 1, 1, 
1,DVs.all_GFR(1),... 
     
DVs.all_CL(1),DVs.all_V(1),DVs.all_fe(1),'VariableNames',var_name)]; 
  
        for d=1:height(DVs) 
            if DVs.ID(d) == n_count 
                TABLE = [TABLE; 
table(DVs.ID(d),DVs.TIME(d),DOT,... 
                
{DVs.all_PDV(d)},0,1,0,DVs.all_GFR(d),DVs.all_CL(d),... 
                
DVs.all_V(d),DVs.all_fe(d),'VariableNames',var_name)]; 
  
                TABLE = [TABLE; 
table(DVs.ID(d),DVs.TIME(d),DOT,... 
                
{DVs.all_UDV(d)},0,2,0,DVs.all_GFR(d),DVs.all_CL(d),... 
                
DVs.all_V(d),DVs.all_fe(d),'VariableNames',var_name)]; 
  
                n_count = n_count + 1; 
                TABLE = [TABLE; table((n_count),0, 1, DOT, 1, 1, 
1,... 
                
DVs.all_GFR(d),DVs.all_CL(d),DVs.all_V(d),DVs.all_fe(d),... 
                'VariableNames',var_name)]; 
                         
                TABLE = [TABLE; 
table(DVs.ID(d),DVs.TIME(d),DOT,... 
                
{DVs.all_PDV(d)},0,1,0,DVs.all_GFR(d),DVs.all_CL(d),... 
                
DVs.all_V(d),DVs.all_fe(d),'VariableNames',var_name)]; 
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                TABLE = [TABLE; 
table(DVs.ID(d),DVs.TIME(d),DOT,... 
                
{DVs.all_UDV(d)},0,2,0,DVs.all_GFR(d),DVs.all_CL(d),... 
                
DVs.all_V(d),DVs.all_fe(d),'VariableNames',var_name)]; 
             end 
        end 
 
%filename - file name for data file for 'iter' replicates; all 
%files are  
%stored in folder 'Mn_nn_data_files' 
filename = sprintf('M%d_n%d_data%d.csv', model, subjects, iter); 
  




% format data file for NONMEM run 
  
datafile = sprintf('M%d_n%d_data%d.csv', model, subjects, iter); 
input = fileread(datafile); 
  
%replace header 'ID' with '#ID' 
input = regexprep(input, 'ID', '#ID'); 
  
%correct header 'EV#ID' to 'EVID' 
input = regexprep(input, 'EV#ID', 'EVID'); 
  
%replace 'NaN' with '.' 
input = regexprep(input, 'NaN', '.'); 
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A5.2. Generating plasma and urine data 
The process of generating plasma and urine data is described below: 
1. Simulation of mGFR and CL: The steps for generating individual values of mGFR 
and CL was similar to that in Chapter 4. The only difference being that the 
simulations with eGFR were not considered. The process of generating individual 
values of mGFR and CL are described in Chapter 4, Section 4.3.3. 
2. Simulation of plasma and urine data: The one-compartment model as described in 
Section 6.4.3. was used to simulate the plasma concentration and Ae based on 
design as described in Section 6.7.1.2. This step was executed two times, where 
simulated values of CL based on mGFR using M1 and M2 were used. 
Details of the pharmacokinetic model are presented in Figure A5.1 and Equation 
A5.1. 
 
Figure A5.1 A schematic representation of a one-compartment pharmacokinetic model for 








= −𝑘𝑘10 ∙ 𝐴𝐴(1) 
𝑑𝑑𝐴𝐴(2)
𝑑𝑑𝑡𝑡
= 𝑓𝑓𝑒𝑒 ∙ 𝑘𝑘10 ∙ 𝐴𝐴(1) 
Equation A5.1 Ordinary differential equations for one compartment pharmacokinetic 
model for drug that is entirely renally cleared and administered as intravenous dose 
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where, 𝐴𝐴(1) and 𝐴𝐴(2) are the amount of drug in the central compartment and urine 
compartment, respectively, 𝑡𝑡 is time, 𝑘𝑘10 is elimination rate constant, which is given 
as a ratio of total clearance (𝐶𝐶𝐶𝐶) and volume of distribution (𝑉𝑉1). The initial condition 
at 𝑡𝑡 = 0 for central compartment is dose and that for urine compartment is zero. Note 
here the drug is entirely renally cleared i.e. 𝑓𝑓𝑒𝑒 = 1. 
The residual variability for plasma concentration and urine amount data were 
modelled as combined i.e., additive plus proportional and additive error model, 
respectively. The standard deviation of the additive error was set to 1% of the average 
concentration or amount and the coefficient of variation of the proportional error was 
set to 10%. 
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